U.S. patent application number 14/196711 was filed with the patent office on 2015-02-26 for regeneration of endogenous myocardial tissue.
This patent application is currently assigned to The Trustees of Columbia University in the City of New York. The applicant listed for this patent is Silviu Itescu. Invention is credited to Silviu Itescu.
Application Number | 20150056161 14/196711 |
Document ID | / |
Family ID | 29215504 |
Filed Date | 2015-02-26 |
United States Patent
Application |
20150056161 |
Kind Code |
A1 |
Itescu; Silviu |
February 26, 2015 |
REGENERATION OF ENDOGENOUS MYOCARDIAL TISSUE
Abstract
This invention provides a method of treating a disorder of a
subject's heart involving loss of cardiomyocytes which comprises
administering to the subject a composition comprising an amount of
a human stromal derived factor-1 and an amount of a human
granulocyte-colony stimulating factor, the composition being
administered in an amount effective to cause proliferation of
cardiomyocytes within the subject's heart so as to thereby treat
the disorder. This invention also provides a method of treating a
subject suffering from a disorder of a tissue involving loss and/or
apoptosis of cells of the tissue which comprises administering to
the subject a composition comprising an amount of an agent which
induces phosphorylation and/or activation of protein kinase B, or
an agent which induces phosphorylation and/or activation of an
extracellular signal-regulated protein kinase, or an agent which
induces activation of CXCR4.
Inventors: |
Itescu; Silviu; (Melbourne,
AU) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Itescu; Silviu |
Melbourne |
|
AU |
|
|
Assignee: |
The Trustees of Columbia University
in the City of New York
New York
NY
|
Family ID: |
29215504 |
Appl. No.: |
14/196711 |
Filed: |
March 4, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10693480 |
Oct 23, 2003 |
8663652 |
|
|
14196711 |
|
|
|
|
PCT/US03/12768 |
Apr 23, 2003 |
|
|
|
10693480 |
|
|
|
|
10128738 |
Apr 23, 2002 |
|
|
|
PCT/US03/12768 |
|
|
|
|
Current U.S.
Class: |
424/85.2 ;
424/93.7; 514/16.4; 514/8.1; 514/9.1 |
Current CPC
Class: |
A61P 9/00 20180101; G01N
2510/00 20130101; A61K 31/506 20130101; A61K 38/195 20130101; A61K
38/195 20130101; C12N 15/1137 20130101; A61P 31/04 20180101; A61K
38/1709 20130101; A61K 35/44 20130101; A61P 1/16 20180101; A61P
9/10 20180101; A61K 38/1866 20130101; A61K 2039/505 20130101; A61P
25/00 20180101; A61P 9/04 20180101; A61K 38/193 20130101; A61K
38/1709 20130101; C12N 5/069 20130101; A61P 35/00 20180101; C07K
2317/76 20130101; A61K 2300/00 20130101; A61K 2300/00 20130101;
A61K 2300/00 20130101; A61K 2300/00 20130101; A61K 2300/00
20130101; A61K 2300/00 20130101; A61K 2300/00 20130101; A61K
38/1866 20130101; A61K 2300/00 20130101; A61K 38/2053 20130101;
A61K 38/1825 20130101; A61P 13/10 20180101; A61P 21/00 20180101;
A61K 38/1825 20130101; A61K 35/34 20130101; C12N 15/113 20130101;
A61K 35/34 20130101; A61K 38/2053 20130101; A61P 11/00 20180101;
A61K 31/7105 20130101; A61K 31/085 20130101; A61K 31/711 20130101;
A61K 45/06 20130101; A61P 29/00 20180101; A61P 1/04 20180101; A61K
35/44 20130101; A61K 38/1891 20130101; A61P 7/02 20180101; A61K
38/1891 20130101; C07K 16/2866 20130101; A61P 43/00 20180101 |
Class at
Publication: |
424/85.2 ;
514/16.4; 514/8.1; 514/9.1; 424/93.7 |
International
Class: |
A61K 38/19 20060101
A61K038/19; A61K 45/06 20060101 A61K045/06 |
Claims
1-42. (canceled)
43. A method of treating a disorder of a subject's heart involving
loss of cardiomyocytes which comprises administering to the subject
a composition comprising an amount of a human stromal derived
factor-1, the composition being administered in an amount effective
to cause proliferation of cardiomyocytes within the subject's heart
so as to thereby treat the disorder.
44. The method of claim 43, wherein the human stromal derived
factor-1 is human stromal derived factor-1.alpha., human stromal
derived factor-1.beta., or human stromal derived
factor-1.gamma..
45. The method of claim 43, wherein the disorder comprises
myocardial infarction, congestive heart failure, chronic ischemia,
or ischemic disease.
46. The method of claim 43, further comprising administering to the
subject an amount of one or more of a human granulocyte-colony
stimulating factor, a human granulocyte macrophage-colony
stimulating factor, a human interleukin-8, a human vascular
endothelial growth factor, a human fibroblast growth factor, a
human Gro family chemokine, human endothelial progenitor cells, or
a pro-angiogenic agent, the amount, or if appropriate amounts,
thereof being effective to cause proliferation of cardiomyocytes
within the subject's heart so as to thereby treat the disorder.
47. The method of claim 43, wherein the composition is administered
intramyocardially or intracoronarily.
48. The method of claim 43, wherein the composition is administered
via a stent, a scaffold, or a slow-release formulation.
49. A method of treating a subject suffering from a disorder of a
tissue involving loss and/or apoptosis of cells of the tissue which
comprises administering to the subject a composition comprising an
amount of an agent which induces phosphorylation and/or activation
of protein kinase B, the composition being administered in an
amount effective to cause proliferation of the cells and/or inhibit
apoptosis of the cells of the tissue within the subject so as to
thereby treat the disorder.
50. The method of claim 49, wherein the agent is human stromal
derived factor-1.alpha., human stromal derived factor-1.beta., or
human stromal derived factor-1.gamma..
51. The method of claim 49, wherein the tissue is heart tissue and
the cells are cardiomyocytes.
52. The method of claim 51, wherein the disorder from which the
subject is suffering comprises myocardial infarction, congestive
heart failure, chronic ischemia, or ischemic disease.
53. The method of claim 49, wherein the tissue is heart tissue and
the cells are progenitors of cardiomyocytes or stem cells that
differentiate to cardiomyocytes.
54. The method of claim 49, wherein the tissue is heart muscle,
striated muscle, liver, kidney, neuronal or gastrointestinal
tissue.
55. The method of claim 49, wherein the agent is insulin,
endothelin-1, urocrotin, cardiotropin-1, erythropoietin, leukemia
inhibitory factor-1, tumor necrosis factor-alpha.
56. The method of claim 49, further comprising administering an
amount of one or more of a human granulocyte-colony stimulating
factor, a human stromal-derived factor-1, a human granulocyte
macrophage-colony stimulating factor, a human interleukin-8, a
human vascular endothelial growth factor, a human fibroblast growth
factor, a human Gro family chemokine, human endothelial progenitor
cells, or a pro-angiogenic agent, the amount, or if appropriate
amounts, effective to cause proliferation of the cells and/or
inhibit apoptosis of the cells of the tissue of the subject so as
to thereby treat the disorder.
57. A composition comprising a human stromal-derived factor-1 and a
human granulocyte-colony stimulating factor.
58. The method of claim 49, wherein the composition is administered
intramyocardially or intracoronarily.
59. The method of claim 49, wherein the composition is administered
via a stent, a scaffold, a slow-release formulation,
intramuscularly, intravenously, intra-arterially, or
sub-cutaneously.
60. A method of treating a subject suffering from a disorder of a
tissue involving loss and/or apoptosis of cells of the tissue which
comprises administering to the subject a composition comprising an
amount of an agent which induces phosphorylation and/or activation
of an extracellular signal-regulated protein kinase, the
composition being administered in an amount effective to inhibit
apoptosis and/or cause proliferation of the cells of the tissue
within the subject so as to thereby treat the disorder.
61. The method of claim 60, wherein the agent is human stromal
derived factor-1.alpha., human stromal derived factor-1.beta., or
human stromal derived factor-1.gamma..
62. The method of claim 60, wherein the tissue is heart tissue and
the cells are cardiomyocytes.
63. The method of claim 62, wherein the disorder from which the
subject is suffering comprises myocardial infarction, congestive
heart failure, chronic ischemia, or ischemic disease.
64. The method of claim 60, wherein the tissue is heart tissue and
the cells are progenitors of cardiomyocytes or stem cells that
differentiate to cardiomyocytes.
65. The method of claim 60, further comprising administering an
amount of one or more of a human granulocyte-colony stimulating
factor, a human stromal-derived factor-1, a human granulocyte,
macrophage-colony stimulating factor, a human interleukin-8, a
human vascular endothelial growth factor, a human fibroblast growth
factor, a human Gro family chemokine, human endothelial progenitor
cells, an activator of protein kinase B, or a pro-angiogenic agent,
the amount, or if appropriate amounts, thereof being effective to
inhibit apoptosis and/or cause proliferation of the cells of the
tissue within the subject so as to thereby treat the disorder.
66. The method of claim 62, wherein the agent is administered
intramyocardially or intracoronarily.
67. The method of claim 60, wherein the agent is administered via a
stent, a scaffold, or a slow-release formulation, intramuscularly,
intravenously, intra-arterially, or sub-cutaneously.
68. A method of treating a subject suffering from a disorder of a
tissue involving loss and/or apoptosis of cells of the tissue which
comprises administering to the subject a composition comprising an
amount of an agent which induces activation of CXCR4, the
composition being administered in an amount effective to cause
proliferation of the cells and/or inhibit apoptosis of the cells of
the tissue within the subject so as to thereby treat the
disorder.
69. The method of claim 68, wherein the tissue is heart tissue and
the cells are cardiomyocytes.
70. The method of claim 69, wherein the agent is administered
intramyocardially or intracoronarily via a stent, a scaffold, or a
slow-release formulation.
71. The method of claim 68, wherein the agent is administered
systemically.
Description
[0001] Throughout this application, various publications are
referenced in parentheses by arabic numbers. Full citations for
these references may be found at the end of the specification
immediately preceding the claims. The disclosures of these
publications in their entireties are hereby incorporated by
reference into this application to more fully describe the state of
the art to which this invention pertains.
BACKGROUND
[0002] Healing of a myocardial infarct is complicated by the need
for viable myocytes at the peri-infarct rim to undergo compensatory
hypertrophy in order to increase pump function in response to the
loss of infarcted tissue (1,2). This initiates a process termed
cardiac remodelling which is characterized by apoptotic loss of
hypertrophied myocytes, expansion of the initial infarct area,
progressive collagen replacement, and heart failure (3-6). We have
recently put forward the hypothesis that hypertrophied cardiac
myocytes undergo apoptosis because the endogenous capillary network
cannot provide the compensatory increase in perfusion required for
cell survival (7).
[0003] Vascular network formation is the end result of a complex
process that begins in the pre-natal period with induction of
vasculogenesis by hemangioblasts--cells derived from the human
ventral aorta which give rise to both endothelial and hematopoietic
elements (8-11). Cells which can differentiate into endothelial
elements also exist in adult bone marrow (12-14) and can induce
vasculogenesis in ischemic tissues (15-17). In the adult, new blood
vessel formation can occur either through angiogenesis from
pre-existing mature endothelium or vasculogenesis mediated by bone
marrow-derived endothelial precursors. Recently, we identified a
specific population of endothelial progenitor cells (angioblasts)
derived from human adult bone marrow which has phenotypic and
functional characteristics of embryonic angioblasts (7). We showed
that intravenous administration of these cells resulted in
selective homing to ischemic myocardium, induction of infarct bed
vasculogenesis, prevention of peri-infarct myocyte apoptosis, and
significant improvement in myocardial function (7).
[0004] We recently discovered that CXC chemokines containing the
ELR motif regulate migration of human bone marrow-derived
endothelial progenitor cells to sites of tissue ischemia. Moreover,
since selective bone marrow homing and engraftment of hematopoietic
progenitors depends on CXCR4 binding to SDF-1 expressed
constitutively in the bone marrow (28-30), we demonstrated that
interruption of CXCR4/SDF-1 interactions could redirect trafficking
of human bone marrow-derived endothelial progenitor cells to sites
of tissue ischemia, thereby augmenting therapeutic vasculogenesis.
Our results indicated that CXC chemokines, including IL-8,
Gro-alpha, and SDF-1, play a central role in regulating human adult
bone marrow-dependent vasculogenesis.
[0005] Recent observations have suggested that a second
compensatory response of viable cardiomyocytes is to proliferate
and regenerate following injury (18,19). We have previously shown
that pro-angiogenic factors, such as endothelial progenitor cells
at a minimum concentration can induce vasculogenesis. Here we
disclose the result that careful dosing of pro-angiogenic agents,
or agents that can activate AKT or ERK, or activate CXCR4 on cells
can induce cardiomyocyte proliferation or prevent loss of
cardiomyoctyes also.
SUMMARY
[0006] This invention provides a method of treating a disorder of a
subject's heart involving loss of cardiomyocytes which comprises
administering to the subject a composition comprising an amount of
a human stromal derived factor-1 and an amount of a human
granulocyte-colony stimulating factor, the composition being
administered in an amount effective to cause proliferation of
cardiomyocytes within the subject's heart so as to thereby treat
the disorder.
[0007] This invention also provides a method of treating a subject
suffering from a disorder of a tissue involving loss and/or
apoptosis of cells of the tissue which comprises administering to
the subject a composition comprising an amount of an agent which
induces phosphorylation and/or activation of protein kinase B, the
composition being administered in an amount effective to cause
proliferation of the cells and/or inhibit apoptosis of the cells of
the tissue within the subject so as to thereby treat the
disorder.
[0008] This invention also provides a method of treating a subject
suffering from a disorder of a tissue involving loss and/or
apoptosis of cells of the tissue which comprises administering to
the subject a composition comprising an amount of an agent which
induces phosphorylation and/or activation of an extracellular
signal-regulated protein kinase, the composition being administered
in an amount effective to inhibit apoptosis and/or cause
proliferation of the cells of the tissue within the subject so as
to thereby treat the disorder.
[0009] This invention also provides a method of treating a subject
suffering from a disorder of a tissue involving loss and/or
apoptosis of cells of the tissue which comprises administering to
the subject a composition comprising an amount of an agent which
induces activation of CXCR4, the composition being administered in
an amount effective to cause proliferation of the cells and/or
inhibit apoptosis of the cells of the tissue within the subject so
as to thereby treat the disorder.
BRIEF DESCRIPTION OF THE FIGURES
[0010] FIGS. 1A-1D: IL-8/Gro-Alpha CXC Chemokines Regulate
Migration Of Human Endothelial progenitor cells (angioblasts) To
Myocardial Tissue In Vivo And Subsequent Development Of
Vasculogenesis.
[0011] (A) DiI-labelled human endothelial progenitor cells
(angioblasts) (>98% CD34+ purity) injected intravenously into
nude rats infiltrate rat myocardium after coronary artery ligation
and infarction but not after sham operation at 48 hours.
[0012] (B) Migration of human endothelial progenitor cells
(angioblasts) to ischemic rat myocardium is inhibited by mAbs
against either rat IL-8 or the IL-8/Gro-alpha chemokine family
receptors CXCR1 and CXCR2 (all p<0.01), but not against VEGF or
its receptor Flk-1 (results are expressed as mean+sem of three
separate experiments).
[0013] (C) Masson's trichrome stain of rat myocardial infarct bed
at two weeks after LAD ligation demonstrating diffuse increase in
matrix deposition and few capillaries in representative animal
injected with saline (.times.400), diffuse increase in capillaries
(arrowheads) and reduction in matrix deposition in representative
animal injected with human bone marrow-derived endothelial
progenitor cells (.times.400), and reduction in capillary numbers
in representative animal injected with human endothelial progenitor
cells (angioblasts) together with mAb against human CXCR1/2
(.times.400).
[0014] (D) Intracardiac injection of IL-8 or SDF-1 at 1 .mu.g/ml
significantly increases in vivo chemotaxis of DiI-labelled human
endothelial progenitor cells (angioblasts)(98% CD34+ purity) into
non-ischemic rat heart in comparison with injection of saline or
stem cell factor (SCF), p<0.01 (results are expressed as
mean+sem of three separate experiments). Below is shown
representative fluorescence microscopy of intravenously-injected
DiI-labelled human endothelial progenitor cells infiltrating
non-ischemic rat heart after intracardiac injection with saline,
IL-8 or SDF-1.
[0015] FIGS. 2A-2C: Blocking CXCR4/SDF-1 Interactions Redirects
Intravenously Injected Human Endothelial progenitor cells From Bone
Marrow To Ischemic Myocardium.
[0016] (A) the proportion of human CD34+CD117.sup.bright
endothelial progenitor cells (angioblasts) in rat bone marrow 2-14
days after intravenous injection is significantly increased
following ischemia induced by LAD ligation (results are expressed
as mean+sem of bone marrow studies in three animals at each time
point).
[0017] (B) and (C) depict the effects of mAbs against CXCR4, SDF-1
or CD34 on trafficking of human CD34+ endothelial progenitor cells
(angioblasts) to rat bone marrow and myocardium following LAD
ligation. Co-administration of anti-CXCR4 or anti-SDF-1
significantly reduced trafficking of intravenously injected human
CD34+ cells to rat bone marrow at 48 hours and increased
trafficking to ischemic myocardium, whereas anti-CD34 mAb had no
effect (results are expressed as mean+sem of bone marrow and
cardiac studies performed in three LAD-ligated animals at 48 hours
after injection).
[0018] FIGS. 3A-3F. Redirected Trafficking Of Human Endothelial
Progenitor Cells (angioblasts) To The Site Of Infarction Induces
Vasculogenesis And Protects Cardiomyocytes Against Apoptosis.
[0019] (A) Myocardial infarct bed two weeks post-LAD ligation from
representative animals in each group stained with Masson's
trichrome (upper panel) or immunoperoxidase after binding of
anti-CD31 mAb (lower panel). The infarct zones of rats receiving
either 10.sup.3 or 10.sup.5 endothelial progenitor cells
(angioblasts) show myocardial scars composed of paucicellular,
dense fibrous tissue stained blue by trichrome (.times.400). In
contrast, the infarct zones of rats injected with 10.sup.5
endothelial progenitor cells plus anti-CXCR4 mAb show significant
increase in cellularity of granulation tissue, minimal matrix
deposition and fibrosis, and numerous medium-sized capillaries of
human origin. The infarct zones of rats injected with
2.times.10.sup.5 endothelial progenitor cells show a similar
reduction in fibrous tissue and increase in medium-sized
capillaries, and an additional increase in large-sized vessels of
human origin.
[0020] (B) and (C) show the relationship between the number of
human CD117.sup.bright endothelial progenitor cells injected
intravenously (10.sup.3, 10.sup.5, 10.sup.5 plus anti-CXCR4 mAb,
and 2.times.10.sup.5) and development of rat infarct bed
vasculogenesis at two weeks, defined as the mean number of
capillaries/high power field (hpf) with medium- or large-sized
lumen diameter (respectively, 0.02 mm mean diameter with 3-6
contiguous endothelial lining cells and 0.05 mm mean diameter with
>6 contiguous endothelial lining cells). Results are expressed
as the mean+sem of at least 15 hpf in three separate
experiments.
[0021] (B) the groups receiving either 2.times.10.sup.5 endothelial
progenitor cells (angioblasts) or 10.sup.5 endothelial progenitor
cells plus anti-CXCR4 mAb demonstrated 1.7-fold higher numbers of
medium-sized capillaries compared with the other two groups
(p<0.01).
[0022] (C) the group receiving 2.times.10.sup.5 endothelial
progenitor cells (angioblasts) additionally demonstrated 3.3-fold
higher numbers of large-lumen capillaries compared with the groups
receiving 10.sup.3 or 10.sup.5 endothelial progenitor cells
(p.sub.<0.01), and 2-fold higher numbers of large-lumen
capillaries compared with the group receiving 10.sup.5 endothelial
progenitor cells plus anti-CXCR4 mAb (p<0.01).
[0023] (D) shows that co-administration of anti-CXCR4 mAb together
with the highest concentration of endothelial progenitor cells
(angioblasts), 2.times.10.sup.5, resulted in a further 23% increase
in growth of large-lumen capillaries. More strikingly, there was a
further 2-fold increase in capillary numbers when 2.times.10.sup.5
endothelial progenitor cells were injected intravenously after
direct intracardiac delivery of 1.0 .mu.g/ml SDF-1 into infarcted
hearts (p<0.01) (results are expressed as mean+sem of three
separate experiments).
[0024] (E) shows that at 2 weeks the numbers of apoptotic myocytes
at the peri-infarct rim, defined by concomitant staining with
anti-desmin mAb and DNA end-labeling using TUNEL technique, are
significantly reduced in rats receiving either 2.0.times.10.sup.5
endothelial progenitor cells or 10.sup.5 endothelial progenitor
cells together with anti-CXCR4 mAb in comparison to rats receiving
10.sup.3 or 10.sup.5 endothelial progenitor cells (p<0.01)
(results are expressed as mean+sem of three separate
experiments).
[0025] (F) shows that co-administration of anti-CXCR4 mAb or
intracardiac injection of SDF-1 resulted in further reductions in
cardiomyocyte apoptosis of 65% and 76%, respectively, at two weeks
(both p<0.001) (results are expressed as mean+sem of three
separate experiments).
[0026] FIGS. 4A-4H. Infarct Bed Vasculogenesis Improves Long-Term
Myocardial Function Through Mechanisms Involving Both Cardiomyocyte
Protection and Proliferation/Regeneration.
[0027] (A) and (B) show the relationship between the number of
human CD117.sup.bright endothelial progenitor cells (angioblasts)
injected intravenously (10.sup.3, 10.sup.5, 10.sup.5 plus
anti-CXCR4 mAb, and 2.times.10.sup.5) and improvement in myocardial
function at 15 weeks, defined as mean improvement in left
ventricular ejection fraction (LVEF) (A) and mean reduction in left
ventricular area at end-systole (LVAs) (B). No significant
improvement in these parameters was observed in the groups
receiving 10.sup.3 or 10.sup.5 endothelial progenitor cells in
comparison to rats receiving saline alone. In contrast, rats
receiving 10.sup.5 endothelial progenitor cells plus anti-CXCR4 mAb
demonstrated significant recovery in LVEF and reduction in LVAs
(both p<0.001). The group receiving 2.times.10.sup.5 endothelial
progenitor cells demonstrated still 50% greater recovery in LVEF
and reduction in LVAs (both p<0.001).
[0028] (C) Section from infarct of representative animal receiving
2.times.10.sup.5 endothelial progenitor cells (angioblasts) showing
a high frequency of cardiomyocytes staining positively for both
cardiac-specific troponin I and rat-specific Ki-67 (arrows). Note
the proximity of Ki-67-positive cardiomyocytes to capillaries
(arrowheads).
[0029] (D) Section from infarct of representative animal receiving
2.times.10.sup.5 endothelial progenitor cells showing "finger" of
cardiomyocytes of rat origin, as determined by expression of rat
MHC class I molecules, extending from the peri-infarct region into
the infarct zone. These cellular islands contain a high frequency
of myocytes staining positively for both cardiac-specific troponin
I and rat-specific Ki-67 (arrows). Sections from infarcts of
representative animals receiving saline do not show same frequency
of dual staining myocytes. Bar graph shows that the group of
animals receiving 2.times.10.sup.5 human endothelial progenitor
cells has a significantly higher index of cell cycling
cardiomyocytes at the peri-infarct region than saline controls or
sham operated animals (both p<0.01). No difference between the
groups is seen at sites distal to the infarct.
[0030] (E) shows that the index of cell-cycling cardiomyocytes at
the peri-infarct rim was increased by a further 1.9-fold when
2.times.10.sup.5 human endothelial progenitor cells were
intravenously co-administered together with SDF-1 injected directly
into the ischemic myocardium alone (p<0.01), or an 8-fold
cumulative increase in cell-cycling cardiomyocytes at two weeks
compared with LAD-ligated controls receiving saline (results are
expressed as mean+sem of three separate experiments).
[0031] (F) shows that intravenous co-administration of anti-CXCR4
mAb, or intracardiac co-administration of SDF-1, but not IL-8,
results in 2.8 to 4-fold greater LVEF improvement, determined by
echocardiography, compared with intravenous injection of
2.times.10.sup.5 endothelial progenitor cells alone (p<0.01)
(results are expressed as mean+sem of three separate
experiments).
[0032] (G) shows that at 15 weeks the mean proportion of
scar/normal left ventricular myocardium in rats receiving either or
10.sup.5 endothelial progenitor cells together with anti-CXCR4 mAb
was significantly reduced in comparison to rats receiving either
10.sup.3 or 10.sup.5 endothelial progenitor cells (angioblasts)
alone, or saline (p<0.01). The group receiving
2.0.times.10.sup.5 endothelial progenitor cells demonstrated still
38% greater reduction in the ratio of scar/muscle tissue (results
are expressed as mean+sem of three separate experiments).
[0033] (H) Sections of rat hearts stained with Masson's trichrome
at 15 weeks after LAD ligation and injection of 2.0.times.10.sup.6
G-CSF mobilized human cells containing 10.sup.3 (left) or
2.0.times.10.sup.5 (right) CD117.sup.bright endothelial progenitor
cells. Hearts of rats receiving 10.sup.3 endothelial progenitor
cells had greater loss of anterior wall mass, collagen deposition
(lighter gray), and septal hypertrophy compared with hearts of rats
receiving 2.0.times.10.sup.5 endothelial progenitor cells.
[0034] FIG. 5: This figure shows mRNA expression of three genes in
the ischemic rat hearts at various time points. You will see that
at 48 hours and 2 weeks after LAD ligation and ischemia, HBP23 (the
rat homologue of human PAG/NKEF-A,B,C, all of which are part of the
family of peroxiredoxins (Prx)) is decreased, and vitamin D3
upregulated protein VDUP-1 is increased. The early (48 hour)
reduction in PRX and increase in VDUP-1 results in a compensatory
increase in thiol reductase thioredoxin (TRX). Note that
endothelial progenitor cell therapy reverses this pattern of mRNA
expression.
[0035] FIG. 6: DNA sequence (SEQ ID NO:1) corresponding to mRNA
encoding VDUP-1.
[0036] FIG. 7: This figure shows catalytic DNA 5'-AT-3' cleavage
sites on VDUP-1 DNA (SEQ ID NO:3) corresponding to the coding
region of VDUP-1 mRNA. Cleavage site pairs are uppercase.
[0037] FIG. 8: This figure shows catalytic DNA 5'-GC-3' cleavage
sites on VDUP-1 DNA (SEQ ID NO:3) corresponding to the VDUP-1 mRNA.
Cleavage site pairs are uppercase.
[0038] FIG. 9: This figure shows catalytic DNA 5'-GT-3' cleavage
sites on VDUP-1 DNA (SEQ ID NO:3) corresponding to the VDUP-1 mRNA.
Cleavage site pairs are uppercase.
[0039] FIG. 10: This figure shows catalytic DNA 5'-AC-3' cleavage
sites on VDUP-1 DNA (SEQ ID NO:3) corresponding to the VDUP-1 mRNA.
Cleavage site pairs are uppercase.
[0040] FIG. 11: This figure shows sites which can be cleaved by a
hammerhead ribozyme in VDUP-1 DNA (SEQ ID NO:3) corresponding to
the VDUP-1 mRNA coding region. Uppercase "T" represents cleavage
site.
[0041] FIG. 12: This figure shows that at VDUP-1 enzyme
concentrations ranging from 0.05 .mu.M to 5 .mu.M the
sequence-specific VDUP1 DNA enzyme cleaved a synthetic rat VDUP1
oligonucleotide in a concentration- and time-dependent manner.
[0042] FIG. 13: (a) Shows intramyocardial injection of the rat
sequence-specific VDUP1 DNA enzyme at 48 hours after LAD ligation
resulted in a 75% mean inhibition of proliferating cardiac
fibroblasts in the infarct zone two weeks later in comparison to
injection of scrambled DNA enzyme control (p<0.01). (b) Shows
injection of VDUP1 DNA enzyme resulted in 20% mean reduction in
apoptotic cardiomyocytes at the peri-infarct region relative to
injection with the scrambled. DNA enzyme control (p<0.05).
[0043] FIG. 14: (a) Shows inhibition of fibroblast proliferation
and cardiomyocyte apoptosis resulted in significant reduction of
mature scar deposition in the infarct zone, from a mean of 35% for
animals receiving control scrambled DNA enzyme to a mean of 20% for
those receiving VDUP1 DNA enzyme (p<0.01). (b) Shows animals
receiving VDUP1 DNA enzyme demonstrated a 50% mean recovery in
cardiac function, as determined by ejection fraction, whereas no
improvement was seen in animals receiving scrambled control DNA
enzyme (p<0.01)
[0044] FIG. 15: (a) Shows that G-CSF, when used systematically at
the same dosages after myocardial infarction, is a more potent
inducer of cardiac neovascularization than GM-CSF. (B) Shows G-CSF
is a more potent inhibitor of cardiomyocyte apoptosis than
GM-CSF.
[0045] FIG. 16: (a) Shows G-CSF is a more potent inducer of
cardiomyocyte regeneration than GM-CSF, and (b) shows that G-CSF
enables significantly greater recovery of cardiac function after
acute myocardial infarction.
[0046] FIG. 17: (a) Shows intravenous administration of anti-CXCR4
monoclonal antibody after acute myocardial infarction induces
significantly greater numbers of blood vessels at the peri-infarct
region. (b) Shows the greater recovery of cardiac/myocardial
function than with control antibodies.
[0047] FIG. 18: Shows myocardial expression of SDF-1 mRNA increased
by two weeks, but not within the first 48 hours after myocardial
infarction, and is inhibited by subcutaneously injecting
GM-CSF.
[0048] FIG. 19: (a) Shows intramyocardial injection of SDF-1
induces neovascularization at the peri-infarct region and (b)
protects cardiomyocytes at the peri-infarct region against
apoptosis.
[0049] FIG. 20: (a) Shows intramyocardial administration of SDF-1
alone, and synergistically with GM-CSF induces cardiomyocyte
regeneration at the peri-infarct region, and (b) improves cardiac
function.
[0050] FIG. 21: (a) Shows Human angioblasts, or endothelial
progenitor cells, induce neovascularization as early as 5 days
post-infarct. (b) Shows Human angioblasts, or endothelial
progenitor cells protect peri-infarct cardiomyocytes against
apoptosis as early as 5 days post infarct.
[0051] FIG. 22: (a) Shows animals receiving human bone
marrow-derived CD34+ cells demonstrated numerous clusters of small,
cycling cells at the peri-infarct region that were of rat origin,
as defined by a monoclonal antibody specific for rat Ki67. (b)
Shows tissues obtained from animals sacrificed at two weeks after
human CD34+ administration no longer demonstrated clusters of
small, cycling cardiomyocyte progenitors, but instead a high
frequency of large, mature rat cardiomyocytes at the peri-infarct
region with detectable DNA activity, as determined by dual staining
with mAbs reactive against cardiomyocyte-specific troponin I and
mAbs reactive against rat Ki67. (c) Shows cycling by the same
staining.
[0052] FIG. 23: Shows by RT-PCR, HBP23 mRNA levels in rat hearts
decreased at two weeks post-LAD ligation by a mean of 34% compared
with normal rat hearts.
[0053] FIG. 24: (a) Shows a DNA enzyme against HBP23 cleaved the
23-base oligonucleotide synthesized from the sequence of rat HBP23
mRNA, in a dose- and time-dependent manner. (b) Shows densitometric
analysis of RT-PCR products following reverse transcription of
cellular mRNA, demonstrating the HBP23 DNA enzyme inhibited
steady-state mRNA levels in cultured rat cells by over 80% relative
to the scrambled DNA.
[0054] FIG. 25: (a) Shows HBP23 DNA enzyme had no effect on
induction of neovascularization by human bone marrow angioblasts,
no increased myocardial capillary density in comparison to saline
controls is seen. (b) Shows injection of the HBP23 DNA enzyme, but
not the scrambled control, abrogated the anti-apoptotic effects of
neovascularization. (c) Shows injection of the HBP23 DNA enzyme,
but not the scrambled control, abrogated the improvement in cardiac
function.
[0055] FIG. 26: (a) This figure shows the pattern of CXCR4
expression following acute myocardial ischemia is focal and
peri-infarct. (b) Myocardial infarct bed two weeks post myocardial
infarction from a representative animal shows CXCR4 staining in
dark gray expressed in peri-infarct cardiomyocytes.
[0056] FIG. 27: Single myocardial injection of SDF-1 after acute
ischemia induces early phosphorylation of potein kinase B (AKT).
SDF-1 intramyocardial administration (4 ug/kg) at time of
infarction results in significant early phosphorylation of AKT at
24 hours post-myocardial infarction compared to animals receiving
saline controls. This effect was not measurable at two weeks
post-myocardial infarction.
[0057] FIG. 28: Cultured rat neonatal cardiomyocytes express CXCR4.
Cultured rat neonatal cardiomyocytes in vitro highly express CXCR4
throughout the cytoplasm as defined by immunohistochemical staining
using a mAb that cross reacts with rat CXCR4 (dark gray in
.times.200 and .times.400).
[0058] FIG. 29: SDF-1 induces phosphorylation of AKT and ERK in rat
neonatal cariomyocytes in time dependent manner. The left hand
panel shows optimal phosphorylation of AKT as early as five minutes
when cultured rat neonatal cardiomyocytes are cultured with 100 nM
of SDF-1. Right hand panel similarly demonstrates maximal ERK
phosphorylation at ten minutes as defined by western blot
analysis.
[0059] FIG. 31: Intracardiac administration of SDF-1 augments
CSF-induced neovascularization and regeneration following acute
ischemia. The left hand panel shows that the combination of
subcutaneous G-CSF and intracardiac SDF-1 administration results in
slightly higher numbers of large diameter blood vessels as defined
by having greater than 6 nuclei per high power field. The right
hand panel shows similar ratios are observed with the number of
cardiomyocytes entering cell cycle as defined by KI67 and troponin
I co-staining at two weeks post myocardial infarction.
[0060] FIG. 32: Intracardiac administration of SDF-1 augments
CSF-induced functional myocardial recovery following myocardial
ischemia. The combination of subcutaneous G-CSF and intracardiac
SDF-1 administration results in over a 35% improvement in ejection
fraction as defined by M-mode echocardiography at two weeks post
myocardial infarction. In contrast animals receiving saline or only
of subcutaneous GM-CSF had an additional regression in cardiac
functional capacity.
[0061] FIG. 30: SDF-1 protects rat neonatal cardiomyocytes against
H.sub.2O.sub.2-induced apoptosis in a dose dependent manner. The
left hand panel demonstrates the protective effect of SDF-1 using
the highest concentration (10 .mu.M). The right hand panel
demonstrates at the highest concentration of H.sub.2O.sub.2 the
protective effects of SDF-1 on cardiomyocyte apoptotic death
following H.sub.2O.sub.2 stimulation is dose dependent with 10
.mu.M having maximal effects. Medium=no SDF.
DETAILED DESCRIPTION
[0062] As used herein, "VEGF" is defined as vascular endothelial
growth factor. "VEGF-R" is defined as vascular endothelial growth
factor receptor. "FGF" is defined as fibroblast growth factor.
"IGF" is defined as Insulin-like growth factor. "SCF" is defined as
stem cell factor. "G-CSF" is defined as granulocyte colony
stimulating factor. "M-CSF" is defined as macrophage colony
stimulating factor. "GM-CSF" is defined as granulocyte-macrophage
colony stimulating factor. "MAPK" is mitogen-activated protein
kinase. "MCP" is defined as monocyte chemoattractant protein. "AKT"
is a serine/threonine kinase also known as protein kinase B (PKB).
"ERK" is extracellular signal-regulated protein kinase.
[0063] As used herein "angioblasts" is synonymous with the term
"endothelial progenitor cells".
[0064] As used herein, "CXC" chemokine refers to the structure of
the chemokine. Each "C" represents a cysteine and "X" represents
any amino acid. "CXCR4" refers to CXC receptor 4.
[0065] As used herein, "CC" chemokine refers to the structure of
the chemokine. Each "C" represents a cysteine.
[0066] A "cardiac progenitor cell" refers to a cell that is
resident in the heart, or that comes into the heart from elsewhere
after acute ischemia, is smaller than mature cardiomyocytes,
expresses alpha sarcomeric actin but is negative for troponin, is
normally quiescent but can be induced to go into cell cycle as
defined by positive Ki67 staining. "Cardiac progenitor cell" may be
used synonymously with "cardiomyocyte progenitor cell".
[0067] "Catalytic" shall mean the functioning of an agent as a
catalyst, i.e. an agent that increases the rate of a chemical
reaction without itself undergoing a permanent structural
change.
[0068] "Nucleic acid" shall include without limitation any nucleic
acid, including, without limitation, DNA, RNA, oligonucleotides, or
polynucleotides, and analogs or derivatives thereof. The
nucleotides that form the nucleic acid may be nucleotide analogs or
derivatives thereof. The nucleic acid may incorporate non
nucleotides.
[0069] "Nucleotides" shall include without limitation nucleotides
and analogs or derivatives thereof. For example, nucleotides may
comprise the bases A, C, G, T and U, as well as derivatives
thereof. Derivatives of these bases are well known in the art, and
are exemplified in PCR Systems, Reagents and Consumables (Perkin
Elmer Catalogue 1996-1997, Roche Molecular Systems, Inc.,
Branchburg, N.J., USA).
[0070] "Proliferation" and "regeneration" are used synonymously
when referring to cardiomyocytes in this application.
"Proliferation" in respect to cardiomyocytes, shall mean a fold
increase in proportion of cardiomyocytes entering the cell cycle
relative to untreated rat heart.
[0071] "Systemic" administration includes, not is not limited to,
intramuslcular, sub-cutaneous, intravascular, and intraperitoneal
administration. In other forms of administration, each and any of
the agents may be administered intracoronarily, intramyocardially,
and by stent, scaffold or slow release formation also.
[0072] "Tissue" includes heart tissue and, in that embodiment,
"cells" include cardiomyocytes. "Tissue" may also include lung,
brain, gastrointestinal, liver, kidney and other tissues. "Cells"
also includes stem cells which can differentiate into the cell type
being lost or progenitors of the cell type being lost in the
disorder of the tissue.
[0073] "Trafficking" means the blood-borne migration of cells, in
particular angioblast/endothelial progenitor cells.
[0074] This invention provides a method of treating a disorder of a
subject's heart involving loss of cardiomyocytes which comprises
administering to the subject a composition comprising an amount of
a human stromal-derived factor-1 and an amount of a human
granulocyte-colony stimulating factor, the composition being
administered in an amount effective to cause proliferation of
cardiomyocytes within the subject's heart so as to thereby treat
the disorder.
[0075] This invention further provides the instant method, wherein
the human stromal-derived factor-1 is human stromal-derived
factor-1.alpha., human stromal-derived factor-1.beta., or human
stromal-derived factor-ly.
[0076] This invention further provides the instant method, wherein
the tissue is heart tissue and the cells are cardiomyocytes. This
invention further provides the instant method, wherein the disorder
comprises myocardial infarction, congestive heart failure, chronic
ischemia, or ischemic disease.
[0077] This invention further provides the instant method, further
comprising administering to the subject an amount of one or more of
a human granulocyte macrophage-colony stimulating factor, a human
interleukin-8, a human vascular endothelial growth factor, a human
fibroblast growth factor, a human Gro family chemokine, human
endothelial progenitor cells, or a pro-angiogenic agent, the
amount, or if appropriate amounts, thereof being effective to cause
proliferation of cardiomyocytes within the subject's heart so as to
thereby treat the disorder.
[0078] This invention further provides the instant method, wherein
the composition is administered intramyocardially, intracoronarily,
via a stent, a scaffold, or a slow-release formulation.
[0079] This invention also provides a method of treating a subject
suffering from a disorder of a tissue involving loss and/or
apoptosis of cells of the tissue which comprises administering to
the subject a composition comprising an amount of an agent which
induces phosphorylation and/or activation of protein kinase B, the
composition being administered in an amount effective to cause
proliferation of the cells and/or inhibit apoptosis of the cells of
the tissue within the subject so as to thereby treat the
disorder.
[0080] This invention further provides the instant method, wherein
the agent is human human stromal-derived factor-la, human
stromal-derived factor-1.beta., or human stromal-derived
factor-1.gamma..
[0081] This invention further provides the instant method, wherein
the tissue is heart tissue and the cells are cardiomyocytes. This
invention further provides the instant method, wherein the disorder
from which the subject is suffering comprises myocardial
infarction, congestive heart failure, chronic ischemia, or ischemic
disease.
[0082] This invention further provides the instant method, wherein
the tissue is heart tissue and the cells are progenitors of
cardiomyocytes or stem cells that differentiate to
cardiomyocytes.
[0083] This invention further provides the instant method, wherein
the tissue is striated muscle, liver, kidney, neuronal or
gastrointestinal tissue.
[0084] This invention further provides the instant method, wherein
the agent is insulin, endothelin-1, urocrotin, cardiotropin-1,
erythropoietin, leukemia inhibitory factor-1, tumor necrosis
factor-alpha.
[0085] This invention further provides the instant method, further
comprising administering an amount of one or more of a human
granulocyte-colony stimulating factor, a human stromal-derived
factor-1, a human granulocyte macrophage-colony stimulating factor,
a human interleukin-8, a human vascular endothelial growth factor,
a human fibroblast growth factor, a human Gro family chemokine,
human endothelial progenitor cells, or a pro-angiogenic agent, the
amount, or if appropriate amounts, effective to cause proliferation
of the cells and/or inhibit apoptosis of the cells of the tissue of
the subject so as to thereby treat the disorder.
[0086] This invention further provides the instant method, wherein
the composition is administered intramyocardially, intracoronarily,
via a stent, a scaffold, a slow-release formulation,
intramuscularly, intravenously, intra-arterially, or
sub-cutaneously.
[0087] This invention also provides a composition comprising a
human stromal-derived factor-1 and a human granulocyte-colony
stimulating factor.
[0088] This invention also provides a method of treating a subject
suffering from a disorder of a tissue involving loss and/or
apoptosis of cells of the tissue which comprises administering to
the subject a composition comprising an amount of an agent which
induces phosphorylation and/or activation of an extracellular
signal-regulated protein kinase, the composition being administered
in an amount effective to inhibit apoptosis and/or cause
proliferation of the cells of the tissue within the subject so as
to thereby treat the disorder.
[0089] This invention further provides the instant method, wherein
the agent is human human stromal-derived factor-la, human
stromal-derived factor-1.beta., or human stromal-derived
factor-1.gamma..
[0090] This invention further provides the instant method, wherein
the tissue is heart tissue and the cells are cardiomyocytes. This
invention further provides the instant method, wherein the disorder
from which the subject is suffering comprises myocardial
infarction, congestive heart failure, chronic ischemia, or ischemic
disease.
[0091] This invention further provides the instant method, wherein
the tissue is heart tissue and the cells are progenitors of
cardiomyocytes or stem cells that differentiate to
cardiomyocytes.
[0092] This invention further provides the instant method, further
comprising administering an amount of one or more of a human
granulocyte-colony stimulating factor, a human stromal-derived
factor-1, a human granulocyte macrophage-colony stimulating factor,
a human interleukin-8, a human vascular endothelial growth factor,
a human fibroblast growth factor, a human Gro family chemokine,
human endothelial progenitor cells, an activator of protein kinase
B, or a pro-angiogenic agent, the amount, or if appropriate
amounts, thereof being effective to inhibit apoptosis and/or cause
proliferation of the cells of the tissue within the subject so as
to thereby treat the disorder.
[0093] This invention further provides the instant method, wherein
the agent is administered intramyocardially, intracoronarily, via a
stent, a scaffold, or a slow-release formulation, intramuscularly,
intravenously, intra-arterially, or sub-cutaneously.
[0094] This invention also provides the method of treating a
subject suffering from a disorder of a tissue involving loss and/or
apoptosis of cells of the tissue which comprises administering to
the subject a composition comprising an amount of an agent which
induces activation of CXCR4, the composition being administered in
an amount effective to cause proliferation of the cells and/or
inhibit apoptosis of the cells of the tissue within the subject so
as to thereby treat the disorder.
[0095] This invention further provides the instant method, wherein
the tissue is heart tissue and the cells are cardiomyocytes. This
invention further provides the instant method, wherein the agent is
administered intramyocardially or intracoronarily via a stent, a
scaffold, or a slow-release formulation.
[0096] This invention further provides the instant method, wherein
the agent is administered systemically.
[0097] This invention further provides the use of an amount of a
human stromal-derived factor-1 and an amount of a human
granulocyte-colony stimulating factor for the manufacture of a
composition for treating a disorder of a subject's heart involving
loss of cardiomyocytes.
[0098] This invention further provides the use of an agent which
induces phosphorylation and/or activation of protein kinase B for
the manufacture of a composition for treating a disorder of a
subject's tissue involving loss of the cells of the tissue.
[0099] This invention further provides the use of an amount of an
agent which induces phosphorylation and/or activation of
extracellular signal regulated protein kinase for the manufacture
of a composition for treating a disorder of a subject's tissue
involving loss of the cells of the tissue.
[0100] This invention further provides the use of an amount of an
agent which induces activation of CXCR4 for the manufacture of a
composition for treating a disorder of a subject's tissue involving
loss of cells of the tissue.
[0101] This invention provides a method of treating a disorder of a
subject's heart involving loss of cardiomyocytes which comprises
administering to the subject an amount of an agent effective to
cause cardiomyocyte proliferation within the subject's heart so as
to thereby treat the disorder.
[0102] In one embodiment the agent is human endothelial progenitor
cells. In one embodiment the endothelial progenitor cells are bone
marrow-derived. In another they are derived from cord blood, or
embryonic or fetal sources. Effective amounts of endothelial
progenitor cells sufficient to cause cardiomyocyte proliferation
can be done based on animal data using routine computational
methods. In one embodiment the effective amount is about
1.5.times.10.sup.5 endothelial progenitor cells per kg body mass to
about 3.times.10.sup.5 per kg body mass. In another embodiment the
effective amount is about 3.times.10.sup.5 per kg body mass to
about 4.5.times.10.sup.5 endothelial progenitor cells per kg body
mass. In another embodiment the effective amount is about
4.5.times.10.sup.5 per kg body mass to about 5.5.times.10.sup.5
endothelial progenitor cells per kg body mass. In another
embodiment the effective amount is about 5.5.times.10.sup.5 per kg
body mass to about 7.times.10.sup.5 endothelial progenitor cells
per kg body mass. In another embodiment the effective amount is
about 7.times.10.sup.5 per kg body mass to about 1.times.10.sup.6
endothelial progenitor cells per kg body mass. In another
embodiment the effective amount is about 1.times.10.sup.6 per kg
body mass to about 1.5.times.10.sup.5 endothelial progenitor cells
per kg body mass. In one embodiment the effective amount of human
endothelial progenitor cells is between about 1.5.times.10.sup.5
and 4.5.times.10.sup.5 endothelial progenitor cells per kg of the
subject's body mass and in a preferred embodiment the effective
amount is about 5.times.10.sup.5 endothelial progenitor cells per
kg of the subject's body mass.
[0103] In one embodiment the endothelial progenitor cells are
allogeneic with respect to the subject. In differing embodiments
the subject is an adult or an embryo or a fetus. In another
embodiment the endothelial progenitor cells are derived from cloned
autologous embryonic stem cells.
[0104] In one embodiment the agent induces expression of a mRNA
encoding a peroxiredoxin. The expression of peroxiredoxin mRNA may
be increased, for example, by administration of
2(3)-t-butyl-4-hydroxyanisole (BHA) (see 106) which has been shown
to increase expression of Peroxiredoxin-1 when administered by
diet. Alternatively, local control of 0.sub.2 can have the same
effect (see 107). Peroxiredoxin mRNA expression, such as that of
thiol peroxidases, may also be induced by heme, cadmium or cobalt
(see 108). Peroxiredoxins include, but are not limited to, PAG,
HBP23, MSP23, NKEF.
[0105] In another embodiment the agent induces expression of a mRNA
encoding NF-E2-related factor 2 (Nrf2). Cytomplasmic NF-E2-related
factor 2 (Nrf2) expression can be indirectly increased by raising
free Nrf2 levels. Since Nrf2 is tightly bound to keap1 in the
cytoplasm then reducing expression of keap1 mRNA is a suitable
target e.g. by keap1 antisense oligonucleotides or catalytic
nucleic acids (see 109 for keap1). Also, blocking the interaction
between Nrf2 and Keap1 by inhibiting the interaction of the Neh2
domain of Nrf2 and the DGR domain of keap1, e.g. by using the
entire Neh2 domain of nrf2, amino acids 1-73, or only the
hydrophilic region, amino acids 33-73 (see 109) will increase free
cytoplasmic Nrf-2. In another embodiment the agent induces
dissociation of a Nrf2 protein from a Keap-1. In another embodiment
the agent inhibits association of a Nrf2 protein with a Keap-1. In
another embodiment the agent inhibits association of a thiol
reductase thioredoxin with a VDUP-1 protein. In another embodiment
the agent inhibits c-Abl tyrosine kinase activation. In a further
embodiment the agent is STI-571.
[0106] In one embodiment the agent is a CXC chemokine. In further
embodiments the agent is Stromal-Derived Factor-1, 11-8 or
Gro-Alpha. In one embodiment the amount of CXC chemokine
administered is between 0.2 and 5 .mu.g/ml at a max volume of 10 ml
for a 70 kg human subject. In a preferred embodiment the amount is
about 1 .mu.g/ml. In one embodiment the agent is an inhibitor of
plasminogen activator inhibitor-1. In another embodiment the agent
is an antibody directed against an epitope of CXCR4. In one
embodiment the amount of antibody directed against an epitope of
CXCR4 is between 25 and 75 .mu.g/ml, at a max volume of 10 ml for a
70 kg human subject. A simple calculation is performed for subjects
of different mass. In a preferred embodiment the amount is about 50
.mu.g/ml.
[0107] In differing embodiments the agent is Stromal-Derived
Factor-1 alpha or Stromal-Derived Factor-1 beta. In differing
embodiments the chemokine can be administered intramyocardially,
intracoronary, and/or via a stent, a scaffold, or as a slow-release
formulation.
[0108] In differing embodiments the agent is G-CSF, GM-CSF, or a
Gro family chemokine. In a further embodiment the agent is Gro
alpha.
[0109] SDF variants may be employed in the present invention. For
example, a mutein, an analog, fusion protein, functional
derivative, isoform, allelic variant or effective fragment of SDF.
The amino acid sequence of a number of different native mammalian
SDF-1 alpha, beta and gamma proteins are known, including human,
rat, mouse, and cat. See, e. g., Shirozu et al., Genomics, 28: 495,
1995; Tashiro et al., Science 261: 600, 1993; Nishimura et al.,
Eur. J. Immunogenet. 25: 303, 1998; and GenBank Accession No.
AF189724. A preferred form of SDF-1 protein is a purified native
SDF-1 protein that has an amino acid sequence identical to one of
the foregoing mammalian SDF-1 proteins. Variants of native
mammalian SDF-1 proteins such as fragments, analogs and derivatives
of native mammalian SDF-1 proteins may also be used in the
invention. Such variants include, e. g., a polypeptide encoded by a
naturally occurring allelic variant of native SDF-1 gene (i. e., a
naturally occurring nucleic acid that encodes a naturally occurring
mammalian SDF-1 protein), a polypeptide encoded by an alternative
splice form of a native SDF-1 gene, a polypeptide encoded by a
homolog of a native SDF-1 gene, and a polypeptide encoded by a
non-naturally occurring variant of a native SDF-1 gene. SDF-1
protein variants have a peptide sequence that differs from a native
SDF-1 protein in one or more amino acids. The peptide sequence of
such variants can feature a deletion, addition, or substitution of
one or more amino acids of a native SDF-1 protein. Amino acid
insertions are preferably of about 1 to 4 contiguous amino acids,
and deletions are preferably of about 1 to 10 contiguous amino
acids. In some applications, variant SDF-1 proteins substantially
maintain a native SDF-1 protein functional activity (e.g., the
ability to cause cellular chemotaxis). For other applications,
variant SDF-1 proteins lack or feature a significant reduction in a
SDF-1 protein functional activity. Where it is desired to retain a
functional activity of native SDF-1 protein, preferred SDF-1
protein variants can be made by expressing nucleic acid molecules
within the invention that feature silent or conservative changes.
Variant SDF-1 proteins with substantial changes in functional
activity can be made by expressing nucleic acid molecules within
the invention that feature less than conservative changes.
[0110] SDF-1 protein fragments corresponding to one or more
particular motifs and/or domains or to arbitrary sizes, for
example, at least 5, 10, 25, 50, or 75 amino acids in length are
within the scope of the present invention. Isolated peptidyl
portions of SDF-1 proteins can be obtained by screening peptides
recombinantly produced from the corresponding fragment of the
nucleic acid encoding such peptides. In addition, fragments can be
chemically synthesized using techniques known in the art such as
conventional Merrifield solid phase f-Moc or t-Boc chemistry. For
example, a SDF-1 protein of the present invention may be
arbitrarily divided into fragments of desired length with no
overlap, of the fragments, or preferably divided into overlapping
fragments of a desired length. The fragments can be produced
(recombinantly or by chemical synthesis) and tested to identify
those peptidyl fragments which can function as either agonists or
antagonists of native SDF-1 protein. Another aspect of the present
invention concerns recombinant forms of the SDF-1 proteins.
Recombinant polypeptides preferred by the present invention, in
addition to a native SDF-1 protein, are encoded by a nucleic acid
that has at least 85% sequence identity (e.g., 85, 86, 87, 88, 89,
90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100%) with the nucleic acid
sequence of a gene encoding a mammalian SDF-1 protein. In a
preferred embodiment, variant SDF-1 proteins have one or more
functional activities of native SDF-1 protein.
[0111] SDF-1 protein variants can be generated through various
techniques known in the art. For example, SDF-1 protein variants
can be made by mutagenesis, such as by introducing discrete point
mutation (s), or by truncation. Mutation can give rise to a SDF-1
protein variant having substantially the same, or merely a subset
of the functional activity of native SDF-1 protein. Alternatively,
antagonistic forms of the protein can be generated which are able
to inhibit the function of a naturally occurring form of the
protein, such as by competitively binding to another molecule that
interacts with a SDF-1 protein. In addition, agonistic forms of the
protein may be generated that constitutively express on or more of
the functional activities of a native SDF-1 protein. Other SDF-1
protein variants that can be generated include those that are
resistant to proteolytic cleavage, as for example, due to mutations
which alter protease target sequences. Whether a change in the
amino acid sequence of a peptide results in a variant having one or
more functional activities of a native SDF-1 protein can be readily
determined by testing the variant for a native SDF-1 protein
functional activity.
[0112] As another example, SDF-1 protein variants can be generated
from a degenerate oligonucleotide sequence. Chemical synthesis of a
degenerate gene sequence can be carried out in an automatic DNA
synthesizer, and the synthetic genes then ligated into an
appropriate expression vector. The purpose of a degenerate set of
genes is to provide, in one mixture, all of the sequences encoding
the desired set of potential SDF-1 protein sequences. The synthesis
of degenerate oligonucleotides is well known in the art (see for
example, Narang, S A (1983) Tetrahedron 39: 3; Itakura et al.
(1981) Recombinant DNA, Proc 3rd Cleveland Sympos. Macromolecules,
ed. AG Walton, Amsterdam: Elsevier pp 273-289; Itakura et al.
[0113] As used herein "a human stromal-derived factor-1" means a
polypeptide which has the same or substantially the same amino acid
sequence and biological activity as a naturally occurring human
stromal-derived factor-1, including specifically, any of human
stromal-derived factor-1.alpha., 1.beta., or 1.gamma.. The term
"human stromal-derived factor-1" thus encompasses polypeptides
which have one or more additional amino acids, typically less than
5 additional amino acids at either the N-terminus or the C-terminus
or both so long as the biological activity is retained, and
specifically includes a polypeptide having an N-terminal methionine
added to the sequence present in a naturally occurring
stromal-derived factor-1. The term also encompasses conjugates with
other substances, polyethylene glycol conjugates, i.e. so-called
pegylated form of the polypeptide.
[0114] As used herein "a human granulocyte-colony stimulating
factor" means a polypeptide which has the same or substantially the
same amino acid sequence and biological activity as a naturally
occurring human granulocyte-colony stimulating factor. The term
"human granulocyte-colony stimulating factor" thus encompasses
polypeptides which have one or more additional amino acids,
typically less than 5 additional amino acids at either the
N-terminus or the C-terminus or both so long as the biological
activity is retained, and specifically includes a polypeptide
having an N-terminal methionine added to the sequence present in a
naturally occurring granulocyte-colony stimulating factor. The term
also encompasses conjugates with other substances, polyethylene
glycol conjugates, i.e. so-called pegylated form of the
polypeptide.
[0115] As used herein "a human granulocyte macrophage-colony
stimulating factor" means a polypeptide which has the same or
substantially the same amino acid sequence and biological activity
as a naturally occurring human granulocyte macrophage-colony
stimulating factor. The term "human granulocyte macrophage-colony
stimulating factor" thus encompasses polypeptides which have one or
more additional amino acids, typically less than 5 additional amino
acids at either the N-terminus or the C-terminus or both so long as
the biological activity is retained, and specifically includes a
polypeptide having an N-terminal methionine added to the sequence
present in a naturally occurring granulocyte macrophage-colony
stimulating factor. The term also encompasses conjugates with other
substances, polyethylene glycol conjugates, i.e. so-called
pegylated form of the polypeptide.
[0116] As used herein "a human interleukin 8" means a polypeptide
which has the same or substantially the same amino acid sequence
and biological activity as a naturally occurring human interleukin
8. The term "human interleukin 8" thus encompasses polypeptides
which have one or more additional amino acids, typically less than
5 additional amino acids at either the N-terminus or the C-terminus
or both so long as the biological activity is retained, and
specifically includes a polypeptide having an N-terminal methionine
added to the sequence present in a naturally occurring interleukin
8. The term also encompasses conjugates with other substances,
polyethylene glycol conjugates, i.e. so-called pegylated form of
the polypeptide.
[0117] As used herein "a human vascular endothelial growth factor"
means a polypeptide which has the same or substantially the same
amino acid sequence and biological activity as a naturally
occurring human vascular endothelial growth factor. The term "human
vascular endothelial growth factor" thus encompasses polypeptides
which have one or more additional amino acids, typically less than
5 additional amino acids at either the N-terminus or the C-terminus
or both so long as the biological activity is retained, and
specifically includes a polypeptide having an N-terminal methionine
added to the sequence present in a naturally occurring vascular
endothelial growth factor. The term also encompasses conjugates
with other substances, polyethylene glycol conjugates, i.e.
so-called pegylated form of the polypeptide.
[0118] As used herein "a human fibroblast growth factor" means a
polypeptide which has the same or substantially the same amino acid
sequence and biological activity as a naturally occurring human
fibroblast growth factor. The term "human fibroblast growth factor"
thus encompasses polypeptides which have one or more additional
amino acids, typically less than 5 additional amino acids at either
the N-terminus or the C-terminus or both so long as the biological
activity is retained, and specifically includes a polypeptide
having an N-terminal methionine added to the sequence present in a
naturally occurring fibroblast growth factor. The term also
encompasses conjugates with other substances, polyethylene glycol
conjugates, i.e. so-called pegylated form of the polypeptide.
[0119] In a further embodiment the instant method further comprises
administering an effective amount of a second agent that increases
the cardiomyocyte proliferation caused by the human endothelial
progenitor cells. Effective amounts of the second agent are amounts
sufficient to enhance or accelerate cardiomyocyte proliferation in
the presence of administered endothelial progenitor cells. In
further embodiments the endothelial progenitor cells express CD117,
CD34, AC133 or a high level of intracellular GATA-2 activity. In
one embodiment the administering comprises injecting directly into
the subject's peripheral circulation, heart muscle, left ventricle,
right ventricle, coronary artery, cerebro-spinal fluid, neural
tissue, ischemic tissue, or post-ischemic tissue.
[0120] In one embodiment the second agent is an antisense
oligonucleotide which specifically inhibits translation of Vitamin
D3 Up-Regulated Protein-1 (VDUP-1) mRNA.
[0121] Therapeutically useful targeted inhibition of VDUP-1 protein
(SEQ ID NO:2) expression can be achieved through the use of
antisense oligonucleotides. Antisense oligonucleotides are small
fragments of DNA and derivatives thereof complementary to a defined
sequence on a specified mRNA. A VDUP-1 antisense oligonucleotide
specifically binds to targets on the VDUP-1 mRNA (SEQ ID NO:1)
molecule and in doing so inhibits the translation thereof into
VDUP-1 protein (SEQ ID NO:2).
[0122] Antisense oligonucleotide molecules synthesized with a
phosphorothioate backbone have proven particularly resistant to
exonuclease damage compared to standard deoxyribonucleic acids, and
so they are used in preference. A phosphorothioate antisense
oligonucleotide for VDUP-1 mRNA can be synthesized on an Applied
Biosystems (Foster City, Calif.) model 380B DNA synthesizer by
standard methods. E.g. Sulfurization can be performed using
tetraethylthiuram disulfide/acetonitrile. Following cleavage from
controlled pore glass support, oligodeoxynucleotides can be base
deblocked in ammonium hydroxide at 60.degree. C. for 8 h and
purified by reversed-phase HPLC [0.1M triethylammonium
bicarbonate/acetonitrile; PRP-1 support]. Oligomers can be
detritylated in 3% acetic acid and precipitated with 2%
lithiumperchlorate/acetone, dissolved in sterile water and
re-precipitated as the sodium salt from 1 M NaCl/ethanol.
Concentrations of the full length species can be determined by UV
spectroscopy.
[0123] Any other means for such synthesis known in the art may
additionally or alternatively be employed. It is well known to use
similar techniques to prepare oligonucleotides such as the
phosphorothioates and alkylated derivatives.
[0124] Hybridization of antisense oligonucleotides with VDUP-1 mRNA
interferes with one or more of the normal functions of VDUP-1 1
mRNA. The functions of mRNA to be interfered with include all vital
functions such as, for example, translocation of the RNA to the
site of protein translation, translation of protein from the RNA,
splicing of the RNA to yield one or more mRNA species, and
catalytic activity which may be engaged in by the RNA.
[0125] Preferred modified oligonucleotide backbones include, for
example, phosphorothioates, chiral phosphorothioates,
phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters,
methyl and other alkyl phosphonates including 3'-alkylene
phosphonates, 5'-alkylene phosphonates and chiral phosphonates,
phosphinates, phosphoramidates including 3'-amino phosphoramidate
and aminoalkylphosphoramidates, thionophosphoramidates,
thionoalkylphosphonates, thionoalkylphosphotriesters,
selenophosphates and borano-phosphates having normal 3'-5'
linkages, 2'-5' linked analogs of these, and those having inverted
polarity wherein one or more internucleotide linkages is a 3' to
3', 5' to 5' or 2' to 2' linkage. Also, oligonucleotides having
inverted polarity comprise a single 3' to 3' linkage at the 3'-most
internucleotide linkage i.e. a single inverted nucleoside residue
which may be abasic (the nucleobase is missing or has a hydroxyl
group in place thereof) are included. Various salts, mixed salts
and free acid forms are also included.
[0126] Representative United States patents that teach the
preparation of the above phosphorus-containing linkages include,
but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863;
4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019;
5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496;
5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306;
5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555;
5,527,899; 5,721,218; 5,672,697 and 5,625,050, certain of which are
commonly owned with this application, and each of which is herein
incorporated by reference.
[0127] In accordance with this invention, persons of ordinary skill
in the art will understand that messenger RNA includes not only the
information to encode a protein using the three letter genetic
code, but also associated ribonucleotides which form a region known
to such persons as the 5'-untranslated region, the 3'-untranslated
region, the 5' cap region and intron/exon junction ribonucleotides.
Thus, antisense oligonucleotides or the catalytic nucleic acids
described below may be formulated in accordance with this invention
which are targeted wholly or in part to these associated
ribonucleotides as well as to the informational ribonucleotides.
The antisense oligonucleotides may therefore be specifically
hybridizable with a transcription initiation site region, a
translation initiation codon region, a 5' cap region, an
intron/exon junction, coding sequences, a translation termination
codon region or sequences in the 5'- or 3'-untranslated region.
Similarly, the catalytic nucleic acids may specifically cleave a
transcription initiation site region, a translation initiation
codon region, a 5' cap region, an intron/exon junction, coding
sequences, a translation termination codon region or sequences in
the 5'- or 3'-untranslated region. As is known in the art, the
translation initiation codon is typically 5'-AUG (in transcribed
mRNA molecules; 5'-ATG in the corresponding DNA molecule). A
minority of genes have a translation initiation codon having the
RNA sequence 5'-GUG, 5'UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG
have been shown to function in vivo. Thus, the term "translation
initiation codon" can encompass many codon sequences, even though
the initiator amino acid in each instance is typically methionine
in eukaryotes. It is also known in the art that eukaryotic genes
may have two or more alternative translation initiation codons, any
one of which may be preferentially utilized for translation
initiation in a particular cell type or tissue, or under a
particular set of conditions. In the context of the invention,
"translation initiation codon" refers to the codon or codons that
are used in vivo to initiate translation of an mRNA molecule
transcribed from a gene encoding VDUP-1, regardless of the
sequence(s) of such codons. It is also known in the art that a
translation termination codon of a gene may have one of three
sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA
sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The term
"translation initiation codon region" refers to a portion of such
an mRNA or gene that encompasses from about 25 to about 50
contiguous nucleotides in either direction (i.e., 5' or 3') from a
translation initiation codon. This region is one preferred target
region. Similarly, the term "translation termination codon region"
refers to a portion of such an mRNA or gene that encompasses from
about 25 to about 50 contiguous nucleotides in either direction
(i.e., 5' or 3') from a translation termination codon. This region
is also one preferred target region. The open reading frame or
"coding region," which is known in the art to refer to the region
between the translation initiation codon and the translation
termination codon, is also a region which may be targeted
effectively. Other preferred target regions include the 5'
untranslated region (5'UTR), known in the art to refer to the
portion of an mRNA in the 5' direction from the translation
initiation codon, and thus including nucleotides between the 5' cap
site and the translation initiation codon of an mRNA or
corresponding nucleotides on the gene, and the 3' untranslated
region (3'UTR), known in the art to refer to the portion of an mRNA
in the 3' direction from the translation termination codon, and
thus including nucleotides between the translation termination
codon and 3' end of an mRNA or corresponding nucleotides on the
gene. mRNA splice sites may also be preferred target regions, and
are particularly useful in situations where aberrant splicing is
implicated in disease, or where an overproduction of a particular
mRNA splice product is implicated in disease. Aberrant fusion
junctions due to rearrangements or deletions may also be preferred
targets.
[0128] Once the target site or sites have been identified,
antisense oligonucleotides can be chosen which are sufficiently
complementary to the target, i.e., hybridize sufficiently well and
with sufficient specificity, to give the desired disruption of the
function of the molecule. "Hybridization", in the context of this
invention, means hydrogen bonding, also known as Watson-Crick base
pairing, between complementary bases, usually on opposite nucleic
acid strands or two regions of a nucleic acid strand.
[0129] Guanine and cytosine are examples of complementary bases
which are known to form three hydrogen bonds between them. Adenine
and thymine are examples of complementary bases which form two
hydrogen bonds between them. "Specifically hybridizable" and
"complementary" are terms which are used to indicate a sufficient
degree of complementarity such that stable and specific binding
occurs between the DNA or RNA target and the catalytic nucleic
acids. Similarly, catalytic nucleic acids are synthesized once
cleavage target sites on the VDUP-1 mRNA molecule.
[0130] It is preferred to administer antisense oligonucleotides or
catalytic nucleic acids or analogs thereof or other agents to
mammals suffering from cardiovascular disease, in either native
form or suspended in a carrier medium in amounts and upon treatment
schedules which are effective to therapeutically treat the mammals
to reduce the detrimental effects of cardiovascular disease. One or
more different catalytic nucleic acids or antisense
oligonucleotides or analogs thereof targeting different sections of
the nucleic acid sequence of VDUP-1 mRNA may be administered
together in a single dose or in different doses and at different
amounts and times depending upon the desired therapy. The catalytic
nucleic acids or antisense oligonucleotides can be administered to
mammals in a manner capable of getting the oligonucleotides
initially into the blood stream and subsequently into cells, or
alternatively in a manner so as to directly introduce the catalytic
nucleic acids or antisense oligonucleotides into the cells or
groups of cells, for example cardiomyocytes, by such means by
electroporation or by direct injection into the heart. Antisense
oligonucleotides whose presence in cells can inhibit transcription
or protein synthesis can be administered by intravenous injection,
intravenous drip, subcutaneous, intraperitoneal or intramuscular
injection, orally or rectally. Human pharmacokinetics of certain
antisense oligonucleotides have been studied. See (105)
incorporated by reference in its entirety. It is within the scale
of a person's skill in the art to determine optimum dosages and
treatment schedules for such treatment regimens.
[0131] Any of the agents employed in this invention can be
administered intracoronary or intramyocardially, for example by
injection. The agents can be delivered in various means as
otherwise discussed, including by stents, such as drug-eluting
stents, and in time-release formats such as slow-release. Where the
agents are proteins, including but not limited to SDF-1, G-CSF,
GM-CSF, and VEGF, the agents can be administered directly or
indirectly, or may be administered via induction of gene
expression, through gene therapy, adenoviral delivery and other
such methods familiar to those skilled in the art.
[0132] Doses of the oligonucleotides or analogs thereof of the
present invention in a pharmaceutical dosage unit will be an
efficacious, nontoxic quantity administered to a human patient in
need of cardiomyocyte regeneration (or inhibition of VDUP-1
expression) from 1-6 or more times daily or every other day. Dosage
is dependent on severity and responsiveness of the effects of
abnormal cardiovascular disease to be treated, with course of
treatment lasting from several days to months or until a cure is
effected or a reduction of the effects is achieved. Oral dosage
units for human administration generally use lower doses. The
actual dosage administered may take into account the size and
weight of the patient, whether the nature of the treatment is
prophylactic or therapeutic in nature, the age, weight, health and
sex of the patient, the route of administration, and other
factors.
[0133] In another embodiment the second agent is a pro-angiogenic
agent. In further embodiments the pro-angiogenic agent is vascular
endothelial growth factor, fibroblast growth factor or
angiopoietin. In another embodiment the second agent induces
expression of a pro-angiogenic factor. In a further embodiment the
second agent is Hypoxia Inducible Factor-1.
[0134] In another embodiment the second agent is a catalytic
nucleic acid which specifically inhibits translation of Vitamin D3
Up-Regulated Protein-1 mRNA. In a further embodiment the catalytic
nucleic acid comprises deoxyribonucleotides. In another embodiment
the catalytic nucleic acid comprises ribonucleotides.
[0135] Catalytic nucleic acid molecules can cleave Vitamin D3
Up-Regulated Protein-1 (VDUP-1) mRNA (corresponding DNA shown in
SEQ ID NO:1, FIG. 5) at each and any of the consensus sequences
therein. Since catalytic ribo- and deoxyribo-nucleic acid consensus
sequences are known, and the VDUP-1 Protein mRNA sequence is known,
one of ordinary skill could readily construct a catalytic ribo- or
deoxyribo nucleic acid molecule directed to any of the VDUP-1
protein mRNA consensus sequences based on the instant
specification. In preferred embodiments of this invention the
catalytic deoxyribonucleic acids include the 10-23 structure.
Examples of catalytic ribonucleic acids include hairpin and
hammerhead ribozymes. In preferred embodiments of this invention,
the catalytic ribonucleic acid molecule is formed in a hammerhead
(50) or hairpin motif (51, 52, 53), but may also be formed in the
motif of a hepatitis delta virus (54), group I intron (60), RNaseP
RNA (in association with an RNA guide sequence) (55,56) or
Neurospora VS RNA (57, 58, 59).
[0136] To target the VDUP-1 mRNA (SEQ ID NO:1), catalytic nucleic
acids can be designed based on the consensus cleavage sites
5'-purine:pyrimidine-3' in the VDUP-1 mRNA sequence (104) (see
FIGS. 6-10) for cleavage sites on DNA corresponding to the mRNA
encoding VDUP-1 (SEQ ID NO:2). Those potential cleavage sites
located on an open loop of the mRNA according to RNA folding
software e.g. RNADRaw 2.1 are particularly preferred as targets
(61). The DNA based catalytic nucleic acids can utilize the
structure where two sequence-specific arms are attached to a
catalytic core based on the VDUP-1 mRNA sequence. Further examples
of catalytic DNA structure are detailed in (62) and (63).
Commercially available mouse brain polyA-RNA (Ambion) can serve as
a template in the in vitro cleavage reaction to test the efficiency
of the catalytic deoxyribonucleic acids. Catalytic RNA, is
described above, is designed similarly. Hammerhead ribozymes can
cleave any 5'-NUH-3' triplets of a mRNA, where U is conserved and N
is any nucleotide and H can be C,U,A, but not G. For example, the
sites which can be cleaved by a hammerhead ribozyme in human VDUP-1
mRNA coding region are shown in FIG. 10.
[0137] Cleaving of VDUP-1 mRNA with catalytic nucleic acids
interferes with one or more of the normal functions of VDUP-1 mRNA.
The functions of mRNA to be interfered with include all vital
functions such as, for example, translocation of the RNA to the
site of protein translation, translation of protein from the RNA,
splicing of the RNA to yield one or more mRNA species, and
catalytic activity which may be engaged in by the RNA.
[0138] The nucleotides may comprise other bases such as inosine,
deoxyinosine, hypoxanthine may be used. In addition, isoteric
purine 2'deoxy-furanoside analogs, 2'-deoxynebularine or
2'deoxyxanthosine, or other purine or pyrimidine analogs may also
be used. By carefully selecting the bases and base analogs, one may
fine tune the hybridization properties of the oligonucleotide. For
example, inosine may be used to reduce hybridization specificity,
while diaminopurines may be used to increase hybridization
specificity.
[0139] Adenine and guanine may be modified at positions N3, N7, N9,
C2, C4, C5, C6, or C8 and still maintain their hydrogen bonding
abilities. Cytosine, thymine and uracil may be modified at
positions N1, C2, C4, C5, or C6 and still maintain their hydrogen
bonding abilities. Some base analogs have different hydrogen
bonding attributes than the naturally occurring bases. For example,
2-amino-2'-dA forms three (3), instead of the usual two (2),
hydrogen bonds to thymine (T). Examples of base analogs that have
been shown to increase duplex stability include, but are not
limited to, 5-fluoro-2'-dU, 5-bromo-2'-dU, 5-methyl-2'-dC,
5-propynyl-2'-dC, 5-propynyl-2'-dU, 2-amino-2'-dA,
7-deazaguanosine, 7-deazadenosine, and
N2-Imidazoylpropyl-2'-dG.
[0140] Nucleotide analogs may be created by modifying and/or
replacing a sugar moiety. The sugar moieties of the nucleotides may
also be modified by the addition of one or more substituents. For
example, one or more of the sugar moieties may contain one or more
of the following substituents: amino, alkylamino, araalkyl,
heteroalkyl, heterocycloalkyl, aminoalkylamino, O, H, an alkyl,
polyalkylamino, substituted silyl, F, Cl, Br, CN, CF.sub.3,
OCF.sub.3, OCN, O-alkyl, S-alkyl, SOMe, SO.sub.2Me, ONO.sub.2,
NH-alkyl, OCH.sub.2CH.dbd.CH.sub.2, OCH.sub.2CCH, OCCHO, allyl,
O-allyl, NO.sub.2, N.sub.3, and NH.sub.2. For example, the 2'
position of the sugar may be modified to contain one of the
following groups: H, OH, OCN, O-alkyl, F, CN, CF.sub.3, allyl,
O-allyl, OCF.sub.3, S-alkyl, SOMe, SO.sub.2Me, ONO, NO.sub.2,
N.sub.3, NH.sub.2, NH-alkyl, or OCH.dbd.CH.sub.2, OCCH, wherein the
alkyl may be straight, branched, saturated, or unsaturated. In
addition, the nucleotide may have one or more of its sugars
modified and/or replaced so as to be a ribose or hexose (i.e.
glucose, galactose) or have one or more anomeric sugars. The
nucleotide may also have one or more L-sugars.
[0141] Representative United States patents that teach the
preparation of such modified bases/nucleosides/nucleotides include,
but are not limited to, U.S. Pat. Nos. 6,248,878, and 6,251,666
which are herein incorporated by reference.
[0142] The sugar may be modified to contain one or more linkers for
attachment to other chemicals such as fluorescent labels. In an
embodiment, the sugar is linked to one or more aminoalkyloxy
linkers. In another embodiment, the sugar contains one or more
alkylamino linkers. Aminoalkyloxy and alkylamino linkers may be
attached to biotin, cholic acid, fluorescein, or other chemical
moieties through their amino group.
[0143] Nucleotide analogs or derivatives may have pendant groups
attached. Pendant groups serve a variety of purposes which include,
but are not limited to, increasing cellular uptake of the
oligonucleotide, enhancing degradation of the target nucleic acid,
and increasing hybridization affinity. Pendant groups can be linked
to any portion of the oligonucleotide but are commonly linked to
the end(s) of the oligonucleotide chain. Examples of pendant groups
include, but are not limited to: acridine derivatives (i.e.
2-methoxy-6-chloro-9-aminoacridine); cross-linkers such as psoralen
derivatives, azidophenacyl, proflavin, and azidoproflavin;
artificial endonucleases; metal complexes such as EDTA-Fe(II),
o-phenanthroline-Cu(I), and porphyrin-Fe(II); alkylating moieties;
nucleases such as amino-1-hexanolstaphylococcal nuclease and
alkaline phosphatase; terminal transferases; abzymes; cholesteryl
moieties; lipophilic carriers; peptide conjugates; long chain
alcohols; phosphate esters; amino; mercapto groups; radioactive
markers; nonradioactive markers such as dyes; and polylysine or
other polyamines. In one example, the nucleic acid comprises an
oligonucleotide conjugated to a carbohydrate, sulfated
carbohydrate, or gylcan. Conjugates may be regarded as a way as to
introduce a specificity into otherwise unspecific DNA binding
molecules by covalently linking them to a selectively hybridizing
oligonucleotide.
[0144] The catalytic nucleic acid binding domains (i.e. the
non-catalytic domains) or antisense oligonucleotide may comprise
modified bonds. For example internucleosides bonds of the
oligonucleotide may comprise phosphorothioate linkages. The nucleic
acid may comprise nucleotides having moiety may be modified by
replacing one or both of the two bridging oxygen atoms of the
linkage with analogues such as --NH, --CH, or --S. Other oxygen
analogues known in the art may also be used. The phosphorothioate
bonds may be stereo regular or stereo random.
[0145] The oligonucleotide moiety may have one or more of its
sugars modified or replaced so as to be ribose, glucose, sucrose,
or galactose, or any other sugar. Alternatively, the
phosphorothioate oligonucleotide may have one or more of its sugars
substituted or modified in its 2' position, i.e. 2'allyl or
2'-O-allyl. An example of a 2'-O-allyl sugar is a
2'-O-methylribonucleotide. Further, the phosphorothioate
oligonucleotide may have one or more of its sugars substituted or
modified to form an .alpha.-anomeric sugar.
[0146] A catalytic nucleic acid may include non-nucleotide
substitution. The non-nucleotide substitution includes either
abasic nucleotide, polyether, polyamine, polyamide, peptide,
carbohydrate, lipid or polyhydrocarbon compounds. The term "abasic"
or "abasic nucleotide" as used herein encompasses sugar moieties
lacking a base or having other chemical groups in place of base at
the 1' position.
[0147] Determining the effective amount of the instant nucleic acid
molecules can be done based on animal data using routine
computational methods. In one embodiment, the effective amount
contains between about 10 ng and about 100 .mu.g of the instant
nucleic acid molecules per kg body mass. In another embodiment, the
effective amount contains between about 100 ng and about 10 .mu.g
of the nucleic acid molecules per kg body mass. In a further
embodiment, the effective amount contains between about 1 .mu.g and
about 5 .mu.g, and in a further embodiment about 2 .mu.g, of the
nucleic acid molecules per kg body mass.
[0148] In an embodiment the second agent promotes trafficking and
is a CC chemokine. In further embodiments the CC chemokine is
RANTES, EOTAXIN, monocyte chemoattractant protein-1 (MCP-1), MCP-2,
MCP-3, or MCP.
[0149] In an embodiment the second agent promotes trafficking and
is a CXC chemokine. In further embodiments the CXC chemokine is
Interleukin-8, Gro-Alpha, or Stromal-Derived Factor-1.
[0150] In an embodiment the second agent promotes mobilization of
angioblasts into the subject's bloodstream.
[0151] In an embodiment the cardiac progenitor cell is resident in
the heart, or that comes into the heart from elsewhere after acute
ischemia, is smaller than mature cardiomyocytes, expresses alpha
sarcomeric actin but is negative for troponin, is normally
quiescent but can be induced to go into cell cycle as defined by
positive Ki67 staining.
[0152] This invention further provides a method of improving
cardiac function in a subject comprising administering to the
subject an amount of an agent effective to induce proliferation of
cardiomyocytes in the heart tissue in the subject so as to thereby
improve cardiac function in the subject.
[0153] Cardiac function, or myocardial function, can be determined
by any combination of improvement in ejection fraction, perfusion,
reduction in anginal symptoms, improvement in quality of life,
increased walking ability, longevity of life, reduction in heart
medication, and/or prevention of heart failure, as this terms are
normally understood in the art. An improvement in cardiac function
in a subject is measured by determining any of these factors in a
subject before and after treatment by any of the instant methods.
In one embodiment of the instant methods, the subject has suffered
myocardial ischemia or myocardial infarct. In different embodiments
the agent is G-CSF, GM-CSF, IL-8, a Gro family chemokine, an
inhibitor of CXCR4, or an inhibitor of SDF-1. In further
embodiments the inhibitor of CXCR4 is a small molecule or a
monoclonal antibody, the inhibitor of CXCR4 is a small molecule and
is AMD 3100, the inhibitor of SDF-1 is a small molecule or a
monoclonal antibody, and the Gro family chemokine is Gro alpha. In
another embodiment the inhibitor is AMD 070. In differing
embodiments the the inhibitor of CXCR4 is a catalytic nucleic acid,
an oligonucleotide, RNAi, (RNA interference) or a small
molecule.
[0154] This invention further provides a method of inducing
apoptosis in a cell comprising inhibiting expression of a
peroxiredoxin in the cell. In one embodiment the cell is a tumor
cell. In different embodiments the peroxiredoxin is peroxiredoxin
I, II, II, IV, or V. In one embodiment the inhibition of expression
of peroxiredoxin is effected by contacting the cell with a
catalytic nucleic acid which binds mRNA encoding peroxiredoxin,
thereby inhibiting the expression thereof. In different embodiments
the inhibition of expression of peroxiredoxin is effected by
contacting the cell with an antisense oligonucleotide, a monoclonal
antibody, RNA interference or a small molecule.
[0155] This invention further provides a method of treating a
disorder of a tissue of a subject involving loss of tissue cells
which comprises administering to the subject an amount of an agent
effective to cause tissue cell proliferation within the tissue of
the subject so as to thereby treat the disorder. In differing
embodiments the tissue is cardiac tissue, brain tissue, peripheral
vascular tissue, hepatic tissue, renal tissue, gastrointestinal
tissue, lung tissue, smooth muscle tissue, or striated muscle
tissue. In differing embodiments the agent is G-CSF, SDF-1, GM-CSF,
IL-8, VEGF. In one embodiment the agent is an inhibitor of
CXCR4/SDF-1 interaction. In further embodiments the inhibitor is a
catalytic nucleic acid, a monoclonal antibody, a antisense
oligonucleotide, a small molecule, or RNAi. In one embodiment the
agent is an inducer of peroxiredoxin expression. In further
embodiments the peroxiredoxin is peroxiredoxin I, II, III, IV, or
V.
[0156] In any of the instant methods wherein the agent is G-CSF,
the G-CSF may be a covalent conjugate of recombinant methionyl
human G-CSF (Filgrastim) and monomethoxypolyethylene glycol, such
as Neulasta. Filgrastim is a water-soluble 175 amino acid protein
with a molecular weight of approximately 19 kilodaltons (kd).
Filgrastim is obtained from the bacterial fermentation of a strain
of Escherichia coli transformed with a genetically engineered
plasmid containing the human G-CSF gene. To produce pegfilgrastim,
a 20 kd monomethoxypolyethylene glycol molecule is covalently bound
to the N-terminal methionyl residue of Filgrastim. The average
molecular weight of pegfilgrastim is approximately 39 kd. Neulasta
is supplied in 0.6 mL prefilled syringes for subcutaneous (SC)
injection. Each syringe contains 6 mg pegfilgrastim (based on
protein weight), in a sterile, clear, colorless, preservative-free
solution (pH 4.0) containing acetate (0.35 mg), sorbitol (30.0 mg),
polysorbate 20 (0.02 mg), and sodium (0.02 mg) in water for
injection, USP.
[0157] This invention provides a method of treating a disorder of a
tissue of a subject involving apoptosis of cells in the tissue
which comprises administering to the subject an amount of an agent
effective to inhibit apoptosis of cells in the tissue within the
subject so as to thereby treat the disorder. In one embodiment the
agent is an inhibitor of VDUP-1 expression. In further embodiments
the inhibitor of VDUP-1 expression is catalytic nucleic acid, a
monoclonal antibody, an antisense oligonucleotide, a small
molecule, or an RNAi. In differing embodiments the tissue is
cardiac tissue, cerebrovascular tissue, or cerebral tissue.
[0158] This invention also provides a method of inhibiting
proliferation of fibroblasts or inflammatory cells in a tissue and
thereby inhibiting collagen formation comprising contacting the
tissue with an inhibitor of VDUP-1 expression. In one embodiment
the inhibitor of VDUP-1 expression is a catalytic nucleic acid, a
monoclonal antibody, an antisense oligonucleotide, a small
molecule, or an RNAi.
[0159] In one embodiment the subject of any of the above methods is
a mammal and in a preferred further embodiment the mammal is a
human being. In one embodiment the subject has a cardiovascular
disease. In further embodiments the subject has congestive heart
failure, has suffered a myocardial infarct, has suffered myocardial
ischemia, has angina, or has a cardiomyopathy.
[0160] This invention will be better understood by reference to the
Experimental Details which follow, but those skilled in the art
will readily appreciate that the specific experiments detailed are
only illustrative of the invention as described more fully in the
claims which follow thereafter.
Experimental Results (I)
CXC Chemokines Regulate Endothelial Progenitor Cell Migration to
the Heart.
[0161] We investigated the in vivo role of CXC receptor-ligand
interactions in mediating chemotaxis of human Endothelial
progenitor cell to ischemic tissue and subsequent induction of
vasculogenesis, using myocardial infarction in the LAD-ligated nude
rat model. As shown in FIG. 1a, DiI-labelled human CD34+ cells
obtained by G-CSF mobilization (>98% CD34 purity, containing
6-12% CD117.sup.bright endothelial progenitor cells) were
selectively detected in infarcted myocardium after intravenous
injection, but not in myocardium from sham-operated rats.
Co-administration of blocking mAbs against rat Cinc (the rat
homologue of human IL-8 and Gro-alpha), or against the human
surface receptors for these pro-angiogenic chemokines, CXCR1 or
CXCR2, reduced myocardial trafficking of human bone marrow-derived
CD34+ cells at 48 hours by 40-60% relative to control antibodies
(p<0.01), FIG. 1b. By two weeks, rats receiving human CD34+
cells demonstrated significantly increased infarct bed
microvascularity in comparison to rats receiving saline, FIG. 1c,
and this was reduced by 50% when anti-CXCR1/2 mAbs were
co-administered. Since we have previously shown that the
vasculogenic properties of CD34+ cells are abolished after
depletion of the minor CD117.sup.bright angioblast fraction (7),
these results indicate that by regulating angioblast migration to
ischemic tissues CXC chemokines influence the development of
vasculogenesis at these sites. In contrast, although direct
intracardiac injection of IL-8 or SDF-1 at 1.0 .mu.g/ml into
non-infarcted hearts resulted in 2.3 and 2.5-fold increases in
myocardial infiltration by human CD34+ cells at 48 hours (both
p<0.01), FIG. 1d, no vasculogenesis was observed at two weeks
under these conditions. Together, these results indicate that
following chemokine-induced migration to the infarct zone,
differentiation of endothelial progenitor cell to mature
endothelial cells and induction of vasculogenesis require
additional factors, as yet undefined, which are produced under
ischemic conditions.
Inhibiting CXCR4/SDF-1 Interactions Redirects Endothelial
Progenitor Cells to the Heart.
[0162] Although LAD coronary artery ligation resulted in
trafficking of intravenously injected human endothelial progenitor
cells to the site of ischemic myocardium, it was also accompanied
by increased distribution of human cells to rat bone marrow. As
shown in FIG. 2a, at 2-14 days after intravenous injection of
2.times.10.sup.6 human CD34+ cells bone marrow from LAD-ligated
rats contained 5-8 fold higher levels of human CD117.sup.bright
endothelial progenitor cells compared with bone marrow from normal
rats, p<0.001. This was presumably due to the proliferative
effects of factors in ischemic serum since we have previously shown
that culture for 2 days with ischemic serum increases proliferation
of CD34+CD117.sup.bright human endothelial progenitor cells by 4-5
fold (7). Because the migration of actively cycling CD34+ cells to
bone marrow is promoted by SDF-1 produced constitutively by marrow
stromal cells (31), we investigated whether the distribution of
human CD34+CD117.sup.bright endothelial progenitor cells to
ischemic rat bone marrow involved SDF-1/CXCR4 interactions. As
shown in FIG. 2b, co-administration of mAbs against either human
CXCR4 or rat SDF-1 significantly inhibited migration of
intravenously administered human endothelial progenitor cells to
ischemic rat bone marrow compared with anti-CD34 control antibody
(both p<0.001). Moreover, co-administration of mAbs against
either human CXCR4 or rat SDF-1 increased trafficking of CD34+
human endothelial progenitor cells to ischemic rat myocardium by
means of 24% and 17%, respectively (both p<0.001), FIG. 2c.
Capillary Lumen Size is Dependent on Absolute Angioblast
Numbers.
[0163] We next examined the relationship between angioblast number,
myocardial neovascularization, and protection against myocyte
apoptosis. Two days following LAD ligation animals were
intravenously injected with G-CSF mobilized CD34+ human cells
reconstituted with varying proportions of CD117.sup.bright
endothelial progenitor cells (10.sup.3, 10.sup.5, 10.sup.5 plus
anti-CXCR4 mAb, 2.times.10.sup.5, and 2.times.10.sup.5 plus
anti-CXCR4 mAb). Similar numbers of DiI-labelled human cells were
detected in the infarct zone 48 hours after injecting each cellular
population, data not shown. Induction of neovascularization at two
weeks was measured by performing quantitative analysis of medium-
and large-sized capillaries, defined, respectively, as having 3-6
or >6 contiguous endothelial lining cells. Medium-sized
capillaries had mean lumen diameter of 0.020 mm+0.002, while
large-sized capillaries had mean lumen diameter of 0.053 mm+0.004
(p<0.001). Notably, large-lumen capillaries overlapped in size
with arterioles which could be distinguished by a thin layer
containing 2-3 smooth muscle cells of rat origin, as determined by
positive staining with desmin and rat MHC class I mAbs. As shown in
FIGS. 3a-c, both the group receiving 2.times.10.sup.5 endothelial
progenitor cells and the one receiving 10.sup.5 endothelial
progenitor cells plus anti-CXCR4 mAb demonstrated 1.7-fold higher
numbers of medium-sized capillaries compared with, the other two
groups (p<0.01). The group receiving 2.times.10.sup.5
endothelial progenitor cells additionally demonstrated 3.3-fold
higher numbers of large-lumen capillaries compared with the groups
receiving 10.sup.3 or 10.sup.5 endothelial progenitor cells
(p<0.01), and 2-fold higher numbers of large-lumen capillaries
compared with the group receiving 10.sup.5 endothelial progenitor
cells plus anti-CXCR4 mAb (p<0.01). As shown in FIG. 3d,
co-administration of anti-CXCR4 mAb together with the highest
concentration of endothelial progenitor cells, 2.times.10.sup.5,
resulted in a further 23% increase in growth of large-lumen
capillaries. More strikingly, there was a further 2-fold increase
in capillary numbers when 2.times.10.sup.5 endothelial progenitor
cells were injected intravenously after direct intracardiac
delivery of 1.0 .mu.g/ml SDF-1 into infarcted hearts (p<0.01).
Since no similar increase in peri-infarct capillary numbers was
seen after intracardiac delivery of IL-8, we interpret these
results to indicate that the endogenous IL-8 concentrations in
ischemic rat hearts were sufficient to saturate angioblast CXCR1/2
receptors in vivo, whereas intracardiac injection of SDF-1 resulted
in a shift in the balance of SDF-1 expression between bone marrow
and heart, and consequently resulted in redirected angioblast
trafficking to the ischemic heart. As shown in FIG. 3e, the number
of apoptotic cardiomyocytes at the infarct rim was significantly
reduced in both rats receiving 10.sup.5 endothelial progenitor
cells plus anti-CXCR4 mAb and those receiving 2.times.10.sup.5
endothelial progenitor cells compared with the groups receiving
either 10.sup.3 or 10.sup.5 endothelial progenitor cells alone
(both p<0.001). Moreover, co-administration of anti-CXCR4 mAb or
intracardiac injection of SDF-1 resulted in further reductions in
cardiomyocyte apoptosis of 65% and 76%, respectively, FIG. 3f (both
p<0.001). Together, these data indicate that post-infarct
cardioprotection against myocyte apoptosis is dependent on
myocardial neovascularization induced by a critical number of
intravenously injected endothelial progenitor cells. This threshold
can apparently be lowered by strategies that prevent endothelial
progenitor cell redistribution to the bone marrow, such as
interrupting CXCR4/SDF-1 interactions, or enhanced SDF-1 expression
in the ischemic myocardium.
Capillary Lumen Size as Determinant of Improvement in Cardiac
Function.
[0164] We next examined the effect of increasing the number of
human endothelial progenitor cells trafficking to ischemic
myocardium on long-term myocardial function, defined as the degree
of improvement in left ventricular ejection fraction (LVEF) and
reduction in left ventricular end-systolic area (LVAs) at 15 weeks
after intravenous injection, FIGS. 4a and b. No improvement in
these parameters was observed in the groups receiving 10.sup.3 or
10.sup.5 endothelial progenitor cells in comparison to rats
receiving saline alone. In contrast, rats receiving 10.sup.5
endothelial progenitor cells plus anti-CXCR4 mAb demonstrated
significant improvement in these parameters, 22+2% mean recovery in
LVEF and 24+4% mean reduction in LVAs (both p<0.001). Even more
strikingly, the group receiving 2.times.10' endothelial progenitor
cells had a mean recovery in LVEF of 34+4% and a mean reduction in
LVAs of 37+6% (both p<0.001), or 50% further improvement in both
parameters. These results were very surprising to us since both
groups of animals had demonstrated the same degree of
neovascularization involving medium-sized capillaries at two weeks
together with similar levels of protection against early apoptosis
of cardiomyocytes. This suggested that the additional functional
long-term improvement in rats receiving 2.times.10.sup.5 human
endothelial progenitor cells was related to the early development
of large-sized capillaries and was mediated through a different
mechanism than protection against myocyte apoptosis.
Large Capillaries Induce Sustained Regeneration of Endogenous
Myocytes.
[0165] Although myocyte hypertrophy and increase in nuclear ploidy
have generally been considered the primary mammalian cardiac
responses to ischemia, damage, and overload (1,2) recent
observations have suggested that human cardiomyocytes have the
capacity to proliferate and regenerate in response to injury
(18,19). Therefore, we investigated whether the additive
improvement in cardiac function observed after injection of
2.times.10.sup.5 human endothelial progenitor cells involved
induction of cardiomyocyte proliferation and/or regeneration. At
two weeks after LAD ligation rats receiving 2.times.10.sup.5 human
endothelial progenitor cells demonstrated numerous "fingers" of
cardiomyocytes of rat origin, as determined by expression of rat
MHC class I molecules, extending from the peri-infarct region into
the infarct zone. Similar extensions were seen less frequently in
animals receiving 10.sup.3 and 10.sup.5 endothelial progenitor
cells, and very rarely in those receiving saline. As shown in FIG.
4c, the islands of cardiomyocytes at the peri-infarct rim in
animals receiving 2.times.10.sup.5 human endothelial progenitor
cells contained a high frequency of rat myocytes with DNA activity,
as determined by dual staining with mAbs reactive against
cardiomyocyte-specific troponin I and rat Ki-67. In contrast, in
animals receiving saline there was a high frequency of cells with
fibroblast morphology and reactivity with rat Ki-67, but not
troponin I, within the infarct zone. The number of cardiomyocytes
progressing through cell cycle at the peri-infarct region of rats
receiving 2.times.10.sup.5 human endothelial progenitor cells was
40-fold higher than that at sites distal to the infarct, where
myocyte DNA activity was no different than in sham-operated rats.
As shown in FIG. 4d, animals receiving 2.times.10.sup.5 human
endothelial progenitor cells had a 20-fold higher number of
cell-cycling cardiomyocytes at the peri-infarct rim than that found
in non-infarcted hearts (1.19+0.2% vs 0.06+0.03%, p<0.01) and
3.5-fold higher than in the same region in LAD-ligated controls
receiving saline (1.19+0.2% vs 0.344+0.1%, p<0.01). When
2.times.10.sup.5 human endothelial progenitor cells were
intravenously injected after direct intracardiac delivery of 1.0
.mu.g/ml SDF-1 into infarcted hearts, the number of cell-cycling
cardiomyocytes at the peri-infarct rim was increased by a further
1.9-fold compared with intravenous injection of 2.times.10.sup.5
human endothelial progenitor cells alone (FIG. 4e, p<0.01).
Thus, intracardiac injection of SDF-1 in combination with
intravenous injection of 2.times.10.sup.5 human endothelial
progenitor cells resulted in approximately an 8-fold cumulative
increase in cell-cycling cardiomyocytes at two weeks compared with
LAD-ligated controls receiving saline, and translated into over
4-fold greater LVEF improvement, determined by echocardiography,
compared with intravenous injection of 2.times.10.sup.5 endothelial
progenitor cells alone (FIG. 4f, p<0.01). Co-administration of
anti-CXCR4 mAb augmented LVEF improvement by 2.8-fold (p<0.01)
while intracardiac injection of IL-8 conferred no additive
benefit.
[0166] Quantitation of the ratio of fibrous tissue to myocytes at
15 weeks demonstrated significantly reduced proportions of
scar/normal left ventricular myocardium in both the group receiving
2.times.10.sup.5 endothelial progenitor cells and the one receiving
10.sup.5 endothelial progenitor cells plus anti-CXCR4 mAb,
respectively 13% and 21% compared with 37-46% for each of the other
groups (p<0.01), FIG. 4g. Since both groups had nearly identical
levels of protection against early cardiomyocyte apoptosis, we
infer that the additional 38% reduction in scar/myocyte ratio seen
in the group injected with 2.times.10.sup.5 endothelial progenitor
cells actually reflects proliferation/regeneration of endogenous
rat cardiomyocytes induced by nutrient supply from large-vessel
neovascularization. This presumably accounts for the increase in
functional improvement seen in this group. We conclude that the
ratio of scar size to left ventricular muscle mass reflects, in
part, positive effects imparted by the ability of the residual
myocardium to proliferate and regenerate, in addition to negative
effects of the initial infarct size and positive effects of
anti-apoptotic, cardioprotective mechanisms. The overall effects of
medium- and large-size neovasculature combining to both protect
against myocyte apoptosis and induce myocyte
proliferation/regeneration are shown dramatically in FIG. 4h where,
in contrast to saline controls, injection with 2.times.10.sup.5
endothelial progenitor cells resulted in almost complete salvage of
the anterior myocardium, normal septal size and minimal collagen
deposition.
Effecting Regeneration
PAI-1-Inhibiting Catalytic Nucleic Acid Augments Human
Angioblast-Dependent Cardiomyocyte Regeneration.
[0167] We investigated whether possible neovascularization induced
by a catalytic nucleic acid (designated E2) capable of inhibiting
expression of PAI-1 was associated with cardiomyocyte regeneration.
Injection of E2 alone did not induce cardiomyocyte regeneration
despite the increase in neovascularization. Combining E2 injection
with intravenously delivered human endothelial progenitor cells
strikingly increased the degree of cardiomyocyte regeneration, to
levels 7.5-fold higher than in saline controls (p<0.01). A
scrambled DNA control enzyme (E0) had no such effect. Moreover,
whereas E2 alone did not improve myocardial function, as determined
by recovery in left ventricular ejection fraction at two weeks
combining E2 with human endothelial progenitor cells resulted in
almost doubling of the positive effect of endothelial progenitor
cells alone on cardiac functional recovery. These results emphasize
the importance of cardiomyocyte regeneration as the primary
mechanism by which cardiac function is improved after infarction.
Since combining E2 with human endothelial progenitor cells resulted
in 62% greater numbers of large capillaries at the peri-infarct,
rim than use of either approach alone, these results indicate that
angioblast-induced cardiomyocyte regeneration and improvement in
cardiac function can be optimized by use of synergistic approaches,
such as strategies that inhibit PAI-1 expression, which augment
neovascularization either directly or through angioblast-dependent
processes.
[0168] We further discovered that intravenous injection of human
CD34+CD117bright angioblasts resulted in a four-fold increase in
proliferation/regeneration of rat cardiomyocytes at the
peri-infarct region relative to saline controls, as determined by
dual staining for troponin and Ki67 (p<0.01). Combining E2
injection with intravenously delivered human angioblasts strikingly
increased the degree of cardiomyocyte regeneration, to levels
7.5-fold higher than in saline controls (p<0.01). The scrambled
DNA enzyme E0 had no such effect.
Gene Effects on Myocyte Proliferation
[0169] We hypothesized that myocardial neovascularization induces
the signals required to elicit myocyte proliferation, and
therapeutic intervention mimicking this could have striking
implications for repair and regeneration of hearts damaged by
episodes of ischemia or other insults.
[0170] To begin approaching this complex problem, we have employed
the technique of cDNA Subtractive Hybridization. This technique
enables comparison of the pattern of gene expression between two
different sets of conditions. Our initial approach was to compare
which genes are differentially expressed between hearts from normal
rats and rats who have undergone left anterior descending (LAD)
coronary artery ligation 48 hours earlier. We hypothesized that
whatever the altered pattern of gene over- or underexpression after
48 hours of ischemia, neovascularization would result in a reversal
in the pattern towards that seen in the non-ischemic rat heart.
[0171] Using cDNA subtractive hybridization we observed a striking
reciprocal change in expression of a group of genes whose function
is linked through their regulation of cellular apoptosis and cell
cycle progression following oxidative stress and other inducers of
DNA damage. Whereas expression of certain antioxidant genes such as
superoxide dismutase was upregulated in ischemic tissue, the
antioxidant stress responsive genes induced by hemin, notably heme
binding protein 23 (HBP23) and glutathione-S-transferase, were
downregulated. Moreover, a recently-identified protein, Vitamin D3
Up-Regulated Protein1(VDUP1), whose mRNA expression is induced by
hydrogen peroxide (H.sub.2O.sub.2) following oxidative stress and
whose function counterbalances that of HBP23, was upregulated in
ischemic hearts. These findings are particularly striking when
considered in the context of previous observations that the
presence of deficits in antioxidants and increased oxidative stress
accompanying myocardial infarction appear to be directly implicated
in the pathogenesis of post-infarct heart failure (74,75).
[0172] As shown in FIG. 5, using RT-PCR, the reciprocal changes in
mRNA expression of HBP23 and VDUP1 in ischemic vs normal rat hearts
were confirmed. Moreover, mRNA expression of these two genes
returned to normal in rat tissue two weeks after intravenous
injection of human adult bone marrow-derived progenitors and
infarct zone neovascularization. In contrast, in LAD-ligated rat
hearts receiving saline, no change in mRNA expression of these
genes was observed at two weeks in comparison to the pattern
observed at 48 hours. To comprehend the relationship between the
effects of neovascularization on these altered expression patterns
of HBP23 and VDUP1 following ischemia, and the observed protection
against cardiomyocyte apoptosis together with induction of
cardiomyocyte proliferation/regeneration, it is important to
understand in detail the molecular effects of the products encoded
by these genes on cellular apoptosis and cell cycle
progression.
[0173] When cells proliferate, the mitotic cycle progression is
tightly regulated by an intricate network of positive and negative
signals. Progress from one phase of the cell cycle to the next is
controlled by the transduction of mitogenic signals to cyclically
expressed proteins known as cyclins and subsequent activation or
inactivation of several members of a conserved family of
serine/threonine protein kinases known as the cyclin-dependent
kinases (cdks) (67). Growth arrest observed with such diverse
processes as DNA damage, terminal differentiation, and replicative
senescence is due to negative regulation of cell cycle progression
by two functionally distinct families of Cdk inhibitors, the Ink4
and Cip/Kip families (64). The cell cycle inhibitory activity of
p21Cip1/WAF1 is intimately correlated with its nuclear localization
and participation in quaternary complexes of cell cycle regulators
by binding to G1 cyclin-CDK through its N-terminal domain and to
proliferating cell nuclear antigen (PCNA) through its C-terminal
domain (68-71). The latter interaction blocks the ability of PCNA
to activate DNA polymerase, the principal replicative DNA
polymerase (72). For a growth-arrested cell to subsequently enter
an apoptotic pathway requires signals provided by specific
apoptotic stimuli in concert with cell-cycle regulators. For
example, caspase-mediated cleavage of p21, together with
upregulation of cyclin A-associated cdk2 activity, have been shown
to be critical steps for induction of cellular apoptosis by either
deprivation of growth factors (73) or hypoxia of cardiomyocytes
(74).
[0174] The apoptosis signal-regulating kinase 1 (ASK1) is a pivotal
component in the mechanism of cytokine- and stress-induced
apoptosis (75,76). Under basal conditions, resistance to
ASK1-mediated apoptosis appears to be the result of complex
formation between ASK1, cytoplasmic p21Cip1/WAF1 (77), and the
thiol reductase thioredoxin (TRX) (78). Intact cytoplasmic
expression of p21Cip1/WAF1 appears to be important for both
prevention of apoptosis in response to ASK1 (75) and in maintaining
a state of terminal differentiation (77). Moreover, the reduced
form of TRX, but not the oxidized form, binds to the N-terminal
portion of ASK1 and is a physiologic inhibitor of ASK1-mediated
cellular apoptosis (78). The recently-identified protein VDUP1 has
been shown to compete with ASK1 for binding of the reduced form of
TRX (78,79), resulting in augmention of ASK1-mediated apoptosis
(80). This indicates that ASK1-mediated cellular apoptosis is
increased by processes that result in a net dissociation of TRX
from ASK1, such as either generation of TRX-VDUP1 complexes or
generation of oxidised TRX by changes in cellular redox status
accompanying oxidative stress.
[0175] TRX and glutathione constitute the major cellular reducing
systems that maintain the thiol-disulfide status of the cytosol
(81). The redox-active/dithiol active site of TRX is highly
conserved across all species, Trp-Cys-Gly-Pro-Cys-Lys. The two
cysteine residues at the active site, Cys-32 and Cys-35, undergo
reversible oxidation-reduction reactions catalyzed by a
NADPH-dependent enzyme TRX reductase. These reactions involve
electron transfer via disulfide bridges formed with members of a
family of antioxidant enzymes known as peroxiredoxins (Prxs), which
show peroxidase activity (82,83). Prxs are distinct from other
peroxidases in that they have no cofactors, such as metals or
prosthetic groups. Prxs generally have two conserved cysteines at
the N- and C-terminal regions (84), and their antioxidant effects
are coupled with the physiological electron donor activity of the
TRX system (82, 85, 86). Prxs with 95-97% sequence homology have
been identified in rats (Herne-binding protein 23, HBP23) (87),
mice (mouse macrophage stress protein 23, MSP23) (88) and humans
(proliferation-associated gene product, PAG (89) and human natural
killer cell-enhancing factor A (90)).
[0176] Prxs are members of a repertoire of oxidative stress
responsive genes whose expression is regulated by NF-E2-related
factor 2 (Nrf2) which binds to an anti-oxidant responsive element
(ARE) present in the promoter of each (91). These include
glutathione-S-transferase, heme oxygenase-1, and TRX. Under basal
conditions, Nrf2 is bound to a specific protein, Keap1, in the
cytosol (92). However, under conditions of oxidative stress Nrf2
dissociates from Keap1 and translocates to the nucleus where it
induces transcriptional activation of the anti-oxidant genes
containing ARE motifs. Although the precise extracellular
signalling pathways have not been elucidated, nuclear translocation
of Nrf2 and subsequent ARE activation appear to be dependent on
pathways activated by phosphatidylinositol 3-kinase (P13 kinase)
(93). In addition, hemin is a potent inducer of Nrf2 dissociation
from Keap1, resulting in TRX gene transcription through the ARE
(94).
[0177] During periods of rapid changes in cellular redox Prxs
presumably serve to maintain the cytosolic levels of reduced TRX by
accepting electrons from the oxidized form of TRX. This homeostatic
mechanism likely enables maintenance of sufficient levels of
reduced TRX to ensure adequate binding to ASK1 and prevention of
cellular apoptosis. If the endogenous Prx system is overloaded, as
might occur during changes in cellular redox when excess oxidized
TRX is generated, cellular apoptosis will occur through the
unopposed effects of ASK1. To counteract this, transcriptional
activation of Prxs must occur following oxidative stress via
nuclear translocation of Nrf2. This can be achieved either by Nrf2
dissociation from Keap1 via hemin- and PI3 kinase-dependent
mechanisms (93,94), or by increasing Nrf2 mRNA and protein
expression as occurs following increase in oxygen tension
(95,96).
[0178] In addition to directly interacting with TRX, the Prx gene
products (PAG, HBP23, MSP23, NKEF, etc) specifically bind the SH3
domain of c-Abl, a non-receptor tyrosine kinase, inhibiting its
activation by various stimuli, including agents that damage DNA
(97). c-Abl activation through the SH3 domain induces either arrest
of the cell cycle in phase G1 or cellular apoptosis (98). Cell
cycle arrest is dependent on the kinase activity of c-Abl (96) and
is mediated by the ability of c-Abl to downregulate the activity of
the cyclin-dependent kinase Cdk2 and induce the expression of p21
(99). The apoptotic effects of c-Abl are dependent on the ability
of nuclear c-Abl to phosphorylate p73, a member of the p53 family
of tumor-suppressor proteins which can induce apoptosis (100,101).
Recently, it has been shown that cytoplasmic, rather than nuclear,
forms of c-Abl are activated by H.sub.2O.sub.2 and that this
results in mitochondrial localization of c-Abl, c-Abl dependent
cytochrome c release, and cellular apoptosis following oxidative
stress (102,103). By associating with c-Abl in vivo, the PAG gene
product (and presumably the other Prxs) can inhibit tyrosine
phosphorylation induced by c-Abl overexpression and rescue cells
from both the cytostatic and pro-apoptotic effects of the activated
c-Abl gene product (97).
[0179] Our finding that Nrf2-dependent oxidative stress responsive
genes are downregulated following myocardial ischemia likely
reflects direct effects of hemin and oxygen deprivation. The end
result of Prx downregulation in the ischemic heart would be
augmentation in ASK1-dependent cellular apoptosis as well as
Abl-dependent apoptosis and cell cycle arrest. The observed
parallel increase in VDUP1 expression would further augment
ASK1-dependent cellular apoptosis. Thus, the ratio in expression of
PAG or other Prx mRNA or protein to VDUP1 mRNA or protein can form
the basis of a diagnostic assay to predict the degree of risk for
cardiomyocyte apoptosis and cell cycle arrest after ischemia, as
well as enable monitoring of the response to specific therapy after
myocardial ischemia that protects cardiomyocytes against apototic
death and enhances myocardial proliferation/regeneration.
[0180] Reversing the reduced expression of the Prxs following
myocardial ischemia would increase Prxs in the heart in order to
protect the ischemic myocardium against apoptosis through both
c-Abl inhibition and reduction of oxidised TRX, and to enable
cardiomyocyte proliferation/regeneration by inhibiting the effects
of c-Abl on cell cycle progression from G1 to S phase.
[0181] Increasing Nrf2 mRNA or causing dissociation of Nrf2 protein
from Keap1, or preferably cause both to occur simultaneously, in
the setting of myocardial ischemia in order to increase
transcription and activity of members of a repertoire of oxidative
stress responsive genes whose expression is regulated by binding of
Nrf2 to an anti-oxidant responsive element (ARE) in their
promoters, including the Prxs, TRX and glutathione-S-transferase
would result in both protection of cardiomyocytes against apoptosis
as well as induce cardiomyocyte cell cycle progression following
oxidative stress.
[0182] Reducing the expression of VDUP1 following myocardial
ischemia would protect the ischemic myocardium against apoptosis by
reducing binding of TRX to VDUP1, and consequently increasing
TRX-ASK1 interactions.
[0183] Neovascularization of the myocardium, by either bone
marrow-derived endothelial progenitors or any other process, is an
example of one method which causes induction of Prx expression and
reduction in VDUP1 expression after myocardial ischemia, and
results in both protection against redox-mediated apoptosis and
induction of myocardial proliferation/regeneration.
[0184] Small molecules which specifically inhibit binding of Nrf2
to Keap1 would be expected to have similar protective effects
against cardiomyocyte apoptosis and to induce myocardial
proliferation/regeneration after ischemia. Similarly, small
molecules that specifically inhibit binding of TRX to VDUP1, would
be expected to have similar protective effects against
cardiomyocyte apoptosis after ischemia.
[0185] Use of small molecules to specifically inhibit c-Abl
tyrosine kinase activation after myocardial ischemia would be
expected to have similar protective effects against cardiomyocyte
apoptosis and to induce myocardial proliferation/regeneration after
ischemia. A specific example of a small molecule to inhibit c-Abl
tyrosine kinase activation is STI-571. Use of this or related
molecules after myocardial infarction would protect against
cardiomyocyte apoptosis and induce myocardial
proliferation/regeneration.
DNA Enzyme Specific for VDUP-1 Cleaves Synthetic Rat VDUP-1
Oligonucleotide
[0186] By subtractive hybridization, we found that mRNA expression
of the protein VDUP1 is significantly increased in the heart after
acute ischemia. VDUP1 has been shown to bind the cytosolic protein
thioredoxin, TRX, which functions to maintain the thiol-disulfide
status of the cytosol. By binding to reduced forms of TRX, VDUP1
prevents the ability of reduced TRX to undergo reversible
oxidation-reduction reactions catalyzed by a NADPH-dependent
enzyme, TRX reductase. This results in cellular apoptosis due to
excessive cytosolic and mitochondrial production of oxygen
radicals.
[0187] VDUP1 competes for TRX binding with another cytosolic
protein that is normally bound to reduced TRX, the apoptosis
signal-regulating kinase 1 (ASK1). ASK-1 is a pivotal component in
the mechanism of cytokine- and stress-induced apoptosis. Its
activation results in excessive phosphorylation and activation of
p38 MAP kinase, a principal mediator of cellular apoptosis. The
reduced form of TRX, but not the oxidised form, binds to the
N-terminal portion of ASK1 and is a physiologic inhibitor of
ASK1-mediated cellular apoptosis. Binding of VDUP1 to TRX results
in a net dissociation of ASK1 from TRX, potentially resulting in
augmentation of ASK1-mediated apoptosis via p38 MAP
kinase-dependent pathways.
[0188] With respect to cardiac overexpression of VDUP1, the
anticipated effects would be those due to excessive p38 MAP kinase
activation and oxidative redox damage, including cardiomyocyte
apoptosis, fibroblast proliferation, collagen secretion and scar
formation. Similar effects would be expected to be the consequence
of VDUP1 overexpression in other tissues undergoing acute or
chronic ischemic injury, for example the brain following
cerebrovascular ischemia/stroke.
[0189] We have developed a DNA enzyme targeting the VDUP1 mRNA. The
DNA enzyme, once delivered to the ischemic myocardium (or other
ischemic tissues such as the brain) can inhibit local VDUP1 mRNA
and protein expression, thus reducing p38 MAP kinase activation and
oxidative damage.
[0190] As shown in FIG. 12, at enzyme concentrations ranging from
0.05 uM to 5 uM the sequence-specific VDUP1 DNA enzyme cleaved a
synthetic rat VDUP1 oligonucleotide in a concentration- and
time-dependent manner.
[0191] VDUP-1 DNAzyme Reduces Fibroblast Proliferation And Protects
Against Cardiomyocyte Apoptosis. As shown in FIG. 13(a),
intramyocardial injection of the rat sequence-specific VDUP1 DNA
enzyme at 48 hours after LAD ligation resulted in a 75% mean
inhibition of proliferating cardiac fibroblasts in the infarct zone
two weeks later in comparison to injection of scrambled DNA enzyme
control (p<0.01). In addition, as seen in FIG. 13(b), injection
of VDUP1 DNA enzyme resulted in 20% mean reduction in apoptotic
cardiomyocytes at the peri-infarct region relative to injection
with the scrambled DNA enzyme control (p<0.05).
[0192] VDUP-1 DNAzyme Reduces Myocardial Scar And Improves Cardiac
Function After Acute Infarction. Inhibition of fibroblast
proliferation and cardiomyocyte apoptosis resulted in significant
reduction of mature scar deposition in the infarct zone, from a
mean of 35% for animals receiving control scrambled DNA enzyme to a
mean of 20% for those receiving VDUP1 DNA enzyme, FIG. 14(a)
(p<0.01). Most dramatic was the effect on cardiac function. As
shown in FIG. 14(b), animals receiving VDUP1 DNA enzyme
demonstrated a 50% mean recovery in cardiac function, as determined
by ejection fraction, whereas no improvement was seen in animals
receiving scrambled control DNA enzyme (p<0.01).
[0193] Clearly, VDUP1 DNA enzyme prevents cardiomyocyte apoptosis,
cardiac fibroblast proliferation and scar formation, resulting in
significant improvement in cardiac function after acute ischemia.
These effects are presumably due to prevention of p38 MAP kinase
activation and protection against redox damage. Similar results
might be obtained by administering the VDUP1 DNA enzyme to other
tissue sites of reduced blood flow such as the brain after
cerebrovascular ischemia.
G-CSF
[0194] G-CSF is a more potent inducer of neovascularization after
myocardial infarction than GM-CSF. As shown in FIG. 15(a), rats
injected subcutaneously with human G-CSF at 10 ug/kg for four days
starting at two days after myocardial infarction induced by left
anterior descending (LAD) coronary artery ligation demonstrated
approximately 7.5-fold greater numbers of large-diameter blood
vessels at the peri-infarct region two weeks later relative to
saline-treated controls (p<0.01). Rat GM-CSF administered at the
same dosage regimen was less effective, though still inducing
4-fold greater numbers of large-lumen vessels than in control
animals.
[0195] Additionally, G-CSF is a more potent inhibitor of
cardiomyocyte apoptosis after myocardial infarction than GM-CSF.
G-CSF injection was a more potent agent for protecting against
cardiomyocyte apoptosis than GM-CSF used at the same dosage
regimen, FIG. 15(b). G-CSF administration resulted in 36+16%
reduction in the numbers of apoptotic cardiomyocytes at the
peri-infarct region by two weeks relative to saline-treated
controls (p<0.01), whereas GM-CSF only reduced apoptotic
cardiomyocyte numbers by 12+9%.
[0196] G-CSF is a more potent inducer of cardiomyocyte regeneration
and functional cardiac recovery after myocardial infarction than
GM-CSF. Next we examined the effects of bone marrow mobilization on
cardiomyocyte cell cycling/regeneration and on functional cardiac
recovery. As shown in FIG. 16(a), rats injected subcutaneously with
human G-CSF at 10 ug/kg for four days starting at two days after
myocardial infarction demonstrated 3.2-fold greater numbers of
cycling cardiomyocytes two weeks later at the peri-infarct region
relative to saline-treated controls (p<0.05). Rat GM-CSF
administered at the same dosage regimen was less effective,
resulting in 2.6-fold greater numbers of cycling cardiomyocytes. As
shown in FIG. 16(b), this correlated with functional cardiac
recovery. Whereas saline-treated animals had a 17% mean loss in
cardiac function from day 2 to day 14 after infarction as measured
by ejection fraction, GM-CSF treated animals had a loss of only 10%
in cardiac function, and G-CSF treated animals actually had a 10%
mean improvement in cardiac function (P<0.01). We interpret
these functional data to reflect the superior effects of G-CSF bone
marrow mobilization on myocardial neovascularization, protection
against cardiomyocyte apoptosis and induction of cardiomyocyte cell
cycling.
Anti-CXCR4 Antibodies
[0197] Intravenous administration of anti-CXCR4 antibody increases
myocardial neovascularization and improves cardiac function after
acute infarction. The major mechanism by which G-CSF causes
mobilization of bone marrow elements is through interruption of
interactions between the chemokine receptor CXCR4 on bone marrow
resident stem cells and its ligand SDF-1. G-CSF induces both
cleavage of the N-terminus of CXCR4 and accumulation of serine
proteases which directly cleave and inactivate SDF-1. To examine
whether similar mechanisms were responsible for the effects of
G-CSF administration on myocardial neovascularization and
improvement in cardiac function, we investigated the effect of
interrupting CXCR4-SDF1 interactions by intravenously administering
a monoclonal anti-CXCR4 antibody 48 hours after LAD ligation. As
shown in FIG. 17(a) at two weeks after antibody administration
animals receiving anti-CXCR4 mAb demonstrated a two-fold increase
in neovascularization at the peri-infarct region compared with
control animals receiving either saline or anti-CXCR2 mAb.
Moreover, as seen in FIG. 17(b) anti-CXCR4 treated animals
demonstrated a mean recovery in ejection fraction of 10% at two
weeks whereas those receiving anti-CXCR2 mAb had a mean loss in
cardiac function of 8% (p<0.05). These data support the concept
that the observed effects of G-CSF administration result from
interrupting CXCR4 interactions in the bone marrow, enabling
endothelial progenitor cells to be mobilized to the peripheral
circulation, and to home to ischemic myocardium where the resultant
neovascularization results in improvement in cardiac function.
SDF-1
[0198] SDF-1 mRNA expression is not induced early in acutely
ischemic myocardium, and its late induction is inhibited by GM-CSF.
Next, we sought to identify a strategy by which the effects of
GM-CSF could be augmented to approach those seen with G-CSF
treatment alone, such as increasing chemotactic signals in the
acutely ischemic myocardium. Since chemotaxis of CD34+ bone marrow
stem cells is regulated by interactions between CXCR4 receptors on
the CD34+ cells and the CXC chemokine SDF-1, we investigated
whether SDF-1 mRNA expression was induced in the acutely ischemic
myocardium. As shown in FIG. 18, no difference in myocardial SDF-1
mRNA was observed at 48 hours after LAD ligation in experimental
animals relative to non-ischemic controls. By two weeks after
infarction, myocardial SDF-1 mRNA expression had increased by
3.3-fold compared with saline-treated controls (p<0.01). We
interpreted this delayed production of SDF-1 as most likely
reflecting elaboration by infiltrating cells such as macrophages.
In contrast, systemic GM-CSF administration was accompanied by
approximately 4.5-fold inhibition in SDF-1 mRNA expression at two
weeks, to levels actually lower than in non-ischemic controls.
Since SDF-1 is a potent chemotactic factor for endothelial
progenitor cells, these data suggested that systemic GM-CSF
administration may result in suboptimal myocardial homing of
endothelial progenitors due to decreased myocardial expression of
chemotactic ligands such as SDF-1.
[0199] Intramyocardial injection of SDF-1 after acute myocardial
infarction results in neovascularization and protection against
cardiomyocyte apoptosis. To determine whether altered SDF-1
expression in the acutely ischemic heart affects endothelial
progenitor cell chemotaxis and cardiomyocyte function, we examined
the effects of direct intramyocardial injection of SDF-1 protein at
48 hours after LAD ligation. As shown in FIGS. 19 (a) and (b),
intramyocardial injection of 4 ug/kg human recombinant SDF-1 in a
total volume of 0.2 ml at 5 peri-infarct sites two days post-LAD
ligation resulted by two weeks in a 5-fold increase in
neovascularization and a 44+9% reduction in apoptotic
cardiomyocytes at the peri-infarct region relative to control
animals receiving intramyocardial saline injections (both
p<0.05). The effects of intramyocardial SDF-1 injection on
neovascularization and on extent of protection against
cardiomyocyte apoptosis were in strikingly close parallel to the
results obtained with systemic administration of G-CSF. Although
addition of subcutaneously administered GM-CSF resulted in a
synergistic increase in myocardial neovascularization, no further
benefit in protection against cardiomyocyte apoptosis was observed.
These results suggest that there is a finite amount of protection
against cardiomyocyte apoptosis that can be induced by
neovascularization, and that this cannot be improved upon by
further by induction of additional new blood vessels.
[0200] Intramyocardial injection of SDF-1 induces cardiomyocyte
regeneration. As shown in FIG. 20(a), intramyocardial injection of
4 ug/kg human recombinant SDF-1 in a total volume of 0.2 ml at 5
peri-infarct sites two days post-LAD ligation resulted in a
4.5-fold increase in the number of cycling cardiomyocytes at the
peri-infarct region relative to saline-injected controls
(p<0.01). Addition of systemic GM-CSF administration resulted in
synergistic effects on cardiomyocyte regeneration. Notably, the
numbers of cycling cardiomyocytes at the peri-infarct region in
animals receiving combined therapy with SDF-1 and GM-CSF
significantly exceeded those seen in animals receiving G-CSF alone
(7-fold versus 3.2-fold above saline treated controls, p<0.01).
Since mean numbers of large-lumen vessels at the peri-infarct
region were similar in animals receiving combined therapy with
SDF-1 and GM-CSF and in those receiving G-CSF alone (8.0 vs
7.5/high power field), these data suggest that SDF-1 enhanced
cardiomyocyte cycling/regeneration by an alternative mechanism in
addition to induction of neovascularization.
[0201] Intramyocardial injection of SDF-1 improves cardiac function
and is synergistic with bone marrow mobilization. Intramyocardial
injection of SDF-1 resulted in a similar degree of functional
myocardial recovery as was seen with systemic G-CSF administration
(10% mean improvement in ejection fraction between days 2 and 14
post-LAD ligation compared with 10% mean improvement for G-CSF
treated animals and 17% mean loss for saline-treated controls,
p<0.01 for both treatment arms). Most strikingly, combining
SDF-1 injection with bone marrow mobilization by GM-CSF resulted in
significant augmentation in functional recovery (21% mean
improvement in ejection fraction, p<0.01), FIG. 20(b). These
data indicate that intramyocardial administration of SDF-1 causes
improvement in cardiac function after acute ischemia through two
separate mechanisms, a direct mechanism which involves induction of
cardiomyocyte cycling and regeneration and an indirect mechanism
operating through enhanced chemotaxis of mobilized bone
marrow-derived endothelial progenitors and cardiac
neovascularization.
[0202] We further investigated the role of SDF as an agent for
inducing cardiac regeneration. We found that CXCR4 expression
occurs following acute induced myocardial ischemia in focal and
peri-infarct areas (see FIG. 26). In separate experiments, we found
that intramyocardial injection of SDF-1 induced early
phosphorylation of AKT (see FIG. 27). Furthermore, in cultured rat
neonatal cardiomyocytes (which also express CXCR4, see FIG. 28),
SDF administration induced phosphorylation of both AKT and ERK in a
time-dependent manner. FIG. 29 shows rapid phosphorylation of AKT
in cultured myocytes in the presence of SDF-1. Consistent with
these results, further investigation demonstrated that intracardiac
administration of SDF-1 augments G-CSF-induced neovascularization
and regeneration of acutely ischemic myocardium (see FIG. 30). In
addition, intracardiac administration of SDF-1 was also found to
augment G-CSF-induced functional myocardial recovery following
myocardial ischemia in rats (see FIG. 31), as well as protect rat
neonatal cardiac myocytes against H.sub.2O.sub.2 apopotsis in a
dose dependent manner (FIG. 32).
DISCUSSION
[0203] Exogenous SDF may induce tissue repair via trophic effects
on local or bone-marrow derived progenitors. In addition,
increasing SDF-1 in the heart after ischemic insult may result in
trophic effects on cardiomyocyte progenitors and induce cardiac
repair and regeneration.
Methods and Materials
Purification and Characterization of Cytokine-Mobilized Human CD34+
Cells:
[0204] Single-donor leukopheresis products were obtained from
humans treated with recombinant G-CSF 10 mg/kg (Amgen, Calif.) sc
daily for four days. Donors were healthy individuals undergoing
standard institutional procedures of bone marrow mobilization,
harvesting and isolation for allogeneic stem cell transplants.
Mononuclear cells were separated by Ficoll-Hypaque, and
highly-purified CD34+ cells (>98% positive) were obtained using
magnetic beads coated with anti-CD34 monoclonal antibody (mAb)
(Miltenyi Biotech, CA). Purified CD34 cells were stained with
fluorescein-conjugated mAbs against CD34 and CD117 (Becton
Dickinson, CA), AC133 (Miltenyi Biotech, CA), CD54 (Immunotech,
CA), CD62E (BioSource, MA), VEGFR-2, Tie-2, vWF, eNOS, CXCR1,
CXCR2, and CXCR4 (all Santa Cruz Biotech, CA), and analyzed by
four-parameter fluorescence using FACScan (Becton Dickinson, CA).
Cells positively selected for CD34 expression were also stained
with phycoerythrin (PE)-conjugated anti-CD117 mAb (Becton
Dickinson, CA), and sorted for bright and dim fluorescence using a
Facstar Plus (Becton Dickinson) and a PE filter. Intracellular
staining for GATA-2 was performed by permeabilizing one million
cells from each of the brightly and dimly fluorescing cell
populations using a Pharmingen Cytofix/Cytoperm.TM. kit, incubating
for 30 minutes on ice with 10 .mu.l of fluorochrome-conjugated mAbs
against both CD117 and CD34 surface antigens (Becton Dickinson,
CA). After resuspension in 250 .mu.l of Cytofix/Cytoperm.TM.
solution for 20 minutes at 4 degrees C., cells were incubated with
a fluorochrome-labeled mAb against GATA-2 (Santa Cruz Biotech, CA)
or IgG control for 30 minutes at 4 degrees C., and analyzed by
three-parameter flow cytometry.
Chemotaxis of Human Bone-Marrow Derived Endothelial
Progenitors:
[0205] Highly-purified CD34+CD117.sup.bright cells (>98% purity)
were plated in 48-well chemotaxis chambers fitted with membranes (8
mm pores) (Neuro Probe, MD). After incubation for 2 hours at
37.degree. C., chambers were inverted and cells were cultured for 3
hours in medium containing IL-8, SDF-1 alpha/beta, and SCF at 0.2,
1.0 and 5.0 .mu.g/ml. The membranes were fixed with methanol and
stained with Leukostat.TM. (Fischer Scientific, Ill). Chemotaxis
was calculated by counting migrating cells in 10 high-power
fields.
Animals, Surgical Procedures, Injection of Human Cells, and
Quantitation of Cellular Migration into Tissues:
[0206] Rowett (rnu/rnu) athymic nude rats (Harlan Sprague Dawley,
Indianapolis, Ind.) were used in studies approved by the "Columbia
University Institute for Animal Care and Use Committee". After
anesthesia, a left thoracotomy was performed, the pericardium was
opened, and the left anterior descending (LAD) coronary artery was
ligated. Sham-operated rats had a similar surgical procedure
without having a suture placed around the coronary artery. For
studies on cellular migration, 2.0.times.10.sup.6 CD34+ cells
obtained from a single donor after G-CSF mobilization were injected
into the tail vein 48 hours after LAD ligation either alone or
together with 50 .mu.g/ml monoclonal antibody (mAb) with known
functional inhibitory activity against either human CXCR1, human
CXCR2, human CXCR4, rat SDF-1 (all R & D Systems, MN), human
CD34 (Pharmingen, CA), or rat IL-8 (ImmunoLaboratories, Japan).
Controls received either isotype control antibodies at the same
concentration or saline after LAD ligation. Prior to injection,
2.0.times.10.sup.6 human cells were incubated with 2.5 ug/mL of the
fluorescent carbocyanine DiI dye (Molecular Probes) for 5 minutes
at 37.degree. C. and 15 minutes at 4.degree. C. After washing in
PBS, DiI-labeled human cells were resuspended in saline and
injected intravenously. 2.0.times.10.sup.6 CD34+ human cells were
also injected into the tail vein of sham-operated or LAD-ligated
rats receiving three intramyocardial injections of 1.0 .mu.g/ml
recombinant human IL-8, SDF-1, SCF or saline. Each group consisted
of 6-10 rats. Quantitation of myocardial infiltration after
injection of human cells was performed by assessment of DiI
fluorescence in hearts from rats sacrificed 2 days after injection
(expressed as number of DiI-positive cells per high power field,
minimum 5 fields examined per sample). Quantitation of rat bone
marrow infiltration by human cells was performed in 12 rats at
baseline, days 2, 7, and 14 by flow cytometric and RT-PCR analysis
of the proportion of HLA class I-positive cells relative to the
total rat bone marrow population. For studies on neoangiogenesis
and effects on myocardial viability and function,
2.0.times.10.sup.6 DiI-labelled human CD34+ cells obtained from a
single donor after G-CSF mobilization were reconstituted with
10.sup.3, 10.sup.5, or 2.0.times.10.sup.5 immunopurified
CD34+CD117.sup.bright cells, and injected into the rat tail vein 48
hours after LAD ligation, in the presence or absence of a mAb with
known inhibitory activity against CXCR4. Each group consisted of
6-10 rats. Histologic and functional studies were performed at 2
and 15 weeks.
Measurement of Rat CXC Chemokine mRNA and Protein Expression:
[0207] Poly(A)+ mRNA was extracted by standard methods from the
hearts of 3 normal and 12 LAD-ligated rats. RT-PCR was used to
quantify myocardial expression of rat IL-8 and Gro-alpha mRNA at
baseline and at 6, 12, 24 and 48 hours after LAD ligation after
normalizing for total rat RNA as measured by GAPDH expression.
After priming with oligo (dT) 15-mer and random hexamers, and
reverse transcribed with Moloney murine lymphotrophic virus reverse
transcriptase (Invitrogen, Carlsbad, Calif., USA), cDNA was
amplified in the polymerase chain reaction (PCR) using Taq
polymerase (Invitrogen, Carlsbad, Calif., USA), radiolabeled
dideoxy-nucleotide ([a32P]-ddATP: 3,000 Ci/mmol, Amersham,
Arlington Heights, Ill.), and primers for rat Cinc (rat homologue
of human IL-8/Gro-alpha and GAPDH (Fisher Genosys, CA). Primer
pairs (sense/antisense) for rat Cinc and GAPDH were,
gaagatagattgcaccgatg (SEQ ID NO:4)/catagcctctcacatttc SEQ ID
NO:5),gcgcccgtccgccaatgagctgcgc SEQ ID
NO:6)/cttggggacacccttcagcatcttttgg SEQ ID NO:7), and
ctctacccacggcaagttcaa SEQ ID NO:8)/gggatgaccttgcccacagc SEQ ID
NO:9), respectively. The labelled samples were loaded into 2%
agarose gels, separated by electrophoresis, and exposed for
radiography for 6 h at -70.degree. C. Serum levels of rat
IL-8/Gro-alpha were measured at baseline and at 6, 12, 24 and 48
hours after LAD ligation in four rats by a commercial ELISA using
polyclonal antibodies against the rat IL-8/Gro homologue Cinc
(ImmunoLaboratories, Japan). The amount of protein in each serum
sample was calculated according to a standard curve of optical
density (OD) values constructed for known levels of rat
IL-8/Gro-alpha protein. Anti-Cinc antibodies were also used
according to the manufacturer's instructions at 1:200 dilution in
immunohistochemical studies to identify the cellular source of Cinc
production in rat myocardium after LAD ligation.
Positively-staining cells were visualized as dark gray through the
Avidin/Biotin system described below.
Histology and Measurement of Infarct Size:
[0208] Following excision at 2 and 15 weeks, left ventricles from
each experimental animal were sliced at 10-15 transverse sections
from apex to base. Representative sections were fixed in formalin
and stained for routine histology (H&E) to determine
cellularity of the myocardium, expressed as cell number per high
power field (HPF) (600.times.). A Masson trichrome stain was
performed, which labels collagen blue and myocardium red, to
evaluate collagen content on a semiquantitative scale (0-3+), with
1+ light blue, 2+ light blue and patches of dark blue, and 3+ dark
blue staining. This enabled measurement of the size of the
myocardial scar using a digital image analyzer. The lengths of the
infarcted surfaces, involving both epicardial and endocardial
regions, were measured with a planimeter digital image analyzer and
expressed as a percentage of the total ventricular circumference.
Final infarct size was calculated as the average of all slices from
each heart. All studies were performed by a blinded pathologist.
Infarct size was expressed as percent of total left ventricular
area. Final infarct size was calculated as the average of all
slices from each heart.
Quantitation of Capillary Density:
[0209] In order to quantitate capillary density and species origin
of the capillaries, additional sections were stained freshly with
mAbs directed against rat or human CD31 (Serotec, UK, and Research
Diagnostics, NJ, respectively), factor VIII (Dako, CA), and rat or
human MHC class I (Accurate Chemicals, CT). Arterioles were
differentiated from large capillaries by the presence of a smooth
muscle layer, identified by staining sections with a monoclonal
antibody against muscle-specific desmin (Dako, Ca). Staining was
performed by immunoperoxidase technique using an Avidin/Biotin
Blocking Kit, a rat-absorbed biotinylated anti-mouse IgG, and a
peroxidase-conjugate (all Vector Laboratories Burlingame, Calif.).
Capillary density was determined at 2 weeks post infarction from
sections labeled with anti-CD31 mAb, and confirmed with anti-factor
VIII mAb, and compared to the capillary density of the unimpaired
myocardium. Values are expressed as the number of CD31-positive
capillaries per HPF (400.times.).
Quantitation of Cardiomyocyte Proliferation:
[0210] Cardiomyocyte DNA synthesis and cell cycling was determined
by dual staining of rat myocardial tissue sections obtained from
LAD-ligated rats at two weeks after injection of either saline or
CD34+ human cells, and from healthy rats as negative controls, for
cardiomyocyte-specific troponin I and human- or rat-specific Ki-67.
Briefly, paraffin embedded sections were microwaved in a 0.1M EDTA
buffer, and stained with either a primary monoclonal antibody
against rat Ki-67 at 1:3000 dilution (gift of Giorgio Catoretti,
Columbia University) or human Ki-67 at 1:300 dilution (Dako, CA)
and incubated overnight at 4 degrees C. Following washes, sections
were incubated with a species-specific secondary antibody
conjugated with alkaline phosphatase at 1:200 dilution (Vector
Laboratories Burlingame, Calif.) for 30 minutes and
positively-staining nuclei were visualized as blue with a BCIP/NBT
substrate kit (Dako, CA). Sections were then incubated overnight at
4 degrees C. with a monoclonal antibody against
cardiomyocyte-specific troponin I (Accurate Chemicals, CT) and
positively-staining cells were visualized as dark gray through the
Avidin/Biotin system described above. Cardiomyocytes progressing
through cell cycle in the infarct zone, peri-infarct region, and
area distal to the infarct were calculated as the proportion of
troponin I-positive cells per high power field co-expressing
Ki-67.
Measurement of Myocyte Apoptosis by DNA End-Labeling of Paraffin
Tissue Sections:
[0211] For in situ detection of apoptosis at the single cell level
we used the TUNEL method of DNA end-labeling mediated by
dexynucleotidyl transferase (TdT) (Boehringer Mannheim, Mannheim,
Germany). Rat myocardial tissue sections were obtained from
LAD-ligated rats at two weeks after injection of either saline or
CD34+ human cells, and from healthy rats as negative controls.
Briefly, tissues were deparaffinized with xylene and rehydrated
with graded dilutions of ethanol and two washes in
phosphate-buffered saline (PBS). The tissue sections were then
digested with Proteinase K (10 .mu.g/ml in Tris/HCL) for 30 minutes
at 37.degree. C. The slides were then washed 3 times in PBS and
incubated with 50 .mu.l of the TUNEL reaction mixture (TdT and
fluorescein-labeled dUTP) and incubated in a humid atmosphere for
60 minutes at 37.degree. C. For negative controls TdT was
eliminated from the reaction mixture. Following 3 washes in PBS,
the sections were then incubated for 30 minutes with an antibody
specific for fluorescein-conjugated alkaline phosphatase (AP)
(Boehringer Mannheim, Mannheim, Germany). The TUNEL stain was
visualized with a substrate system in which nuclei with DNA
fragmentation stained blue, (BCIP/NBT substrate system, Dako,
Carpinteria, Calif.). The reaction was terminated following three
minutes of exposure with PBS. To determine the proportion of
blue-staining apoptotic nuclei within myocytes, tissue was
counterstained with a monoclonal antibody specific for desmin.
Endogenous peroxidase was blocked by using a 3% hydrogen
perioxidase solution in PBS for 15 minutes, followed by washing
with 20% goat serum solution. An anti-troponin I antibody (Accurate
Chemicals, CT) was incubated overnight (1:200) at 40 degrees C.
Following 3 washes sections were then treated with an anti-rabbit
IgG, followed by a biotin conjugated secondary antibody for 30
minutes (Sigma, Saint Louis, Mo.). An avidin-biotin complex (Vector
Laboratories, Burlingame, Calif.) was then added for an additional
30 minutes and the myocytes were visualized dark gray following 5
minutes exposure in DAB solution mixture (Sigma, Saint Louis, Mo.).
Tissue sections were examined microscopically at 200.times.
magnification. Within each 200.times. field 4 regions were
examined, containing at least 250 cells per region and cumulatively
approximating 1 mm.sup.2 of tissue, at both the peri-infarct site
and distally to this site. Stained cells at the edges of the tissue
were not counted. Results were expressed as the mean number of
apoptotic myocytes per mm.sup.2 at each site examined.
Analysis of Myocardial Function:
[0212] Echocardiographic studies were performed using a high
frequency liner array transducer (SONOS 5500, Hewlett Packard,
Andover, Mass.). 2D images were obtained at mid-papillary and
apical levels. End-diastolic (EDV) and end-systolic (ESV) left
ventricular volumes were obtained by bi-plane area-length method,
and % left ventricular ejection fraction was calculated as
[(EDV-ESV)/EDV].times.100.
CDNA Subtractive Hybridization:
[0213] Briefly, messenger RNA was isolated from each heart, and 1
.mu.g was used for first-strand cDNA synthesis with random primers.
The subtractive hybridization was performed with the PCR-select
cDNA subtraction kit (CLONTECH), following the manufacturer's
recommendations. After second-strand synthesis, the two cDNA
libraries were digested with RsaI. Digestion products of the
"tester" library were ligated to a specific adapter (T7 promoter),
then hybridized with a 30-fold excess of the "driver" library for
subtraction. After hybridization, the remaining products were
further amplified by PCR. In the forward subtraction, which
determines the genes that are overexpressed in the ischemic sample,
the ischemic tissue is the "tester" and the normal tissue is the
"driver." In the reverse subtraction, the "tester" and the "driver"
are switched to determine the genes that are down-regulated in the
ischemic sample.
Rat Neonatal Cardiac Myocyte Culture:
[0214] Neonatal cardiac myocytes were isolated from ventricles of 1
to 3-day old Sprague Dawley rats. Myocytes were isolated by
step-wise enzymatic digestion using a modification of a previously
described method (Sadoshima et al., 1992, J. Biol. Chem.
267:10551-10560). PERCOLL gradient was used to enrich for cardiac
myocytes during isolation. Myocytes were plated onto gelatin-coated
dishes or chamber slides (LABTEK PERMANOX, Nunc) in DMEM/F12 media
containing 5% horse serum. Sixteen hours following plating cells
were washed and serum starved if required.
Protein Isolation:
Rat Isolated Ventricle.
[0215] Isolated ventricles were frozen in liquid nitrogen and
stored at -80.degree. C. Frozen ventricle were Polytron homogenised
on ice (3 times, 10-s bursts) in RIPA buffer containing 50 mM
Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 nM PMSF, 1 .mu.g/ml
aprotinin, 1 .mu.g/ml leupeptin, 1 mM Na.sub.3VO.sub.4 and 1 mM
NaF. NP-40 (final concentration 1%) was added for 30 min, then
samples were Dounce homogenized on ice (60 strokes). Following
centrifugation (6000 rpm, 15 min) the protein concentration of the
supernatant was determined (BIORAD Protein Assay).
Neonatal Rat Cardiac Myocytes.
[0216] Myocytes were washed twice with ice-cold PBS before
collection in RIPA buffer containing the above described
components. Following 15-min incubation on an orbital rocker at
4.degree. C., samples were passed 4 times through a 21G needle.
Supernatant was collected after centrifugation (14,000 rpm, 15 min)
and protein concentration determined (BIORAD Protein Assay).
Western Blot Method:
Rat Isolated Ventricle.
[0217] Protein extracts (100 .mu.g) prepared in SDS sample buffer
were resolved by SDS/PAGE. PVDF membranes were blocked in PBST
containing 5% BSA for 1 h, before overnight incubation with
anti-phospho AKT or anti-AKT antibodies diluted 1:1000 in PBST
containing 5% BSA (CELL SIGNALING). Densitometric quantification
was performed using IMAGEQUANT software (Molecular Dynamics).
Neonatal Rat Cardiac Myocytes.
[0218] Serum starved cells were stimulated with SDF-1.alpha. at the
concentrations and times described. Protein extracts (50 .mu.g)
prepared in SDS sample buffer were resolved by SDS/PAGE. PVDF
membranes were blocked in PBST containing 5% BSA and incubated
overnight with anti-phospho AKT or anti-AKT antibodies diluted
1:1000 in PEST containing 5% BSA (Cell Signalling). Nitrocellulose
membranes were blocked in PBST containing 5% skim milk for 1 h
prior to overnight incubation with anti-phospho ERK or anti-ERK
antibodies diluted 1:1000 in PBST containing 5% skim milk (CELL
SIGNALING). Densitometric quantification was performed using
IMAGEQUANT software (Molecular Dynamics).
CXCR4 Immunostaining:
Rat Isolated Ventricle.
[0219] Cross-sections of ventricle were formalin (10%) fixed and
embedded in paraffin. Sections (4 .mu.m) were de-waxed and
endogenous peroxide activity was blocked using 3% H.sub.2O.sub.2
(20 min). After 1 h blocking using swine serum (1:5 dilution,
DAKO), sections were incubated overnight with fusin (CXCR4; H-118,
Santa Cruz Biotechnology) at a 1:400 dilution. Immunostaining was
developed using a biotinylated secondary antibody (DAKO) linked to
avidin/HRP (VectaStain Elite ABC Kit, Vector Laboratories) followed
by DAB chromagen (DAKO). Slides were counterstained with
haematoxylin.
Neonatal Rat Cardiac Myocytes.
[0220] Cells cultured on chamber slides (LabTek Permanox, Nunc)
were rinsed with PBS and fixed with ice-cold methanol for 5 min.
Endogenous peroxide activity was inhibited using 3% H.sub.2O.sub.2
diluted in methanol for 5 min. Slides were blocked for 1 h in swine
serum (1:5 dilution, DAKO), and then incubated overnight with fusin
(CXCR4; H-118, Santa Cruz Biotechnology) at a 1:200 dilution.
Immunostaining was developed using a biotinylated secondary
antibody (DAKO) linked to avidin/HRP (VECTASTAIN ELITE ABC Kit,
Vector Laboratories) followed by DAB chromagen (DAKO).
REFERENCES
[0221] 1. Soonpaa M H, Field L J. Assessment of cardiomyocyte DNA
synthesis in normal and injured adult mouse hearts. Am J Physiol
272, H220-6 (1997). [0222] 2. Kellerman S, Moore J A, Zierhut W,
Zimmer H G, Campbell J, Gerdes A M. Nuclear DNA content and
nucleation patterns in rat cardiac myocytes from different models
of cardiac hypertrophy. J Mol Cell Cardiol 24, 497-505 (1992).
[0223] 3. Colucci, W. S. Molecular and cellular mechanisms of
myocardial failure. Am. J. Cardiol. 80(11A), 15L-25L (1997). [0224]
4. Ravichandran, L. V. and Puvanakrishnan, R. In vivo labeling
studies on the biosynthesis and degradation of collagen in
experimental myocardial myocardial infarction. Biochem. Intl. 24,
405-414 (1991). [0225] 5. Agocha, A., Lee, H. W., Eghali-Webb, M.
Hypoxia regulates basal and induced DNA synthesis and collagen type
I production in human cardiac fibroblasts: effects of TGF-beta,
thyroid hormone, angiotensis I I and basic fibroblast growth
factor. J. Mol. Cell. Cardiol. 29, 2233-2244 (1997). [0226] 6.
Pfeffer, J. M., Pfeffer, M. A. Fletcher, P. J., Braunwald, E.
Progressive ventricular remodeling in rat with myocardial
infarction. Am. J. Physiol. 260, H1406-414 (1991). [0227] 7.
Kocher, A A, et al. Neovascularization of ischemic myocardium by
human bone-marrow-derived endothelial progenitor cells prevents
cardiomyocyte apoptosis, reduces remodeling and improves cardiac
function. Nat Med 7, 430-6 (2001). [0228] 8. Kennedy, M. et al. A
common precursor for primitive erythropoiesis and definitive
haematopoiesis. Nature 386, 488-493 (1997). [0229] 9. Choi, K.,
Kennedy, M., Kazarov, A., Papadimitriou, Keller, G. A common
precursor for hematopoietic and endothelial cells. Development 125,
725-732 (1998). [0230] 10. Elefanty, A. G., Robb, L., Birner, R.,
Begley, C. G. Hematopoietic-specific genes are not induced during
in vitro differentiation of scl-null embryonic stem cells. Blood
90, 1435-1447 (1997). [0231] 11. Labastie, M. C., Cortes, F.,
Romeo, P. H., Dulac, C., Peault, B. Molecular identity of
hematopoietic precursor cells emerging in the human embryo. Blood
92, 3624-3635 (1998). [0232] 12. Rafii S, et al. Isolation and
characterization of human bone marrow microvascular endothelial
cells: hematopoietic progenitor cell adhesion. Blood 84, 10-19
(1994). [0233] 13. Shi, Q. et al. Evidence for circulating bone
marrow-derived endothelial cells. Blood 92, 362-367 (1998). [0234]
14. Lin, Y., Weisdorf, D. J., Solovey, A., Hebbel, R. P. Origins of
circulating endothelial cells and endothelial outgrowth from blood.
J. Clin. Invest. 105, 71-77 (2000). [0235] 15. Asahara, T. et al.
Isolation of putative progenitor cells for endothelial
angiogenesis. Science 275, 964-967 (1997). [0236] 16. Takahashi, T.
et al. Ischemia- and cytokine-induced mobilization of bone
marrow-derived endothelial progenitor cells for neovascularization.
Nat. Med. 5, 434-438 (1999). [0237] 17. Kalka, C. et al.
Transplantation of ex vivo expanded endothelial progenitor cells
for therapeutic neovascularization. Proc. Natl. Acad. Sci. USA 97,
3422-3427 (2000). [0238] 18. Kajstura J, Leri A, Finato N, di
Loreto N, Beltramo C A, Anversa P. Myocyte proliferation in
end-stage cardiac failure in humans. Proc Natl Acad Sci USA 95,
8801-8805 (1998). [0239] 19. Beltrami A P, et al. Evidence that
human cardiac myocytes divide after myocardial infarction. N Engl J
Med 344, 1750-7 (2001). [0240] 20. Folkman J. Angiogenesis in
cancer, vascular, rheumatoid and other disease. Nat. Med. 1:27
(1995). [0241] 21. Strieter, R M. et al. Interleukin-8: a corneal
factor that induces neovascularization. Am. J. Pathol. 141,
1279-1284 (1992). [0242] 22. Murdoch C, Monk P N, Finn A. Cxc
chemokine receptor expression on human endothelial cells. Cytokine
11, 704-12 (1999). [0243] 23. Koch, A E. et al. Interleukin-8
(IL-8) as a macrophage-derived mediator of angiogenesis. Science,
258:1798-1801 (1992). [0244] 24. Strieter, R M, et al The
functional role of the ELR motif in CXC chemokine-mediated
angiogenesis. J. Biol. Chem. 270, 27348-27357 (1995). [0245] 25.
Angiolillo, A L, et al. Human interferon-inducible protein 10 is a
potent inhibitor of angiogenesis in vivo. J Exp Med 182, 155-62
(1995). [0246] 26. Feil C, Augustin H G. Endothelial cells
differentially express functional CXC-chemokine receptor-4
(CXCR-4/fusin) under the control of autocrine activity and
exogenous cytokines. Biochem Biophys Res Commun 247, 38-45 (1998).
[0247] 27. Tachibana, K. et al. The chemokine receptor CXCR4 is
essential for vascularization of the gastrointestinal tract. Nature
393, 591-594 (1998). [0248] 28. Mohle R, Bautz F, Rafii S, Moore M
A, Brugger W, Kanz L. The chemokine receptor CXCR-4 is expressed on
C D34+ hematopoietic progenitors and leukemic cells and mediates
transendothelial migration induced by stromal cell-derived
factor-1. Blood 91, 4523-30 (1998). [0249] 29. Imai, K. et al.
Selective secretion of chemoattractants for haemopoietic progenitor
cells by bone marrow endothelial cells: a possible role in homing
of haemopoietic progenior cells to bone marrow. Br J Haematol 106,
905-11 (1999). [0250] 30. Peled, A. et al. Dependence of human stem
cell engraftment and repopulation of NOD/SCID mice on CXCR4.
Science 283, 845-88 (1999). [0251] 31. Voermans C, Gerritsen W R,
von dem Borne A E, van der Schoot C E. Increased migration of cord
blood-derived C D34+ cells, as compared to bone marrow and
mobilized peripheral blood C D34+ cells across uncoated or
fibronectin-coated filters. Exp. Hematol. 27, 1806-14 (2000).
[0252] 32. Janowska-Wieczorek, A. et al. Growth factors and
cytokines upregulate gelatinase expression in bone marrow C D34+
cells and their transmigration through reconstituted basement
membrane. Blood 93, 3379-3390 (1999). [0253] 33. Heymans, S. et al.
Inhibition of plasminogen activators or matrix metalloproteinases
prevents cardiac rupture but impairs therapeutic angiogenesis and
causes cardiac failure. Nat. Med. 5, 1135-1142 (1999). [0254] 34.
Luca M, Huang S, Gershenwald J E, Singh R K, Reich R, Bar-Eli M.
Expression of interleukin-8 by human melanoma cells up-regulates
MMP-2 activity and increases tumor growth and metastasis. Am J
Pathol 151, 1105-1113 (1997). [0255] 35. Masure, S., Proost, P.,
Van Damme, J., Opdenakker, M D. Purification and identification of
91-kDa neutrophil gelatinase. Release by the activating peptide
interleukin-8. Eur. J. Biochem. 198, 391-398 (1991). [0256] 36.
Hart, P. H. et al. Activation of human monocytes by
granulocyte-macrophage colony-stimulating factor: increased
urokinase-type plasminogen activator activity. Blood 77, 841-848
(1991). [0257] 37. Stacey, K. J., Fowles, L. F., Colman, M. S.,
Ostrowski, M. C., Hume, D. A. Regulation of urokinase-type
plasminogen activator gene transcription by macrophage
colony-stimulating factor. Mol. Cell. Biol. 15, 3430-3441 (1995).
[0258] 38. Pei, X. H. et al. G-CSF increases secretion of
urokinase-type plasminogen activator by human lung cancer cells.
Clin. Exp. Metastasis 16, 551-558 (1998). [0259] 39. Semerad, C L,
et al. A role for G-CSF receptor signalling in the regulation of
hematopoietic cell function but not lineage commitment or
differentiation. Immunity 11, 153-161 (1999). [0260] 40. Nagasawa,
T, et al. Defects of B-cell lymphopoiesis and bone-marrow
myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature
382, 635-638 (1996). [0261] 41. Rempel S A, Dudas S, Ge S,
Gutierrez J A. Identification and localization of the cytokine SDF1
and its receptor, CXC chemokine receptor 4, to regions of necrosis
and angiogenesis in human glioblastoma. Clin Cancer Res 6, 102-11
(2000). [0262] 42. Globerson, A. Hematopoietic stem cells and
aging. Exp. Gerontol. 34, 137-146 (1999). [0263] 43. de la Rubia,
J., Diaz, M. A., Verdeguer, A., et al. Donor age-related
differences in PBPC mobilization with rHuG-CSF. Transfusion 41,
201-205 (2001). [0264] 44. Leferovich J M, et al. Heart
regeneration in adult MRL mice. Proc Natl Acad Sci USA 98,
9830-9835 (2001). [0265] 45. Vander Heiden M G, Plas D R, Rathmell
J C, Fox C J, Harris M H, Thompson C B. Growth factors can
influence cell survival through effects on glucose metabolism. Mol
Cell Biol 21, 5899-5912 (2001). [0266] 46. Rossig L, Jadidi A S,
Urbich C, Badorff C, Zeiher A M, and Dimmeler S. Akt-dependent
phosphorylation of p21Cip1 regulates PCNA binding and proliferation
of endothelial cells. Mol Cell Biol 21, 5644-5657 (2001). [0267]
47. Tomita S, et al. Autologous transplantation of bone marrow
cells improves damaged heart function. Circulation 100, 11-247
(1999). [0268] 48. Orlic D, et al. Bone marrow cells regenerate
infarcted myocardium. Nature 410, 701-705 (2001) [0269] 49. Kehat
I, et al. Human embryonic stem cells can differentiate into
myocytes with structural and functional properties of
cardiomyocytes. J Clin Invest. 108, 407-14 (2001). [0270] 50. Rossi
et al., 1992, Aids Research and Human Retroviruses 8, 183. [0271]
51. Hampel et al., E P0360257 [0272] 52. Hampel and Tritz, 1989
Biochemistry 28, 4929. [0273] 53. Hampel et al., 1990 Nucleic Acids
Res. 18, 299. [0274] 54. Perrotta and Been, 1992 Biochemistry 31,
16. [0275] 55. Guerrier-Takada et al., 1983 Cell 35, 849. [0276]
56. Forster and Altman, 1990 Science 249, 783. [0277] 57. Saville
and Collins, 1990 Cell 61, 685-696. [0278] 58. Saville and Collins,
1991 Proc. Natl. Acad. Sci. USA 88, 8826-8830. [0279] 59. Guo and
Collins, 1995 EMBO J. 14, 368. [0280] 60. Cech et al., U.S. Pat.
No. 4,987,071. [0281] 61. Matzura O, Wennborg A (1996) RNAdraw: an
integrated program for RNA secondary structure calculation and
analysis under 32-bit Microsoft Windows. Comput Appl Biosci
12:247-9. [0282] 49. Santoro S W, Joyce G F (1997) A general
purpose RNA-cleaving DNA enzyme. Proc Nati Acad Sci USA 94:4262-6.
[0283] 50. Santoro S W, Joyce G F (1998) Mechanism and utility of
an RNA-cleaving DNA enzyme. Biochemistry 37:13330-42. [0284] 51.
MacLellan W R and Schneider M D. Genetic dissection of cardiac
growth control pathways Annu. Rev. Physiol. 2000. 62:289-320.7.
[0285] 52. Sherr C J, Roberts J M. CDK inhibitors: positive and
negative regulators of G(1)-phase progression. Genes Dev. 1999;
13:1501-1512. [0286] 53. Hill M F, Singal P K. Antioxidant and
oxidative stress changes during heart failure subsequent to
myocardial infarction in rats. Am J Pathol. 1996, 148:291-300.
[0287] 54. Hill M F, Singal P K. Right and left myocardial
antioxidant responses during heart failure subsequent to myocardial
infarction. Circulation 1997 96:2414-20. [0288] 55. Li, Y.,
Jenkins, C. W., Nichols, M. A. and Xiong, Y. (1994) Cell cycle
expression and p53 regulation of the cyclin-dependent kinase
inhibitor p21. Oncogene, 9, 2261-2268 [0289] 56. Steinman, R. A.,
Hoffman, B., Iro, A., Guillouf, C., Liebermann, D. A. and
El-Houseini, M. E. (1994) Induction of p21 (WAF1/CIP1) during
differentiation. Oncogene, 9, 3389-3396 [0290] 57. Halevy, O.,
Novitch, B. G., Spicer, D. B., Skapek, S. X., Rhee, J., Hannon, G.
J., Beach, D. and Lassar, A. B. (1995) Correlation of terminal cell
cycle arrest of skeletal muscle with induction of p21 by MyoD.
Science, 267, 1018-1021. [0291] 58. Andres, V. and Walsh, K. (1996)
Myogenin expression, cell cycle withdrawal and phenotypic
differentiation are temporally separable events that precedes cell
fusion upon myogenesis. J. Cell Biol., 132, 657-666. [0292] 59.
Tsurimoto, T. PCNA Binding Proteins. Frontiers in Bioscience,
4:849-858, 1999. [0293] 60. Levkau B, Koyama H, Raines E W, Clurman
B E, Herren B, Orth K, Roberts J M, Ross R. Cleavage of
p21cip1/waf1 and p27 kip1 mediates apoptosis in endothelial cells
through activation of cdk2: role of a caspase cascade. Mol Cell.
1998; 1:553-563. [0294] 61. Adachi S, et al. Cyclin A/cdk2
activation is involved in hypoxia-induced apoptosis in
cardiomyocytes Circ Res. 88:408, 2001. [0295] 62. Ichijo H, et al.
Induction of apoptosis by ASK1, a mammalian MAPKKK that activates
SAPK/JNK and p38 signaling pathways. Science 275:90-94 (1997).
[0296] 63. Tobiume, K., Inage, T., Takeda, K., Enomoto, S.,
Miyazono, K. and Ichijo, H. (1997) Molecular cloning and
characterization of the mouse apoptosis signal-regulating kinase 1.
Biochem. Biophys. Res. Commun., 239, 905-910. [0297] 64. Asada M,
Yamada T, Ichijo h, Delia D, Miyazono K, Fukumuro K, and Mizutani S
Apoptosis inhibitory activity of cytoplasmic p21Cip1/WAF1 in
monocytic differentiation. EMBO J, 18:1223-1234, 1999. [0298] 65.
Saitoh H, et al. Mammalian thioredoxin is a direct inhibitor of
apoptosis signal-regulating kinase (ASK)1. EMBO J. 17: 2596-2606,
1998. [0299] 66. Nishiyama A, et al. Identification of
Thioredoxin-binding Protein-2/Vitamin D3 Up-regulated Protein 1 as
a Negative Regulator of Thioredoxin Function and Expression. J Biol
Chem, 31, 21645-21650, 1999. [0300] 67. Junn E, et al. Vitamin D3
Up-Regulated Protein1 Mediates Oxidative Stress Via Suppressing the
Thioredoxin Function. J Immunol. 164:6287-6295, 2000. [0301] 68.
Holmgren, A. (1985) Annu. Rev. Biochem. 54, 237-271. [0302] 69.
Chae, H. Z., Chung, S. J. & Rhee, S. G. (1994) J. Biol. Chem.
269, 27670-27678. [0303] 70. Netto, L. E. S., Chae, H. Z., Kang,
S., Rhee, S. G. & Stadtman, E. R. (1996) J. Biol. Chem. 271,
15315-15321. [0304] 71. Chae, H. Z., Uhm, T. B. & Rhee, S. G.
(1994) Proc. Natl. Acad. Sci USA. 91, 7022-7026. [0305] 72. Kwon,
S. J., Park, J., Choi, W., Kim, I. H. & Kim, K. (1994) Biochem.
Biophys. Res. Comm. 201, 8-15. [0306] 73. Kang, S. W., Baines, I.
C. & Rhee, S. G. (1998) J. Biol. Chem. 273, 6303-6311. [0307]
74. Hirotsu, S, et al. Crystal structure of a multifunctional 2-Cys
peroxiredoxin heme-binding protein 23 kDa/proliferation-associated
gene product. Proc. Natl Acad Sci, USA. 96, 12333-12338, 1999.
[0308] 75. Siow, R. C. M., et al. (1995) FEBS Lett. 368, 239-242.
[0309] 76. Prosperi, M., Ferbus, D., Karczinski, I. & Goubin,
G. (1993) J. Biol. Chem. 268, 11050-11056. [0310] 77. Sauri, H.,
Butterfield, L., Kim, A. & Shau, H. (1995) Biochem. Biophys.
Res. Commun. 208, 964-969. [0311] 78. Ishii T et al. Transcription
factor Nrf2 coordinately regulates a group of oxidative
stress-inducible genes in macrophages. J Biological Chem 2000,
275:16023-16029 [0312] 79. Itoh K, Wakabayashi N, Katoh Y, Ishii T,
Igarashi K, Engel J D, Yamamoto M. Keap1 represses nuclear
activation of antioxidant responsive elements by Nrf2 through
binding to the amino-terminal Neh2 domain. Genes Dev. 1999 Jan. 1;
13(1):76-86. [0313] 80. Lee, J-M, et al. Phosphatidylinositol
3-Kinase, Not Extracellular Signal-regulated Kinase, Regulates
Activation of the Antioxidant-Responsive Element in IMR-32 Human
Neuroblastoma Cells J. Biol. Chem., 276:20011-20016, 2001. [0314]
81. Kim Y C, Masutani H, Yamaguchi Y, Itoh K, Yamamoto M, Yodoi J.
Hemin-induced activation of the thioredoxin gene by Nrf2. A
differential regulation of the antioxidant responsive element by a
switch of its binding factors. J Biol Chem. 2001 276:18399-406.
[0315] 82. Cho H Y, Jedlicka A E, Reddy S P, Kensler T W, Yamamoto
M, Zhang L Y, Kleeberger S R. Role of NRF2 in Protection Against
Hyperoxic Lung Injury in Mice. Am J Respir Cell Mol Biol 2002,
26:175-182.
[0316] 83. Kumuda C. Das, Paula M. B. Pahl, Xiao-Ling Guo, and Carl
W. White. Induction of Peroxiredoxin Gene Expression by Oxygen in
Lungs of Newborn Primates. Am. J. Respir. Cell Mol. Biol. 2001,
25:226-232. [0317] 84. Wen S-T, and Van Etten, R A The PAG gene
product, a stress-induced protein with antioxidant properties, is
an Abl SH3-binding protein and a physiological inhibitor of c-Abl
tyrosine kinase activity. Genes and Development, 19: 2456-2467,
1997. [0318] 85. Kharbanda, S., Yuan, Z. M., Weichselbaum, R. &
Kufe, D. Determination of cell fate by c-Abl activation in the
response to DNA damage. Oncogene 17, 3309-3318 (1998). [0319] 86.
Yuan Z M et al, Nature 1996 18; 382(6588):272-4. [0320] 87. Jost,
C. A., Marin, M. C. & Kaelin, W. J. p73 is a human p53-related
protein that can induce apoptosis. Nature 389, 191-194 (1997).
[0321] 88. Agami, R, Blandino G, Oren M, Shaul Y. Interaction of
c-Abl and p73[alpha] and their collaboration to induce apoptosis
Nature 399, 809-813 (1999). [0322] 89. Sun X, et al. Activation of
the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species. J
Biol. Chem. 2000, 275:17237-17240. [0323] 90. Kumar S, et al.
Targeting of the c-Abl Tyrosine Kinase to Mitochondria in the
Necrotic Cell Death Response to Oxidative Stress J. Biol. Chem.,
276, 17281-17285, 2001. [0324] 91. Chen, K. S. and DeLuca, H. F.
Isolation and characterization of a novel cDNA from HL-60 cells
treated with 1,25-dihydroxyvitamin D-3 JOURNAL Biochim. Biophys.
Acta 1219 (1), 26-32 (1994). [0325] 92. Zhang et al. Clinical
Pharmacology & Therapeutics (1995) 58(1), 44-53. [0326] 93.
Tetsuro Ishii, Ken Itoh, Junetsu Akasaka, Toru Yanagawa, Satoru
Takahashil, Hiroshi Yoshida, Shiro Bannai and Masayuki Yamamoto,
Carcinogenesis Vol. 21(5):1013-1016, (2000). [0327] 94. Das K C,
Pahl P M, Guo X L, White C W, Am. J. Respir. Cell Mol. Biol.,
(2001), 25(2):226-32. [0328] 95. Immenschuh S, Iwahara S, Satoh H,
Nell C, Katz N, Muller-Eberhard U., Biochemistry (1995) 17;
34(41):13407-11. [0329] 96. Ken Itoh, Nobunao Wakabayashi, Yasutake
Katoh, Tetsuro Ishii, Kazuhiko Igarashi, James Douglas Engel, 1 and
Masayuki Yamamoto, Genes and Development, 13(1):76-86, (1999).
Experimental Results II
[0330] Intravenous Administration of Human Bone Marrow-Derived
Endothelial Progenitor Cells Induces Neovascularization and
Prevents Cardiomyocyte Apoptosis within Five Days
Post-Infarction.
[0331] We sought to determine how soon after intravenous injection
of bone marrow-derived endothelial progenitor cells does
neovascularization develop in hearts of rats having undergone
permanent LAD ligation 48 hours earlier. When animals were
sacrificed at two days after intravenous injection of DiI-labelled
human CD34+ cells obtained by G-CSF mobilization (>98% CD34
purity, containing 6-12% CD117bright angioblasts), numerous DiI
positive interstitial cells were seen in the peri-infarct region,
but no defined vascular structures expressing DiI could be
identified, data not shown. In contrast, animals sacrificed at five
days post-infusion of human CD34+ cells demonstrated numerous
DiI-positive vascular structures at the peri-infarct region and
3.5-fold higher numbers of capillaries in comparison to rats
receiving saline, FIG. 21(a) (p<0.01). The increase in
microvascularity at 5 days was accompanied by 3.3-fold lower
numbers of apoptotic cardiomyocytes at the peri-infarct region,
defined by dual positivity for troponin I and TUNEL, in comparison
to controls receiving saline, FIG. 21(b) (p<0.01). Together,
these data indicate that the vasculogenic process of
differentiation and organization of bone marrow-derived angioblasts
to a mature, functional network of capillaries in the ischemic
myocardium takes from two to five days.
Intravenous Administration of Human Bone Marrow-Derived Endothelial
Progenitor Cells Induces Cell Cycling of Cardiomyocyte Progenitors
and Cardiomyocyte Differentiation.
[0332] We examined cardiac tissue from experimental and control
animals sacrificed at five days by immunohistochemistry and
confocal microscopy for evidence of cycling cardiomyocytes, as has
been suggested to occur rarely in the adult heart after acute
ischemia. While no mature troponin-positive cycling cardiomyocytes
were detected in any control or experimental animals at day 5
post-infarction, animals receiving human bone marrow-derived CD34+
cells demonstrated numerous clusters of small, cycling cells at the
peri-infarct region that were of rat origin, as defined by a
monoclonal antibody specific for rat Ki67, FIG. 22(a). These cells
were negative for cardiomyocyte-specific troponin I, a marker of
cardiomyocyte differentiation, but stained positively for
alpha-sarcomeric actin, indicating they were immature cells of
cardiomyocyte lineage. Similar clusters of cycling cardiomyocyte
progenitors were not seen in control animals injected with
saline.
[0333] Tissues obtained from animals sacrificed at two weeks after
human CD34+ administration no longer demonstrated clusters of
small, cycling cardiomyocyte progenitors, but instead a high
frequency of large, mature rat cardiomyocytes at the peri-infarct
region with detectable DNA activity, as determined by dual staining
with mAbs reactive against cardiomyocyte-specific troponin I and
rat Ki67, FIGS. 22 (b) and (c). The number of cycling, mature
cardiomyocytes at the peri-infarct region was 4-fold higher in
animals receiving human endothelial progenitor cells than in
LAD-ligated controls receiving saline (p<0.01) in whom there was
a high frequency of cells with fibroblast morphology and reactivity
with rat Ki67, but not troponin I. We speculate that the cycling,
mature cardiomyocytes seen at day 14 post-infarction in animals who
received human endothelial progenitor cells are the differentiated
progeny of the small, cycling immature cardiomyocyte progenitors
seen in the same anatomical location at day 5 and accompanying the
onset of neovascularization. Whether the cycling cardiomyocyte
progenitors represent in situ cardiac stem cells normally residing
in the heart in a quiescent state, or whether these cells have
migrated to the heart from elsewhere in the body, such as the bone
marrow, remains to be determined.
Myocardial Expression of HBP23, a Rat Peroxiredoxin Protecting
Cells Against Damage by Oxygen Radicals, is Decreased by Ischemia
and Increased by Neovascularization.
[0334] We next sought to identify a molecular mechanism to explain
the relationship between neovascularization at the peri-infarct
region and proliferation/regeneration of adjacent cardiomyocyte
progenitors. We first performed cDNA subtractive hybridization in
order to identify patterns of changes in gene expression between
normal rat hearts and rat hearts 48 hours after LAD ligation. Since
deficits in antioxidants and increased oxidative stress
accompanying myocardial infarction have been directly implicated in
the pathogenesis of post-infarct heart failure (13-15), we chose to
examine changes in expression of particular antioxidant genes. A
family of antioxidant enzymes known as peroxiredoxins, which
demonstrate peroxidase activity (16) and are induced by oxygen
(17), play a critical role in regulating cell survival during
periods of oxidative stress, such as ischemia. They serve to
maintain the thiol-disulfide status of the cytosol by undergoing
reversible oxidation-reduction reactions involving electron
transfer via disulfide bridges formed with thioredoxin (TRX), which
constitutes one of the principal cellular reducing systems in
mammals (18). In addition, peroxiredoxins can inhibit c-Abl
tyrosine kinase activity induced by oxidative stress (19,20) and
can rescue cells from both a pro-apoptotic state and cell cycle
arrest induced by the activated c-Abl gene product (21). By cDNA
subtractive hybridization, we found that expression of the rat
peroxiredoxin HBP23 mRNA was reduced in rat hearts 48 hours after
LAD ligation compared with normal rat hearts. By RT-PCR, HBP23 mRNA
levels in rat hearts decreased at two weeks post-LAD ligation by a
mean of 34% compared with normal rat hearts, FIG. 23 (p<0.01).
In contrast, HBP23 mRNA levels in LAD-ligated rat hearts two weeks
after receiving human angioblasts returned to levels only 14% lower
than in non-ischemic controls. Since mRNA expression of
peroxiredoxins is induced by oxygen, these data suggested that
HBP23 mRNA expression was inhibited by the acute ischemic event and
induced following angioblast-dependent neovascularization.
Generation Of A DNA Enzyme To Cleave HBP23 mRNA.
[0335] To investigate whether induced expression of HBP23 is
involved in the mechanism by which neovascularization affects
myocardial cellular apoptosis, regeneration/proliferation, and
function, we generated a catalytic DNA enzyme targeting specific
sequences within the rat HBP23 gene (22,23). We chose to
specifically target pyrimidine-purine junctions at or near the
translational start site AUG of messenger RNA for rat HBP23, a
region that is conserved between species and has low relative free
energy (24). In this region, the rat HBP23 sequence differs by only
one base from the human homologue, proliferation-associated gene
(PAG). To produce the control DNA enzyme, the nucleotide sequence
in the two flanking arms of the HBP23 DNA enzyme was scrambled
without altering the catalytic domain. The 3' terminus of each
molecule was capped with an inverted 3'-3'-linked thymidine for
resistance to 3'-to-5' exonuclease digestion.
[0336] The DNA enzyme against HBP23 cleaved the 23-base
oligonucleotide synthesized from the sequence of rat HBP23 mRNA, in
a dose- and time-dependent manner, FIG. 24 (a). In contrast, the
DNA enzyme did not cleave a 23-base oligonucleotide form the human
homologue PAG which differs from the rat HBP23 oligonucleotide by
only one base, demonstrating its exquisite target specificity. A
DNA enzyme with specificity for the same translational start site
in the human PAG gene efficiently cleaved the PAG oligonucleotide,
but not the one derived from HBP23 (data not shown). The scrambled
control DNA enzyme did not cleave either oligonucleotide. To
determine the effect of the DNA enzyme on endogenous HBP23
production, cardiomyocyte monolayers obtained from fetal rat hearts
were grown to confluence and transfected with species-specific DNA
enzymes or scrambled control. Densitometric analysis of RT-PCR
products following reverse transcription of cellular mRNA showed
that the HBP23 DNA enzyme inhibited steady-state mRNA levels in
cultured rat cells by over 80%, FIG. 24 (b), relative to the
scrambled DNA.
In Vivo Administration of a DNA Enzyme to Prevent Induction of
HBP23 mRNA in Rat Myocardium: Neovascularization is not Affected,
but its Effects on Cardiomyocyte Apoptosis, Regeneration, and
Function are Abrogated.
[0337] To investigate the in vivo relevance of induced expression
of HBP23 in experimental myocardial infarction, 48 hours after LAD
ligation rats were injected with human bone marrow-derived
endothelial progenitor cells intravenously together with
intramyocardial injections of either HBP23 DNA enzyme or scrambled
control. As shown in FIG. 25 (a), HBP23 DNA enzyme had no effect on
induction of neovascularization by human bone marrow angioblasts.
When sacrificed at day 5 post-infusion, rats who received human
endothelial progenitors, irrespective of whether HBP23 DNA enzyme
or scrambled control was co-injected, demonstrated increased
myocardial capillary density in comparison to saline controls. In
contrast, injection of the HBP23 DNA enzyme, but not the scrambled
control, abrogated the anti-apoptotic effects of
neovascularization, FIG. 25 (b), and the improvement in cardiac
function, FIG. 25 (c). Among animals receiving human endothelial
progenitor cells and demonstrating myocardial neovascularization,
treatment with HBP23 DNA enzyme resulted in 1.7-fold higher levels
of cardiomyocyte apoptosis (p<0.01) and 38% mean deterioration
in cardiac function as assessed by echocardiography (p<0.01). In
addition, the HBP23 DNA enzyme exerted striking effects on
cardiomyocyte progenitor proliferation/regeneration. Whereas
peri-infarct clusters of small rat cells expressing Ki67 and
alpha-sarcomeric actin were easily detected in animals receiving
angioblasts together with the scrambled control DNA, none were
identified in animals receiving the HBP23 DNA enzyme. These results
clearly demonstrate that angioblast-dependent neovascularization
protects cardiomyocytes against apoptosis and induces
proliferation/regeneration of resident cardiomyocyte lineage
progenitors via pathways regulated by peroxiredoxin gene
products.
DISCUSSION
[0338] In this study we showed that neovascularization of ischemic
myocardium by human bone marrow derived angioblasts results in both
protection of mature cardiomyocytes at the peri-infarct region
against apoptosis and stimulation of cardiomyocyte progenitors at
the same site to enter cell cycle, proliferate and regenerate.
Moreover, we showed that the mechanism by which
angioblast-dependent neovascularization regulates cardiomyocyte
survival and self-renewal appears to involve at least one family of
genes involved in anti-apoptotic and pro-proliferative pathways
accompanying oxidative stress, the peroxiredoxins. While oxygen
tension positively regulates peroxiredoxin gene expression (17),
whether this alone explains the positive effect of
angioblast-mediated neovascularization on HBP mRNA expression is
not clear. Since peroxiredoxin mRNA expression is induced by
protein kinase C delta (25) it is possible that bone marrow
angioblasts may be a source of extracellular signals regulating
protein kinase C delta activation and consequently cell survival,
such as FGF-1 (26).
[0339] Deficits in antioxidants and increased oxidative stress
accompanying myocardial infarction have been directly implicated in
the pathogenesis of post-infarct heart failure (13-15). Our study
suggests that reduced levels of peroxiredoxins post-infarction may
be of direct causality in the subsequent remodelling and failure of
the left ventricle. The antioxidant effects of peroxiredoxins are
coupled with the physiological electron donor activity of the TRX
system (27-29). In addition to directly interacting with TRX, the
peroxiredoxin gene products specifically bind the SH3 domain of
c-Abl, a non-receptor tyrosine kinase, inhibiting its activation
(21). Activation of c-Abl through the SH3 domain by stimuli such as
agents that damage DNA induces either arrest of the cell cycle in
phase G1 or cellular apoptosis (30). Cell cycle arrest is dependent
on the kinase activity of c-Abl which downregulates the activity of
the cyclin-dependent kinase Cdk2 and induces the expression of p21
(31). By associating with c-Abl in vivo, peroxiredoxins can inhibit
tyrosine phosphorylation induced by c-Abl overexpression and rescue
cells from both the cytostatic and pro-apoptotic effects of the
activated c-Abl gene product (32). Our in vivo demonstration that
co-administration of a DNA enzyme directed against the rat
peroxiredoxin HBP23 abrogated the anti-apoptotic and
pro-proliferative effects of human angioblast-dependent
neovascularization in the infarcted rat heart argues strongly that
this family of genes is directly implicated in the mechanism of
action by which neovascularization results in improvement in
cardiac function and prevention of heart failure.
[0340] Throughout life, a mixture of young and old cells is present
in the normal myocardium. Although most myocytes seem to be
terminally differentiated, there is a fraction of younger myocytes
that retains the capacity to replicate (33). In the present study,
human angioblast-dependent neovascularization resulted, Within five
days, in proliferation of small, endogenous rat cardiomyocyte
precursors at the peri-infarct region. The dividing myocyte
precursors could be identified by immunohistochemical criteria on
the basis of concomitant cell surface expression of
alpha-sarcomeric actin, but not troponin I, and proliferating
nuclear structures, defined by an antibody specific for rat Ki67.
Since this process was followed within fourteen days by increasing
numbers in the same location of mature, cycling cardiomyocytes,
defined on the basis of morphology, cell surface expression of
troponin I, and nuclear expression of Ki67, we conclude that
cycling cardiomyocyte precursors differentiated in situ to become
new, mature, functional cardiomyocytes. Whether these precursors
are derived from a resident pool of cardiomyocyte stem cells or
from a renewable source of circulating bone marrow-derived stem
cells that home to the damaged myocardium remains to be determined.
Moreover, while the signals required for in situ expansion of
cardiomyocyte precursors appear to involve, at least in part,
pathways regulated by members of the peroxiredoxin gene family, the
signals required for cardiomyocyte differentiation are, at present,
unknown. Gaining an understanding of these issues may open the
possibility of manipulating the biology of endogenous
cardiomyocytes in order to augment the healing process after
myocardial ischemia.
Methods and Materials
Purification and Characterization of Cytokine-Mobilized Human CD34+
Cells.
[0341] Single-donor leukopheresis products were obtained from
humans treated with recombinant G-CSF 10 mg/kg (Amgen, Calif.) sc
daily for four days. Donors were healthy individuals undergoing
standard institutional procedures of bone marrow mobilization,
harvesting and isolation for allogeneic stem cell transplants.
Mononuclear cells were separated by Ficoll-Hypaque, and
highly-purified CD34+ cells (>98% positive) were obtained using
magnetic beads coated with anti-CD34 monoclonal antibody (mAb)
(Miltenyi Biotech, CA). Purified CD34 cells were stained with
fluorescein-conjugated mAbs against CD34 and CD117 (Becton
Dickinson, CA), AC133 (Miltenyi Biotech, CA), CD54 (Immunotech,
CA), CD62E (BioSource, MA), VEGFR-2, Tie-2, vWF, eNOS, CXCR1,
CXCR2, and CXCR4 (all Santa Cruz Biotech, CA), and analysed by
four-parameter fluorescence using FACScan (Becton Dickinson, CA).
Cells positively selected for CD34 expression were also stained
with phycoerythrin (PE)-conjugated anti-CD117 mAb (Becton
Dickinson, CA), and sorted for bright and dim fluorescence using a
Facstar Plus (Becton Dickinson) and a PE filter. Intracellular
staining for GATA-2 was performed by permeabilizing one million
cells from each of the brightly and dimly fluorescing cell
populations using a Pharmingen Cytofix/Cytoperm kit, incubating for
30 minutes on ice with 10 ul of fluorochrome-conjugated mAbs
against both CD117 and CD34 surface antigens (Becton Dickinson,
CA). After resuspension in 250 ul of Cytofix/Cytoperm solution for
20 minutes at 4 degrees C., cells were incubated with a
fluorochrome-labeled mAb against GATA-2 (Santa Cruz Biotech, CA) or
IgG control for 30 minutes at 4 degrees C., and analyzed by
three-parameter flow cytometry.
Animals, Surgical Procedures, and Injection of Human Cells.
[0342] Rowett (rnu/rnu) athymic nude rats (Harlan Sprague Dawley,
Indianapolis, Ind.) were used in studies approved by the "Columbia
University Institute for Animal Care and Use Committee". After
anesthesia, a left thoracotomy was performed, the pericardium was
opened, and the left anterior descending (LAD) coronary artery was
ligated. Sham-operated rats had a similar surgical procedure
without having a suture placed around the coronary artery.
Histology and Measurement of Infarct Size.
[0343] Following excision at 2 and 15 weeks, left ventricles from
each experimental animal were sliced at 10-15 transverse sections
from apex to base. Representative sections were fixed in formalin
and stained for routine histology (H&E) to determine
cellularity of the myocardium, expressed as cell number per high
power field (HPF) (600.times.). A Masson trichrome stain was
performed, which labels collagen blue and myocardium red, to
evaluate collagen content on a semiquantitative scale (0-3+), with
1+ light blue, 2+ light blue and patches of dark blue, and 3+ dark
blue staining. This enabled measurement of the size of the
myocardial scar using a digital image analyzer. The lengths of the
infarcted surfaces, involving both epicardial and endocardial
regions, were measured with a planimeter digital image analyzer and
expressed as a percentage of the total ventricular circumference.
Final infarct size was calculated as the average of all slices from
each heart. All studies were performed by a blinded pathologist
(MJS). Infarct size was expressed as percent of total left
ventricular area. Final infarct size was calculated as the average
of all slices from each heart.
Quantitation of Capillary Density.
[0344] In order to quantitate capillary density and species origin
of the capillaries, additional sections were stained freshly with
mAbs directed against rat or human CD31 (Serotec, UK, and Research
Diagnostics, NJ, respectively), factor VIII (Dako, CA), and rat or
human MHC class I (Accurate Chemicals, CT). Arterioles were
differentiated from large capillaries by the presence of a smooth
muscle layer, identified by staining sections with a monoclonal
antibody against muscle-specific desmin (Dako, Ca). Staining was
performed by immunoperoxidase technique using an Avidin/Biotin
Blocking Kit, a rat-absorbed biotinylated anti-mouse IgG, and a
peroxidase-conjugate (all Vector Laboratories Burlingame, Calif.).
Capillary density was determined at 5 days and 2 weeks post
infarction from sections labeled with anti-CD31 mAb, and confirmed
with anti-factor VIII mAb, and compared to the capillary density of
the unimpaired myocardium. Values are expressed as the number of
CD31-positive capillaries per HPF (400.times.).
Quantitation of Cardiomyocyte Proliferation.
[0345] Cardiomyocyte DNA synthesis and cell cycling was determined
by dual staining of rat myocardial tissue sections obtained from
LAD-ligated rats at two weeks after injection of either saline or
CD34+ human cells, and from healthy rats as negative controls, for
cardiomyocyte-specific troponin I and human- or rat-specific Ki67.
Briefly, paraffin embedded sections were microwaved in a 0.1M EDTA
buffer, and stained with either a primary monoclonal antibody
against rat Ki67 at 1:3000 dilution (gift of Giorgio Catoretti,
Columbia University) or human Ki67 at 1:300 dilution (Dako, CA) and
incubated overnight at 4 degrees C. Following washes, sections were
incubated with a species-specific secondary antibody conjugated
with alkaline phosphatase at 1:200 dilution (Vector Laboratories
Burlingame, Calif.) for 30 minutes and positively-staining nuclei
were visualized as blue with a BCIP/NBT substrate kit (Dako, CA).
Sections were then incubated overnight at 4 degrees C. with a
monoclonal antibody against cardiomyocyte-specific troponin I
(Accurate Chemicals, CT) and positively-staining cells were
visualized as brown through the Avidin/Biotin system described
above. Cardiomyocytes progressing through cell cycle in the infarct
zone, peri-infarct region, and area distal to the infarct were
calculated as the proportion of troponin I-positive cells per high
power field co-expressing Ki67. For confocal microscopy,
fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse IgG
was used as secondary antibody to detect Ki67 in nuclei. A
Cy5-conjugated mouse mAb against alpha-sarcomeric actin (clone 5C5;
Sigma) was used to detect cardiomyocytes, and propidium iodide was
used to identify all nuclei.
Measurement of Myocyte Apoptosis by DNA End-Labeling of Paraffin
Tissue Sections.
[0346] For in situ detection of apoptosis at the single cell level
we used the TUNEL method of DNA end-labeling mediated by
dexynucleotidyl transferase (TdT) (Boehringer Mannheim, Mannheim,
Germany). Rat myocardial tissue sections were obtained from
LAD-ligated rats at two weeks after injection of either saline or
CD34+ human cells, and from healthy rats as negative controls.
Briefly, tissues were deparaffinized with xylene and rehydrated
with graded dilutions of ethanol and two washes in
phosphate-buffered saline (PBS). The tissue sections were then
digested with Proteinase K (10 ug/ml in Tris/HCL) for 30 minutes at
370 C. The slides were then washed 3 times in PBS and incubated
with 50 ul of the TUNEL reaction mixture (TdT and
fluorescein-labeled dUTP) and incubated in a humid atmosphere for
60 minutes at 370 C. For negative controls TdT was eliminated from
the reaction mixture. Following 3 washes in PBS, the sections were
then incubated for 30 minutes with an antibody specific for
fluorescein-conjugated alkaline phosphatase (AP) (Boehringer
Mannheim, Mannheim, Germany). The TUNEL stain was visualized with a
substrate system in which nuclei with DNA fragmentation stained
blue, (BCIP/NBT substrate system, DAKO, Carpinteria, Calif.). The
reaction was terminated following three minutes of exposure with
PBS. To determine the proportion of blue-staining apoptotic nuclei
within myocytes, tissue was counterstained with a monoclonal
antibody specific for desmin. Endogenous peroxidase was blocked by
using a 3% hydrogen perioxidase solution in PBS for 15 minutes,
followed by washing with 20% goat serum solution. An anti-troponin
I antibody (Accurate Chemicals, CT) was incubated overnight (1:200)
at 40 degrees C. Following 3 washes sections were then treated with
an anti-rabbit IgG, followed by a biotin conjugated secondary
antibody for 30 minutes (Sigma, Saint Louis, Mo.). An avidin-biotin
complex (Vector Laboratories, Burlingame, Calif.) was then added
for an additional 30 minutes and the myocytes were visualized brown
following 5 minutes exposure in DAB solution mixture (Sigma, Saint
Louis, Mo.). Tissue sections were examined microscopically at
20.times. magnification. Within each 20.times. field 4 regions were
examined, containing at least 250 cells per region and cumulatively
approximating 1 mm2 of tissue, at both the peri-infarct site and
distally to this site. Stained cells at the edges of the tissue
were not counted. Results were expressed as the mean number of
apoptotic myocytes per mm2 at each site examined.
Analyses of Myocardial Function:
[0347] Echocardiographic studies were performed using a high
frequency liner array transducer (SONOS 5500, Hewlett Packard,
Andover, Mass.). 2D images were obtained at mid-papillary and
apical levels. End-diastolic. (EDV) and end-systolic (ESV) left
ventricular volumes were obtained by bi-plane area-length method,
and % left ventricular ejection fraction was calculated as
[(EDV-ESV)/EDV].times.100.
cDNA Subtractive Hybridization:
[0348] This technique enabled comparison of the pattern of gene
expression between hearts from normal rats and rats who underwent
left anterior descending (LAD) coronary artery ligation 48 hours
earlier. Briefly, messenger RNA was isolated from each heart, and 1
.mu.g was used for first-strand cDNA synthesis with random primers.
The subtractive hybridization was performed with the PCR-select
cDNA subtraction kit (CLONTECH), following the manufacturer's
recommendations. After second-strand synthesis, the two cDNA
libraries were digested with RsaI. Digestion products of the
"tester" library were ligated to a specific adapter (T7 promoter),
then hybridized with a 30-fold excess of the "driver" library for
subtraction. After hybridization, the remaining products were
further amplified by PCR. In the forward subtraction, which
determines the genes that are overexpressed in the ischemic sample,
the ischemic tissue is the "tester" and the normal tissue is the
"driver." In the reverse subtraction, the "tester" and the "driver"
are switched to determine the genes that are down-regulated in the
ischemic sample.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Analysis
of HBP23 mRNA Expression:
[0349] Total RNA was extracted using RNeasy Kits from Qiagen
(Valencia, Calif.) from normal rat hearts or from hearts of rats
who underwent LAD ligation two weeks earlier and received either
saline or human angioblasts. RNA was reverse transcribed with SMART
cDNA Synthesis Kit (Clontech, Palo Alto, Calif.). Amplification
reactions were conducted in a 25 ul volume with an initial step of
94 C for 5 min, followed by 26-32 cycles of 94 C for 30 sec and 68
C for 1 min, using TITANIUM Taq PCR Kits (Clontech, Palo Alto,
Calif.). Primers for HBP23 were 5'-GCTGATGAAGGTATCTCTTTCAGGGGCCTC
(SEQ ID NO:10) and 5'-GATGGTCTGCCCCTTACCAATAGTGGAAG (SEQ ID NO:11).
Rat GAPDH was used as internal control (forward primer
5'TGAAGGTCGGAGTCAACGGATTTG3' (SEQ ID NO:12), reverse primer
5'CATGTGGGCCA TGAGG TCCA CCAC3' (SEQ ID NO:13)). Ethidium bromide
stained bands of amplified fragments were quantified by
densitometric.
DNA Enzymes and RNA Substrates:
[0350] DNA enzymes with 3'-3' inverted thymidine were synthesized
by Integrated DNA technologies (Coralville, Iowa) and purified by
RNase-free IE-HPLC or RP-HPLC. The short RNA substrates
corresponding to target DNA enzyme sequences were chemically
synthesized followed by RNAse-free PAGE purification and also made
by in vitro transcription from a DNA template. Rat HBP23 cDNA and
human PAG cDNA were amplified by RT-PCR from total RNA of cultured
rat fetal cardiomyocytes and HUVEC, respectively, using the
following primer pair: 5'TTTACCCTCTTGACTTTACTTTTGTGTGTCCCAC3'
(forward primer) (SEQ ID NO:10) and 5'CCAGCTGGGCACACTTCACCATG3'
(reverse primer) (SEQ ID NO:11). HBP23 and PAG cDNA were cloned
into pGEM-T vectors (Promega) to obtain plasmid constructs
pGEM-ratHBP23 and pGEM-humanPAG. cDNA sequences were verified using
an automatic sequencing machine. 32P-labeled-nucleotide rat HBP23
and human PAG RNA transcripts were prepared by in vitro
transcription (SP6 polymerase, Promega) in a volume of 20 ml for 1
hour at 32.degree. C. Unincorporated label and short nucleotides
(<350base) were separated from radiolabeled species by
centrigugation on Chromaspin-200 columns (Clontech, Palo Alto, CA).
Synthetic RNA substrates were end-labeled with 32P using T4
polynucleotide kinase and incubated with 0.053/45uM HBP23 or
scrambled DNA enzyme. Reactions were allowed to proceed at
37.degree. C. and were "quenched" by transfer of aliquots to tubes
containing 90% formamide, 20 mM EDTA and loading dye. Samples were
separated by electrophoresis on 15% TBE-urea denaturing
polyacrylamide gels and detected by autoradiography at -80.degree.
C. Primary rat fetal cardiomyocytes were obtained from Clonetic
(USA) and grown in medium containing 2% FCS, 100 ug/ml streptomycin
and 100 IU/ml penicillin at 37.degree. C. in a humidified
atmosphere of 5% CO2. Cells were used in experiments between
passage 6 and 8. Subconfluent (70.about.80%) rat fetal
cardiomyocytes were transfected using 0.5 ml of serum-free medium
containing 0.05%5 uM HBP23 or scrambled DNA enzyme and 20 ug/ml
cationic lipids (DOTAP). After incubation for eight hours cells
were lysed using Trizol reagent (LifeSciences, CA) to isolate RNA
for RT-PCR of HBP23 expression, as above.
REFERENCES
[0351] 1. MacLellan W R and Schneider M D. Genetic dissection of
cardiac growth control pathways Annu. Rev. Physiol. 2000.
62:289-320. [0352] 2. Soonpaa M H, Field L J. Assessment of
cardiomyocyte DNA synthesis in normal and injured adult mouse
hearts. Am J Physiol 272, H220-6 (1997). [0353] 3. Kellerman S,
Moore J A, Zierhut W, Zimmer H G, Campbell J, Gerdes A M. Nuclear
DNA content and nucleation patterns in rat cardiac myocytes from
different models of cardiac hypertrophy. J Mol Cell Cardiol 24,
497-505 (1992). [0354] 4. Colucci, W. S. Molecular and cellular
mechanisms of myocardial failure. Am. J. Cardiol. 80(11A), 15L-25L
(1997). [0355] 5. Ravichandran, L. V. and Puvanakrishnan, R. In
vivo labeling studies on the biosynthesis and degradation of
collagen in experimental myocardial myocardial infarction. Biochem.
Intl. 24, 405-414 (1991). [0356] 6. Agocha, A., Lee, H. W.,
Eghali-Webb, M. Hypoxia regulates basal and induced DNA synthesis
and collagen type I production in human cardiac fibroblasts:
effects of TGF-beta, thyroid hormone, angiotensis II and basic
fibroblast growth factor. J. Mol. Cell. Cardiol. 29, 2233-2244
(1997). [0357] 7. Pfeffer, J. M., Pfeffer, M. A., Fletcher, P. J.,
Braunwald, E. Progressive ventricular remodeling in rat with
myocardial infarction. Am. J. Physiol. 260, H1406-414 (1991).
[0358] 8. Kajstura J, Leri A, Finato N, di Loreto N, Beltramo C A,
Anversa P. Myocyte proliferation in end-stage cardiac failure in
humans. Proc Natl Acad Sci USA 95, 8801-8805 (1998). [0359] 9.
Beltrami A P, et al. Evidence that human cardiac myocytes divide
after myocardial infarction. N Engl J Med 344, 1750-7 (2001).
[0360] 10. Kocher, A A, et al. Neovascularization of ischemic
myocardium by human bone-marrow-derived angioblasts prevents
cardiomyocyte apoptosis, reduces remodeling and improves cardiac
function. Nat. Med. 7, 430-6 (2001). [0361] 11. Vander Heiden M G,
Plas D R, Rathmell J C, Fox C J, Harris M H, Thompson C B. Growth
factors can influence cell survival through effects on glucose
metabolism. Mol Cell Biol 21, 5899-5912 (2001). [0362] 12. Rossig
L, Jadidi A S, Urbich C, Badorff C, Zeiher A M, and Dimmeler S.
Akt-dependent phosphorylation of p21Cip1 regulates PCNA binding and
proliferation of endothelial cells. Mol Cell Biol 21, 5644-5657
(2001). [0363] 13. Hill M F, Singal P K. Antioxidant and oxidative
stress changes during heart failure subsequent to myocardial
infarction in rats. Am J Pathol. 148, 291-300 (1996). [0364] 14.
Hill M F, Singal P K. Right and left myocardial antioxidant
responses during heart failure subsequent to myocardial infarction.
Circulation 96, 2414-20 (1997). [0365] 15. Cesselli D, et al.
Oxidative stress-mediated cardiac cell death is a major determinant
of ventricular dysfunction and failure in dog dilated
cardiomyopathy. Circ Res 89, 279-86 (2001). [0366] 16. Chae, H. Z.,
Chung, S. J. & Rhee, S. G. Thioredoxin-dependent peroxide
reductase from yeast. J. Biol. Chem. 269, 27670-27678 (1994).
[0367] 17. Das K C, Pahl P M, Guo X-L, and White C W. Induction of
peroxiredoxin gene expression by oxygen in lungs of newborn
primates. Am. J. Respir. Cell Mol. Biol., 25, 226-232, 2001. [0368]
18. Holmgren, A. Thioredoxin. Annu. Rev. Biochem. 54, 237-271
(1985). [0369] 19. Sun X, et al. Activation of the cytoplasmic
c-Abl tyrosine kinase by reactive oxygen species. J Biol. Chem.
275, 17237-17240 (2000). [0370] 20. Kumar S, et al. Targeting of
the c-Abl tyrosine kinase to mitochondria in the necrotic cell
death response to oxidative stress. J. Biol. Chem. 276, 17281-17285
(2001). [0371] 21. Wen S-T, and Van Etten, R A. The PAG gene
product, a stress-induced protein with antioxidant properties, is
an Abl S H3-binding protein and a physiological inhibitor of c-Abl
tyrosine kinase activity. Genes and Development 19, 2456-2467
(1997). [0372] 22. Breaker, R. R. Making catalytic DNAs. Science
290, 2095-2096 (2000). [0373] 23. Khachigian, L. M. Catalytic DNAs
as potential therapeutic agents and sequence-specific molecular
tools to dissect biological function. J Clin Invest 106, 1189-1195
(2000). [0374] 24. Zuker, M. On finding all suboptimal foldings of
an RNA molecule. Science 244, 48-52 (1989). [0375] 25. Li B, Ishii
T, Choon Ping Tan C P, Soh J W, and Goff S P. Pathways of induction
of Peroxiredoxin I expression in osteoblasts. Roles of p38
mitogen-activated protein kinase and protein kinase c. J. Biol.
Chem., 277, 12418-12422 (2002). [0376] 26. Wert M M and Palfrey H
C. Divergence in the anti-apoptotic signalling pathways used
awareness by nerve growth factor and basic fibroblast growth factor
(bFGF) in PC12 cells: rescue by bFGF involves protein kinase Cd.
Biochem. J. 352:175-182 (2000). [0377] 27. Chae, H. Z., Chung, S.
J. & Rhee, S. G. J. Biol. Chem. 269, 27670-27678 (1994). [0378]
28. Kwon, S. J., Park, J., Choi, W., Kim, I. H. & Kim, K.
Biochem. Biophys. Res. Comm. 201, 8-15 (1994). [0379] 29. Kang, S.
W., Baines, I. C. & Rhee, S. G. J. Biol. Chem. 273, 6303-6311
(1998). [0380] 30. Wen S-T, and Van Etten, R A. The PAG gene
product, a stress-induced protein with antioxidant properties, is
an Abl SH3-binding protein and a physiological inhibitor of c-Abl
tyrosine kinase activity. Genes and Development 19, 2456-2467
(1997). [0381] 31. Kharbanda, S., Yuan, Z. M., Weichselbaum, R I
and Kufe, D. Determination of cell fate by c-Abl activation in the
response to DNA damage. Oncogene 17, 3309-3318 (1998). [0382] 32.
Yuan Z M, Huang Y, Whang Y, Sawyers C, Weichselbaum R, Kharbanda S,
and Kufe D. Role for c-Abl tyrosine kinase in growth arrest
response to DNA damage. Nature 382, 272-4 (1996).
[0383] 33. Anversa P and Nadal-Ginard B. Myocyte renewal and
ventricular remodelling Nature 415, 240-243 (2002).
Sequence CWU 1
1
1112780DNAHOMO SAPIENS 1aaactaaccc ctctttttct ccaaaggagt gcttgtggag
atcggatctt ttctccagca 60attgggggaa agaaggcttt ttctctgact tcgcttagtg
taaccagcgg cgtatatttt 120ttaggcgcct tttcgaaaac ctagtagtta
atattcattt gtttaaatct tattttattt 180ttaagctcaa actgcttaag
aataccttaa ttccttaaag tgaaataatt ttttgcaaag 240gggtttcctc
gatttggagc tttttttttc ttccaccgtc atttctaact cttaaaacca
300actcagttcc atcatggtga tgttcaagaa gatcaagtct tttgaggtgg
tctttaacga 360ccctgaaaag gtgtacggca gtggcgagaa ggtggctggc
cgggtgatag tggaggtgtg 420tgaagttact cgtgtcaaag ccgttaggat
cctggcttgc ggagtggcta aagtgctttg 480gatgcaggga tcccagcagt
gcaaacagac ttcggagtac ctgcgctatg aagacacgct 540tcttctggaa
gaccagccaa caggtgagaa tgagatggtg atcatgagac ctggaaacaa
600atatgagtac aagttcggct ttgagcttcc tcaggggcct ctgggaacat
ccttcaaagg 660aaaatatggg tgtgtagact actgggtgaa ggcttttctt
gaccgcccga gccagccaac 720tcaagagaca aagaaaaact ttgaagtagt
ggatctggtg gatgtcaata cccctgattt 780aatggcacct gtgtctgcta
aaaaagaaaa gaaagtttcc tgcatgttca ttcctgatgg 840gcgggtgtct
gtctctgctc gaattgacag aaaaggattc tgtgaaggtg atgagatttc
900catccatgct gactttgaga atacatgttc ccgaattgtg gtccccaaag
ctgccattgt 960ggcccgccac acttaccttg ccaatggcca gaccaaggtg
ctgactcaga agttgtcatc 1020agtcagaggc aatcatatta tctcagggac
atgcgcatca tggcgtggca agagccttcg 1080ggttcagaag atcaggcctt
ctatcctggg ctgcaacatc cttcgagttg aatattcctt 1140actgatctat
gttagcgttc ctggatccaa gaaggtcatc cttgacctgc ccctggtaat
1200tggcagcaga tcaggtctaa gcagcagaac atccagcatg gccagccgaa
ccagctctga 1260gatgagttgg gtagatctga acatccctga taccccagaa
gctcctccct gctatatgga 1320tgtcattcct gaagatcacc gattggagag
cccaaccact cctctgctag atgacatgga 1380tggctctcaa gacagcccta
tctttatgta tgcccctgag ttcaagttca tgccaccacc 1440gacttatact
gaggtggatc cctgcatcct caacaacaat gtgcagtgag catgtggaag
1500aaaagaagca gctttaccta cttgtttctt tttgtctctc ttcctggaca
ctcacttttt 1560cagagactca acagtctctg caatggagtg tgggtccacc
ttagcctctg acttcctaat 1620gtaggaggtg gtcagcaggc aatctcctgg
gccttaaagg atgcggactc atcctcagcc 1680agcgcccatg ttgtgataca
ggggtgtttg ttggatgggt ttaaaaataa ctagaaaaac 1740tcaggcccat
ccattttctc agatctcctt gaaaattgag gccttttcga tagtttcggg
1800tcaggtaaaa atggcctcct ggcgtaagct tttcaaggtt ttttggaggc
tttttgtaaa 1860ttgtgatagg aactttggac cttgaactta cgtatcatgt
ggagaagagc caatttaaca 1920aactaggaag atgaaaaggg aaattgtggc
caaaactttg ggaaaaggag gttcttaaaa 1980tcagtgtttc ccctttgtgc
acttgtagaa aaaaaagaaa aaccttctag agctgatttg 2040atggacaatg
gagagagctt tccctgtgat tataaaaaag gaagctagct gctctacggt
2100catctttgct taagagtata ctttaacctg gcttttaaag cagtagtaac
tgccccacca 2160aaggtcttaa aagccatttt tggagcctat tgcactgtgt
tctcctactg caaatatttt 2220catatgggag gatggttttc tcttcatgta
agtccttgga attgattcta aggtgatgtt 2280cttagcactt taattcctgt
caaatttttt gttctcccct tctgccatct taaatgtaag 2340ctgaaactgg
tctactgtgt ctctagggtt aagccaaaag acaaaaaaaa ttttactact
2400tttgagattg ccccaatgta cagaattata taattctaac gcttaaatca
tgtgaaaggg 2460ttgctgctgt cagccttgcc cactgtgact tcaaacccaa
ggaggaactc ttgatcaaga 2520tgcccaaccc tgtgatcaga acctccaaat
actgccatga gaaactagag ggcaggtctt 2580cataaaagcc ctttgaaccc
ccttcctgcc ctgtgttagg agatagggat attggcccct 2640cactgcagct
gccagcactt ggtcagtcac tctcagccat agcactttgt tcactgtcct
2700gtgtcagagc actgagctcc acccttttct gagagttatt acagccagaa
agtgtgggct 2760gaagatggtt ggtttcatgt 27802391PRTHOMO SAPIENS 2Met
Val Met Phe Lys Lys Ile Lys Ser Phe Glu Val Val Phe Asn Asp1 5 10
15Pro Glu Lys Val Tyr Gly Ser Gly Glu Lys Val Ala Gly Arg Val Ile
20 25 30Val Glu Val Cys Glu Val Thr Arg Val Lys Ala Val Arg Ile Leu
Ala 35 40 45Cys Gly Val Ala Lys Val Leu Trp Met Gln Gly Ser Gln Gln
Cys Lys 50 55 60Gln Thr Ser Glu Tyr Leu Arg Tyr Glu Asp Thr Leu Leu
Leu Glu Asp65 70 75 80Gln Pro Thr Gly Glu Asn Glu Met Val Ile Met
Arg Pro Gly Asn Lys 85 90 95Tyr Glu Tyr Lys Phe Gly Phe Glu Leu Pro
Gln Gly Pro Leu Gly Thr 100 105 110Ser Phe Lys Gly Lys Tyr Gly Cys
Val Asp Tyr Trp Val Lys Ala Phe 115 120 125Leu Asp Arg Pro Ser Gln
Pro Thr Gln Glu Thr Lys Lys Asn Phe Glu 130 135 140Val Val Asp Leu
Val Asp Val Asn Thr Pro Asp Leu Met Ala Pro Val145 150 155 160Ser
Ala Lys Lys Glu Lys Lys Val Ser Cys Met Phe Ile Pro Asp Gly 165 170
175Arg Val Ser Val Ser Ala Arg Ile Asp Arg Lys Gly Phe Cys Glu Gly
180 185 190Asp Glu Ile Ser Ile His Ala Asp Phe Glu Asn Thr Cys Ser
Arg Ile 195 200 205Val Val Pro Lys Ala Ala Ile Val Ala Arg His Thr
Tyr Leu Ala Asn 210 215 220Gly Gln Thr Lys Val Leu Thr Gln Lys Leu
Ser Ser Val Arg Gly Asn225 230 235 240His Ile Ile Ser Gly Thr Cys
Ala Ser Trp Arg Gly Lys Ser Leu Arg 245 250 255Val Gln Lys Ile Arg
Pro Ser Ile Leu Gly Cys Asn Ile Leu Arg Val 260 265 270Glu Tyr Ser
Leu Leu Ile Tyr Val Ser Val Pro Gly Ser Lys Lys Val 275 280 285Ile
Leu Asp Leu Pro Leu Val Ile Gly Ser Arg Ser Gly Leu Ser Ser 290 295
300Arg Thr Ser Ser Met Ala Ser Arg Thr Ser Ser Glu Met Ser Trp
Val305 310 315 320Asp Leu Asn Ile Pro Asp Thr Pro Glu Ala Pro Pro
Cys Tyr Met Asp 325 330 335Val Ile Pro Glu Asp His Arg Leu Glu Ser
Pro Thr Thr Pro Leu Leu 340 345 350Asp Asp Met Asp Gly Ser Gln Asp
Ser Pro Ile Phe Met Tyr Ala Pro 355 360 365Glu Phe Lys Phe Met Pro
Pro Pro Thr Tyr Thr Glu Val Asp Pro Cys 370 375 380Ile Leu Asn Asn
Asn Val Gln385 39031176DNAHOMO SAPIENS 3atggtgatgt tcaagaagat
caagtctttt gaggtggtct ttaacgaccc tgaaaaggtg 60tacggcagtg gcgagaaggt
ggctggccgg gtgatagtgg aggtgtgtga agttactcgt 120gtcaaagccg
ttaggatcct ggcttgcgga gtggctaaag tgctttggat gcagggatcc
180cagcagtgca aacagacttc ggagtacctg cgctatgaag acacgcttct
tctggaagac 240cagccaacag gtgagaatga gatggtgatc atgagacctg
gaaacaaata tgagtacaag 300ttcggctttg agcttcctca ggggcctctg
ggaacatcct tcaaaggaaa atatgggtgt 360gtagactact gggtgaaggc
ttttcttgac cgcccgagcc agccaactca agagacaaag 420aaaaactttg
aagtagtgga tctggtggat gtcaataccc ctgatttaat ggcacctgtg
480tctgctaaaa aagaaaagaa agtttcctgc atgttcattc ctgatgggcg
ggtgtctgtc 540tctgctcgaa ttgacagaaa aggattctgt gaaggtgatg
agatttccat ccatgctgac 600tttgagaata catgttcccg aattgtggtc
cccaaagctg ccattgtggc ccgccacact 660taccttgcca atggccagac
caaggtgctg actcagaagt tgtcatcagt cagaggcaat 720catattatct
cagggacatg cgcatcatgg cgtggcaaga gccttcgggt tcagaagatc
780aggccttcta tcctgggctg caacatcctt cgagttgaat attccttact
gatctatgtt 840agcgttcctg gatccaagaa ggtcatcctt gacctgcccc
tggtaattgg cagcagatca 900ggtctaagca gcagaacatc cagcatggcc
agccgaacca gctctgagat gagttgggta 960gatctgaaca tccctgatac
cccagaagct cctccctgct atatggatgt cattcctgaa 1020gatcaccgat
tggagagccc aaccactcct ctgctagatg acatggatgg ctctcaagac
1080agccctatct ttatgtatgc ccctgagttc aagttcatgc caccaccgac
ttatactgag 1140gtggatccct gcatcctcaa caacaatgtg cagtga
1176420DNAARTIFICIAL SEQUENCEPRIMER DIRETCTED TO RAT Cinc
4gaagatagat tgcaccgatg 20518DNAARTIFICIAL SEQUENCEPRIMER DIRETCTED
TO RAT Cinc 5catagcctct cacatttc 18625DNAARTIFICIAL SEQUENCEPRIMER
DIRETCTED TO RAT Cinc 6gcgcccgtcc gccaatgagc tgcgc
25728DNAARTIFICIAL SEQUENCEPRIMER DIRETCTED TO RAT Cinc 7cttggggaca
cccttcagca tcttttgg 28821DNAARTIFICIAL SEQUENCEPRIMER DIRETCTED TO
RAT Cinc 8ctctacccac ggcaagttca a 21920DNAARTIFICIAL SEQUENCEPRIMER
DIRETCTED TO RAT Cinc 9gggatgacct tgcccacagc 201034DNAARTIFICIAL
SEQUENCEPRIMER DIRECTED TO RAT HBP23 10tttaccctct tgactttact
tttgtgtgtc ccac 341123DNAARTIFICIAL SEQUENCEPRIMER DIRECTED TO RAT
HBP23 11ccagctgggc acacttcacc atg 23
* * * * *